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SUMMARY 
Bone is a highly vascularized tissue, and adequate vascularity is an essential 
requirement for proper bone healing. Revascularization is a challenge in critical-sized 
defects, especially those with concomitant muscle damage typical of traumatic injury. 
Patients with these injuries heal slowly and exhibit higher rates of infection and non-union, 
underscoring the critical importance of vasculature to bone healing. Additionally, the bone 
defect environment is a complex niche, involving mechanical cues in addition to a host of 
biochemical signals. It is well known that mechanical loading affects bone growth and 
remodeling, and while flow-mediated mechanics influence the vasculature, remarkably 
little is known about the effects of bulk matrix deformation on neovascularization. The 
overall objective of this thesis was to leverage mechanical cues to enhance vascular 
network formation and to use enhanced vascularization to improve bone regeneration.  
First, we evaluated the effect of multicellular microvascular fragments (MVF) co-
delivered with BMP-2 to a model of composite bone-muscle trauma using collagen sponge, 
the clinically available BMP-2 delivery vehicle. MVF did not improve bone healing as 
hypothesized; however, we also investigated the effect of a modestly increased BMP-2 
dose, which did significantly improve functional healing. While MVF maintained viability 
within the collagen sponge in vitro, they first dissociated to single cells, which we 
speculated may have prevented their inosculation with the host vasculature. Next, we 
developed and characterized decorin-supplemented collagen gels for use as both an in vivo 
co-delivery vehicle for MVF and BMP-2 and as a dimensionally stable biomaterial scaffold 
to investigate the effects of compressive loading on MVF growth in vitro. Despite in vitro 
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results demonstrating synergistic effects of BMP-2 and MVF, there was no effect of MVF 
on bone healing, and MVF significantly decreased early revascularization following injury. 
However, the addition of decorin increased the compressive properties and dimensional 
stability of collagen while still supporting robust in vitro MVF growth.  
We then evaluated the effects of dynamic compressive loading on MVF growth. 
While the vasculature has long been recognized as mechanosensitive, the effects of 
abluminal forces experienced by healing tissues on angiogenesis are poorly understood. 
We demonstrated that delayed compressive loading led to longer, more extensively 
branched microvascular networks than early loading at all strain magnitudes tested. Across 
strain magnitudes, delayed loading increased vascular network length and branching 
compared to non-loaded controls; however, early high strain loading inhibited network 
formation. Gene expression analysis revealed differential mechanoregulation of gene 
expression profiles by early vs. delayed loading. Genes associated with angiogenic sprout 
tip cells were downregulated by early loading and upregulated by delayed loading. Delayed 
loading also led to the upregulation of genes involved in cell adhesion and migration. Using 
a pharmacological inhibitor, we established that the YAP mechanotrasduction pathway is 
involved in the pro-angiogenic response to delayed loading.  
Overall, this thesis has tested MVF as a therapeutic for bone healing, developed and 
characterized a novel biomaterial for in vitro and in vivo applications, and increased 
fundamental knowledge about the effects of bulk loading on neovascularization. These 
findings can be leveraged to more effectively treat composite bone-muscle defects, both 
through future tissue engineering work and with physical rehabilitation regimens informed 
by knowledge of loading effects on nascent vasculature.    
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CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Bone is a highly vascularized tissue, and adequate vascularity is an essential 
requirement for proper bone healing. Revascularization is a challenge in critical-sized 
defects, especially those with concomitant muscle damage typical of traumatic injury. The 
Gustilo Classification system scores open fractures from I to IIIC in order of increasing 
severity, increasing complication rate, and increasing patient morbidity. The hallmark of 
the most severe class IIIC injuries is the presence of vascular damage. Patients with these 
injuries heal slowly and exhibit higher rates of infection and non-union, underscoring the 
critical importance of vasculature to bone healing. Additionally, the bone defect 
environment is a complex niche, involving mechanical cues in addition to a host of 
biochemical signals. It is well known that mechanical loading affects bone growth and 
remodeling, and while flow-mediated mechanics influence the vasculature, remarkably 
little is known about the effects of bulk matrix deformation on neovascularization. To most 
effectively leverage the use of a vascular therapeutic in this space, we must better 
understand the effect of the relevant mechanical loading environment on the vasculature. 
Microvascular fragments (MVF), multicellular structures derived from mature vasculature, 
form networks in vitro and anastamose with the host vasculature when implanted in vivo. 
As such, they are a useful in vitro model of mature vasculature and are an attractive 
therapeutic candidate. Stromal vascular fraction (SVF) is a single cell digestion of mature 
vasculature that also forms networks in vitro and has been used as an in vivo therapeutic.  
 2 
The overall objective of this thesis is to leverage mechanical cues to enhance vascular 
network formation and to use enhanced vascularization to improve bone regeneration. The 
overarching hypothesis is that cell source, biomaterial scaffold, and mechanical 
environment each influence the formation of engineered vascular networks.  
 
1.2 Specific Aims   
Specific Aim 1: Evaluate effect of vascular cell source co-delivered with BMP-2 to 
composite defect model. The primary objective of this aim was to overcome the bone 
healing deficit observed in composite tissue injuries. Microvascular fragments (MVF) and 
stromal vascular fraction (SVF) were cultured in the presence of BMP-2 in a collagen 
sponge in vitro. Cell viability and BMP-2 release kinetics were assessed. MVF-seeded 
sponges released significantly more BMP-2 than acellular or SVF-seeded sponges. Based 
on these in vitro results and those of a pilot in vivo study, MVF were co-delivered with two 
doses of BMP-2 in collagen sponge to a critical sized bone defect within a composite bone-
muscle defect model. Bone regeneration was evaluated with x-ray radiography and µCT 
along with endpoint mechanical testing. Inflammatory serum cytokine levels were also 
quantified. We hypothesized that BMP-2-mediated functional regeneration of composite 
extremity injuries is dose dependent and can be further enhanced via co-delivery of 
adipose-derived MVF.  
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Specific Aim 2: Develop a biomaterial for in vitro studies and in vivo delivery of 
microvascular fragments. The primary objective of this aim was to develop a 
dimensionally stable biomaterial to evaluate effects of in vitro loading on MVF over time 
and to co-deliver MVF and BMP-2 in vivo. Candidate materials were assessed in vitro 
based on four criteria: 1) robust MVF growth, 2) dimensional stability over time in culture, 
3) suitable compressive properties, and 4) sustained BMP-2 release. The material meeting 
all criteria, decorin (DCN)-supplemented collagen hydrogels, was used to co-deliver MVF 
and BMP-2 to a composite defect model. We hypothesized that using a biomaterial 
designed to meet these criteria to deliver MVF and BMP-2 would increase early 
vascularization and facilitate improved bone healing.  
 
Specific Aim 3: Investigate effects of mechanical loading on microvascular growth and 
remodeling. The primary objectives of this aim were to elucidate the effects of different 
abluminal mechanical loading regimes on in vitro MVF growth and network remodeling 
and to determine the molecular changes associated with observed morphological changes. 
MVF seeded in collagen+DCN gels were dynamically loaded in either unconfined 
compression or compression with a shear interface zone to mimic the loading experienced 
in an in vivo bone defect environment. Vascular growth under loading was assessed by 
quantifying network length and branch number. We hypothesized that vascular growth 
would be enhanced by delayed, moderate compression and inhibited by early, high 
magnitude compression and in regions of high shear. We subsequently investigated the 
changes in viability, proliferation, perivascular coverage, and gene expression profiles 
associated with early vs. delayed loading. Based on our morphological results, we 
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hypothesized that early loading would decrease cell viability, pericyte-vessel attachment, 
and expression of genes associated with early stage angiogenesis, such as sprout tip cell 
selection, thereby leading to impaired vascular networks. Conversely, we hypothesized that 
delayed loading would increase cellular proliferation and increase expression of genes 
associated with later stages of angiogenesis, such as matrix invasion, collective cell 
migration, and cell recruitment, thereby leading to more extensive and mature vascular 
networks. Finally, we investigated the role of YAP mechanotransduction in the differential 
angiogenic responses to early and delayed loading.  
 
1.3 Significance 
A clinically available delivery vehicle was utilized in Aim 1, while Aim 2 developed a 
material designed to criteria specific to this application to improve its efficacy. Aim 3 then 
used the material developed in Aim 2 to study MVF networks under the types of loading 
they experience in vivo and interrogated the molecular changes accompanying 
morphological changes. Overall, this thesis has tested MVF as a therapeutic for bone 
healing, developed and characterized a novel biomaterial for in vitro and in vivo 
applications, and increased fundamental knowledge about the effects of abluminal loading 
on neovascularization. These findings can be leveraged to more effectively treat composite 
bone-muscle defects, both through future tissue engineering work and potentially with 
physical rehabilitation regimens informed by knowledge of loading effects on nascent 
vasculature.    
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CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 
2.1 Bone  
2.1.1 Function and Structure 
While often regarded as primarily structural, bone is a dynamic living tissue that 
performs multiple vital physiological functions. In addition to providing structural support, 
protection for other organ systems, and leverage for movement, bone also regulates 
systemic calcium homeostasis and is the primary site of hematopoiesis [1]. Calcium is a 
crucial element for regulating cell survival and signalling [2], and its systemic 
concentration is maintained in a delicate balance through coordinated bone resorption and 
deposition [1]. As the site of immune cell production, bone marrow is intimately linked to 
systemic immune system function [3]. Bone marrow is also rich in other stem and 
progenitor cells, including multipotent mesenchymal stem cells [4].  
Bone is composed of both inorganic and organic phases. Inorganic mineral, 
primarily hydroxyapatite (HA; Ca10(PO4)6(OH)2), comprises approximately 67% of bone 
by weight, and organic matrix material, primarily type I collagen, comprises the remaining 
33%. The organic phase of bone also includes the primary cells of bone tissue: osteoblasts, 
osteoclasts, and osteocytes. Osteoblasts, derived from mesenchymal lineage, are 
responsible for bone formation. Osteoblasts secrete extracellular matrix proteins, including 
type I collagen, to form osteoid – the template for mineralized bone tissue. In addition to 
type I collagen, osteoblasts also secrete proteins with high affinity for calcium, such as 
bone sialoprotein and osteonectin [1]. Following matrix protein secretion, osteoblasts 
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increase expression of alkaline phosphatase, which cleaves surrounding phosphate groups. 
Together with calcium, these phosphate groups form crystals that mineralize the osteoid 
matrix [5]. Osteoblasts also participate in bone resorption through signalling activity that 
regulates the activity of osteoclasts, the cell type responsible for bone resorption [1]. 
Osteoclasts are derived from monocytic lineage and thus represent an additional link 
between bone and the immune system [3]. Rather than matrix proteins, osteoclasts instead 
secrete acids and proteases that lead to the breakdown of the organic matrix and dissolution 
of HA, releasing calcium into circulation [1]. After matrix deposition activity, osteoblasts 
can undergo apoptosis (approximately 60%), become quiescent bone lining cells (~10-
30%), or mature into osteocytes that are embedded within the bone matrix (~10-30%) [6]. 
Osteocytes represent nearly 95% of bone cells and reside within cavities called lacunae, 
which are embedded within concentric layers of mineralized tissue. Osteocytes have a 
dendritic phenotype, with extended processes called canaliculi. The canaliculi of distinct 
osteocytes form gap junctions with one another to allow for cell-cell communication, which 
is thought to play a key role in bone mechanosensation [1]. 
Bone can be classified as either cortical bone or trabecular bone. Cortical bone 
forms the dense exterior of long bones, while trabecular bone makes up the spongy interior. 
In cortical bone, the concentric mineral layers containing embedded lacunae are called 
lamellae, which are organized into packed, circular structures called osteons. At the center 
of each osteon is a Haversian canal, which contains the blood vessels that supply osteocytes 
through the lacunar-canalicular network. This complex network is required for survival of 
such a densely structured tissue. In contrast, trabecular bone is organized into rod-like 
structures surrounding pores filled with bone marrow and blood vessels. The cortical bone 
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of long bones is lined on its exterior by the periosteum and on its interior (along the 
medullary canal, which houses bone marrow) by the endosteum, both of which are involved 
in bone remodelling. As such, the endosteum is particularly rich in osteoblasts, osteoclasts, 
and bone lining cells. The periosteum has a fibrous outer layer and a highly vascularized 
inner layer rich in progenitor cells [1]. Structures called Volkmann’s canals connect the 
vasculature of the periosteum to the Haversian canal system and interconnect Haversian 
canals to one another [7]. 
 
2.1.2 Normal Bone Healing Cascade 
Bone tissue has a native capacity for repair, and the majority of fractures heal with 
only immobilization as primary treatment [8]. Fracture healing follows the typical stages 
of wound healing cascade: hemostasis, inflammation, proliferation, and remodeling [9, 10]. 
During the proliferation stage, fractures can heal through either of the two modes of bone 
development: endochondral ossification or intramembranous ossification. In endochondral 
ossification, typical of long bone development, a cartilaginous template becomes 
mineralized, whereas in intramembranous ossification, typical of flat bone development, 
mesenchymal stem cells differentiate into osteoblasts that directly mineralize [11]. In some 
cases, the two modes can occur simultaneously [12, 13].    
Hemostasis, the first stage of fracture healing, is simply the stoppage of active 
bleeding through coagulation [9]; this forms a hematoma surrounding the fracture. 
Inflammatory cells, including neutrophils, monocytes, macrophages, T cells, and B cells, 
then invade the hematoma. Phagocytic cells remove necrotic tissue and, along with other 
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immune cells, secrete cytokines and chemokines that recruit and mature stem and 
progenitor cells [10]. A critical event demarcating the transition from the inflammatory 
stage, which persists on the order of days, to the proliferative stage of wound healing is the 
invasion of new blood vessels in response to the hypoxic injury niche [14]. Without 
adequate angiogenesis, bone healing cannot proceed [15, 16]. Osteoprogenitor cells, which 
can occupy a perivascular niche [17], invade into the injury site along with vasculature 
[18]. Additional progenitor cells are recruited from the periosteum. Once within the 
hematoma, osteoprogenitors proliferate, differentiate, and lay down a provisional 
extracellular matrix that constitutes the initial, nonmineralized fracture callus [10]. In 
endochondral ossification, chondrocytes deposit a cartilaginous matrix, become 
hypertrophic, and begin mineralizing. In intramembranous ossification, mesenchymal 
condensates differentiate into osteoblasts, which begin to mineralize the callus [11]. In both 
modes of ossification, the soft callus eventually (on the order of weeks) becomes a hard, 
mineralized structure made of woven bone that is relatively disorganized and mechanically 
weak compared to mature bone [12]. In the final stage of wound healing, woven bone is 
remodeled to achieve a mature structure through a balance of osteoclast-mediated bone 
resorption and osteoblastic deposition of lamellar bone [10]. The remodeling process, 
which is important for the restoration of intact bone mechanical properties, can take weeks 
or even years to complete [12].  
 
 
2.2  Vasculature  
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2.2.1 Function and Structure 
Bone receives up to 15% of cardiac output [11, 19, 20] and is well-vascularized at 
both the macroscopic scale, with the periosteum serving as a rich vascular source, and at 
the microscopic scale, with the intricate Haversian canal system supporting the interior of 
mineralized bone tissue. Vasculature itself also exhibits multiple size scales. Arteries are 
the largest vessels in a hierarchical structure and transport blood out of the heart. Arteries 
branch into smaller arterioles, which branch into smaller still capillaries. Capillaries are the 
vessels through which tissues exchange oxygen and nutrients [21], and diffusion 
limitations require tissues be within a few hundred microns of a capillary to survive [22]. 
Capillaries transport deoxygenated blood into venules, veins, and ultimately back to the 
heart [21]. Arterioles, capillaries, and venules constitute the microvasculature [23].  
Both arterial and venous structures consist of three structurally distinct layers: 
tunica intima, media, and adventitia. Capillaries consist only of the tunica intima. The 
tunica intima is directly adjacent to the vessel lumen and is composed of monolayer of 
endothelial cells (ECs) apposed to pericyte support cells [21]. ECs are the cell type closest 
to blood and form a permeable barrier that selectively allows for transport of metabolites, 
hormones, proteins, and cells across the vascular system [21, 24]. The endothelial 
glycocalyx, a layer of proteoglycans and glycoproteins bound to EC membranes, plays an 
important role in determining the degree of EC permeability and is thought to be involved 
in vessel mechanotransduction [25]. Pericytes support the thin EC monolayer and are a 
hallmark of mature vasculature [26]. Without pericytes, vessels are leaky and can become 
hemorrhagic [27]. Additionally, pericytes are multipotent and capable of differentiating 
into mesenchymal lineage cells [21, 27, 28]. The tunica media is composed of multiple 
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layers of perivascular smooth muscle cells within a collagen and elastin matrix, and the 
tunica adventitia is primarily fibro-elastic connective tissue. These two outer layers allow 
vessels to contract and dilate in response to physiological demands and tend to be thicker 
in arterial than venous structures [21].  
 
2.2.2 Angiogenesis 
Angiogenesis is the process of new blood vessels forming by sprouting from existing 
vessel structures. This is in contrast to vasculogenesis, in which progenitor cells assemble 
into de novo tubular structures. Angiogenesis follows vasculogenesis in embryonic 
development and continues throughout life to accommodate tissue growth, metabolic 
demands, and tissue regrowth/healing [29]. In response to hypoxia, cells within an 
inadequately perfused tissue secrete vascular endothelial growth factor (VEGF), which acts 
in concert with additional factors as a stimulus to trigger sprouting angiogenesis [22]. 
Sprouting angiogenesis can be considered in three main steps: tip cell selection, sprout 
formation, and sprout elongation.   
In response to a VEGF gradient, ECs become activated and express a balance of both 
notch, a receptor, and delta-like ligand 4 (Dll4), its ligand. To prevent complete 
destabilization of the parent vessel, ECs become either migratory leader tip cells or 
follower stalk cells through notch-mediated lateral inhibition. Those ECs that express 
slightly more Dll4 than notch will be selected as tip cells, while those that express slightly 
more notch become stalk cells. Stalk cells will then also express Jagged-1 (Jag1), which 
acts as a competitive antagonist and binds notch without activating it, to reinforce the 
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lateral inhibition signalling [30]. Once selected, the tip cell extends filopodia [22] and 
begins to migrate along the VEGF gradient into the surrounding matrix. Tip cells 
upregulate VEGF receptor 2 (VEGFR2) to increase sensitivity to VEGF, and surrounding 
stalk cells produce soluble VEGF receptor 1 (VEGFR1), which may both reinforce tip-
stalk cell dynamics and provide directional guidance to the outgrowing sprout [30]. As the 
tip and stalk cells collectively migrate, stalk cell proliferation allows sustained sprout 
elongation [30]. To migrate, cells must interact with the surround matrix through adhesion 
molecules such as integrins [31]. Proteases, especially matrix metalloproteases (MMPs), 
also play an important role in sprout elongation, as the surrounding matrix must be 
disrupted for an elongating sprout to invade. MMP-2, MMP-9, [31, 32] and MMP-14 [30, 
33] are known to be especially critical for angiogenesis.   
A key step of the maturation of newly formed sprouts is pericyte recruitment, which 
is mediated through paracrine secretion of factors including platelet-derived growth factor 
B (PDGF-B) and transforming growth factor β1 (TGF-ß1) [30, 31]. Angiopoietin-1 
(Ang1)-Tie2 signalling also promotes the attachment of pericytes to endothelial cells, 
stabilizing mature vessels [34]. Following lumenization and pericyte recruitment, ECs 
transition into a quiescent phalanx phenotype [30]. However, in the presence of 
destabilizing Angiopoietin-2 (Ang2) and VEGF, ECs will become activated and begin 
sprout angiogenesis [34].  
 
2.3 Composite Bone-Muscle Injuries  
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2.3.1 Epidemiology and Classification 
Fracture healing is a well-orchestrated process that typically restores full function 
to the affected bone. However, of the six million fractures that occur each year in the United 
States alone, about 5-10% do not heal with standard treatment and are termed non-unions 
[35]. Open fractures, which penetrate the soft tissue surrounding the bone, have a higher 
incidence of complication, with a 25% rate of delayed or nonunion [36]. These 
complications often involve infection, rehospitalization, and additional surgeries, all of 
which contribute to a financial burden of over $4 billion on the American healthcare system 
[37].  
Open fractures are commonly classified according to the Gustilo classification 
systems, which grades fractures in increasing severity from I-IIIC. Class I open fractures 
are smaller than 1 cm with a relatively clean wound, and class II injuries range from 1 to 
10 cm but have only minimal soft tissue damage. Class III injuries are further classified 
from A-C. Injuries falling into IIIA are larger than 10 cm with extensive soft tissue damage 
but retain periosteal coverage, while IIIB injuries are stripped of periosteum. Finally, the 
hallmark of class IIIC injuries is vascular damage – regardless of the degree of soft tissue 
damage [38]. The fact that the degree of vascular damage is considered the “single most 
important determinant of complications after an open fracture” [39] underscores the critical 
importance of vasculature to bone healing. Attenuated healing of bone defects with 
concomitant muscle damage has also been observed in pre-clinical animal models [40-42], 
as has reduced vascularity [43, 44]. 
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2.3.2 Current Clinical Treatment Strategies  
The current clinical standard of care for long bone defects is an autologous iliac crest 
bone graft (ICBG) [45], which is osteoconductive, osteoinductive, and osteogenic [46].  
Recently, the reamer-irrigator-aspriator (RIA) technique, an alternative autograft source, 
has become more widely used. RIA harvests a large volume of graft material from the 
intramedullary canal or either the femur or the tibia and has shown similar efficacy as ICBG 
[47].  Although RIA is associated with significantly less donor site pain pain than ICBG 
[47], tissue availability and donor site morbidity are serious disadvantages inherent to any 
autograft procedure [48]. Allografting is an option but is also challenged by tissue 
availability. Additionally, relying on an allogeneic source introduces risks of tissue 
rejection and disease transmission [46]. Several bone graft substitutes, commonly referred 
to as bone void fillers, are currently clinically available. One commonly used material is 
demineralized bone matrix (DBM), which is demineralized, sterilized allograft tissue [49]. 
DBM retains many of the osteoinductive growth factors natively present within bone but 
is less osteogenic than vital bone graft. Both allograft tissue and DBM are less consistently 
successful than autografting, which may be driven at least in part by donor-to-donor 
variability [46].  
In addition to the above bone grafting techniques, the standard of care for open 
fractures includes debriding the wound and covering the bone defect/graft with a flap of 
intact local muscle, if available, or with muscle tissue from an uncompromised donor site 
[38, 39]. Coverage with a vascularized muscle flap improves patient outcomes [50], but 
the mechanism of action is unknown; increased angiogenesis, growth factor availability, 
and cell recruitment may all be involved [42]. However, functional outcomes of severe 
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traumatic injuries remain poor. Two-thirds of patients experience long-term (≥ 7 years) 
disability [51], and limb function often cannot be restored to above that of a prosthesis [52]  
– particularly for Gustilo type IIIC open fractures with vascular damage [53]. Current 
treatment strategies can be used to salvage the limb in most cases, but the painful and 
protracted limb salvage process may actually significantly impair patient quality of life 
compared to amputation [54]. Some patients even elect to amputate the limb even after 
enduring the salvage process due to severe lack of function [55]. 
 
2.4 Bone Tissue Engineering (BTE) 
The limitations of current treatments present a clear need for tissue engineered 
therapeutics for bone defects with concomitant muscle injury. Key factors to consider in 
BTE include biochemical cues such as growth factors, biomaterial scaffold, and cell source 
– either exogenously delivered within the construct or recruited from endogenous 
populations.  
 
2.4.1 Biological Factors: Growth Factors and Cells  
Biochemical signaling plays a key regulatory role in the endogenous fracture 
healing process, providing many of the cell recruitment and differentiation stimuli required 
for healing [12]. The bulk of the existing literature has focused on growth factors involved 
in the proliferative stage of wound healing, including approaches focusing on augmenting 
vascularization [56], which will be highlighted in 2.4.3. More recent work has also begun 
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to focus on modulating the cytokine signaling characteristic of the early inflammatory stage 
of wound healing [57].  
There are at least 20 members of the BMP family of growth factors, seven of which 
have known osteogenic activity [56]. Two of these growth factors, BMP-2 and BMP-7, 
also known as osteogenic protein-1 (OP-1), have been commercialized within collagen 
delivery vehicles as Metronic’s Infuse and Stryker’s OP-1 Putty, respectively [48, 58]. 
BMP-2 is one of the earliest expressed proteins during osteogenesis and can regulate the 
subsequent expression of additional BMPs. BMP-2 plays a central role in MSC recruitment 
and osteoblastic differentiation as well as chondrogenesis, relevant to endochondral 
ossification [59]. BMP-7 expression temporally follows BMP-2 during endogenous 
healing. BMP-7 has demonstrated potent osteogenic effects [60] as well as regulatory roles 
in both endochondral and intramembranous ossification [59]. BMPs are members of the 
TGF-ß super family along with TGF-ß1, -ß2, and -ß3, which also act as potent 
chemoattractants for osteoprogenitor cells. Fibroblast growth factor (FGF) and insulin-like 
growth factor (IGF) are additional factors involved in progenitor cell recruitment and 
proliferation [59]. TGF-ß [61], FGF [62, 63], and IGF [62] have all been co-delivered with 
BMPs in preclinical bone defect models. [64] Depending on the growth factor dose ratios 
and model used, studies have demonstrated synergistic, null, and even inhibitory effects of 
the additional growth factor as compared to BMP alone [56]. BMP alone, however, 
consistently displays potent osteoinductive activity.  
When exogenous cells are delivered, mesenchymal stem cells (MSCs) are most 
common. While MSCs have been shown to improve healing pre-clinically [65-67], other 
similar studies have shown no benefit [67, 68].  This may be due in part to the relatively 
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poor definition of MSC potency and thus high degree of variability. For example, MSCs 
that express the same surface markers but are isolated from different tissues can have 
differential effects on bone healing; bone marrow-derived MSCs augmented BMP-2-
mediated mineralization, whereas adipose-derived MSCs inhibited mineralization [67]. 
This study and others have seen that BMP-2 delivery alone tends to have a much stronger 
effect than MSCs alone and that co-delivery of MSCs often provides only marginal 
enhancement of BMP-2-mediated healing [67, 68]. 
 
2.4.2 Biomaterials 
The biomaterial delivery vehicle for BMP-2 in the clinically approved Medtronic 
Infuse product is absorbable collagen sponge. Infuse was first clinically approved for and 
is still most commonly used in spinal fusion cases [69] but has also demonstrated clinical 
success in open tibia fractures [70]. However, BMP-2 is retained by collagen sponge only 
through weak electrostatic interactions, leading to an initial burst release of growth factor 
and therefore requiring supraphysiological doses to be delivered [71]. This release profile, 
which does not match the natural expression of BMP-2 [72], can lead to adverse effects 
including extensive local inflammation, ectopic bone formation, and even bone resorption 
[73]. These challenges motivate the development of a superior delivery vehicle [73].  
Biomaterial delivery systems that better control BMP-2 release both spatially and 
temporally, such as a nanofiber mesh surrounding a BMP-2-laden alginate hydrogel, have 
shown improved pre-clinical bone healing as compared to collagen sponge [74, 75]. Other 
naturally derived materials, including chitosan [76], fibrin [77], hyaluronic acid [78], and 
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silk fibroin [79] have been used as pre-clinical hydrogel delivery vehicles for BMP-2. 
While natural polymers are often biodegradable and offer bioactivity in the form of native 
cell binding motifs, they also tend to be more immunogenic, challenging to process, and 
difficult to modify. Synthetic polymers with tunable chemical and mechanical properties 
such as poly-ethylene glycol (PEG) [80] and poly-lactic-co-glycolic acid (PLGA) [81] 
based materials have also been explored in bone regeneration applications [82, 83]. 
Ceramic materials including hydroxyapatite (HA) and tri-calcium phosphate have also 
been widely utilized in pre-clinical studies [83, 84]. While ceramics better match the 
composition of native bone than hydrogels, they are brittle. Composite materials that 
combine two or more materials (e.g. alginate+PEG or HA+PLGA) into a single construct 
have also begun to be investigated to combine the desirable properties of two different 
materials [85-87]. Regardless of the specific material chosen, growth factor release kinetics 
and support of cellular invasion and viability are critical.  
 
2.4.3 Vascularization Strategies  
Vascularization is critically important to bone regeneration and remodeling and plays 
an enabling role in the wound healing cascade [11, 88]. Moreover, tissue engineered 
constructs are diffusion-limited in terms of nutrient and oxygen transport, meaning that any 
implanted cells beyond the range of ~200 µm will die unless perfused [89]. Previous 
research has investigated co-delivery of BMP-2 and VEGF), a key regulator of 
angiogenesis during bone repair [90]. A number of studies suggest that these two growth 
factors have a synergistic effect on healing [91-93], while others note no improvement as 
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compared to BMP alone [94]. Several studies note an initial improvement in bone volume 
at early time points (4 weeks) but no ultimate effect at terminal time points (8-12 weeks) 
[56, 95, 96]. In vitro studies have demonstrated positive, bi-directional signaling crosstalk 
between the two growth factors [97, 98], but the balance of BMP and VEGF ratios and 
differential release profiles may require optimization before this strategy can be reliably 
effective in vivo [94, 99]. Additional studies have delivered VEGF without BMP and seen 
no improvement in bone healing [96, 100], suggesting that some osteoinductive signaling 
is required in addition to targeting vascularization alone.  
Another approach to promote both angiogenesis and osteogenesis is the delivery of 
cells rather than growth factors. Co-implantation of endothelial cells and MSCs within a 
bone defect has shown increased vascularity and bone volume [101], particularly when the 
cells have been pre-cultured prior to implantation to allow for effective pre-vascularization 
of the constructs [102, 103]. Mechanical properties of regenerate bone have also been 
improved by increased vascularization facilitated by implanted endothelial cells [104]. 
However, vascularization formed from implanted endothelial cells tends to be leaky and 
immature [105]. Cell-based therapies in general tend to display low survival and retention 
rates [68, 106], perhaps due in part to hypoxia created by delayed anastomosis with the 
host vasculature.  
 
2.5 Adipose-Derived Vascular Cell Sources 
2.5.1 Microvascular Fragments 
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Microvascular fragments (MVF) are multicellular segments of intact vasculature 
that can sprout and form networks in vitro. They are isolated from mature vasculature and 
are composed of a variety of cell populations including endothelial cells, smooth muscle 
cells, pericytes, mesenchymal stem cells, and endothelial progenitor cells  [107, 108]. 
While MVF are typically isolated from adipose tissue, their angiogenic potential is 
independent of tissue source [109]; the adipose site has translational advantages, with 
potential for autologous use. MVF are typically cultured in a low-density type I collagen 
gel [110-113] and are sensitive to matrix properties such as density and stiffness [110, 113]. 
In combination with an appropriate 3D matrix, MVF allow for cell-cell interactions among 
multiple cell types and cell-matrix interactions, thereby better representing the complex in 
vivo processes of angiogenesis than models utilizing single cells or 2D substrates. As such, 
they are a useful in vitro model system for angiogenesis.  
Additionally, MVF have been implanted in vivo, where they have been shown to 
inosculate with the host vasculature [114, 115], increase vascularity of tissue defects [116, 
117], and improve tissue grafting in pre-clinical models [118, 119]. Many therapeutic 
applications have used freshly isolated MVF, although inosculation has been shown to 
occur more rapidly when MVF are precultured prior to implantation [115]. Due to their 
lumenized structure and retention of support cells [107], MVF are an attractive therapeutic 
option to restore mature vascular networks.  
 
2.5.2 Stromal Vascular Fraction 
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Stromal vascular fraction (SVF) is a single cell level digestion consisting of a 
heterogeneous mixture of endothelial cells, mesenchymal stem cells, smooth muscle cells, 
fibroblasts, and macrophages and is also most commonly obtained from adipose tissue 
[120]. SVF also forms interconnected, lumenized networks in vitro [121], but because they 
must first assemble into tubular structures, the timescale is longer for SVF than for MVF. 
In vivo, SVF forms vascular networks along with endogenous cells that inosculate with 
host vasculature and become perfused. This is true using both freshly isolated and pre-
cultured SVF [122]. SVF has been isolated clinically from liposuction aspirates and used 
as a therapeutic [123], representing a significant translational advantage over MVF.  
 
2.6 Mechanics 
2.6.1 Effect of Mechanical Stimulation on Bone 
Normal bone physiology is strongly influenced by mechanical loading. 
Physiological levels of loading typical of normal use prevent bone resorption, while greater 
loading promotes an increase in bone mass [124, 125]. This is a cell-mediated process, in 
which osteocytes are thought to act as the primary mechanotransducers [126]. Mechanics 
also influence bone healing, and these effects are driven primarily by osteoblast 
differentiation, proliferation, and matrix production [127-129]. The interfragmentary strain 
hypothesis postulates that cells present within the defect repair tissue sequentially 
differentiate to form tissues with higher ultimate strain than the interfragmentary strain 
presently experienced. Thus, as tissue grows and differentiates within the defect space, the 
interfragmentary strain decreases and the defect stiffness increases [130]. This long-
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standing hypothesis has been supported by studies directly comparing in vivo osteotomy 
healing with the healing predicted by strain-directed computational models [131] and by 
in vitro studies demonstrating that matrix stiffness directs MSC differentiation lineage 
[132]. Mechanical stimulation mediated by fluid flow [102] and by tension and 
compression applied to the culture surface [133] also promote enhanced osteogenic 
differentiation of MSCs in vitro. Mechanical stimulation broadly encompasses multiple 
parameters, including strain magnitude, mode of loading (e.g. compression vs. tension), 
frequency, and timing, all of which are known to influence bone’s response to loading.     
 
2.6.1.1 Compressive Strain Magnitude 
Native bone tissue is responsive to strain magnitude, and bone mass increases in a 
dose dependent manner. There is a lower threshold required to achieve a response [134] 
and an upper threshold above which bone formation is halted and damage may be sustained 
[135]. Mechanical cues can serve as either an anabolic or catabolic stimuli to regenerating 
bone tissue [136].  Moderate strain micromovements have consistently been shown to 
improve fracture healing [127, 137, 138]. However, when these micromovements are too 
large, fracture healing can be delayed [139] or altogether halted [140], and mechanical 
instability is noted as a principal cause of fracture non-union [141]. Reliance on various 
different in vivo models to vary the mechanical environment (e.g. size of osteotomy gap 
[140], rigidity of fixator [136, 139], and application of force through external fixator [137]) 
has made it difficult to reconcile all the existing literature to arrive at a defined threshold 
for anabolic vs. catabolic, and therefore therapeutically desirable, strain magnitude. In a 
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pseudarthrosis model, loading was applied to a hinged fixator to apply spatial gradients of 
strain magnitudes across the defect tissue. These force gradients were quantified and 
spatially correlated with resulting tissue type by histology. Below 10% strain, the highest 
probability tissue type was bone, with the peak probability of bone formation occurring 
around 2-5% strain. Above 10%, the highest probability tissue type was non-healed fibrous 
tissue [142]. In an osteotomy model, Claes et al. identified 5% strain as a threshold for 
intramembranous ossification and 15% strain for endochondral ossification [143].  
 
2.6.1.2 Mode of Loading Compression, Tension, and Shear 
Fracture healing is sensitive to the mode of loading, e.g. compression, tension, 
bending, or shear. Compression has been the most commonly studied and is widely 
accepted to improve healing up to a critical strain threshold [144]. Bone tissue is also 
sensitive to tensile loads [135], and tension affects fracture healing similarly to 
compression; moderate applied tension is stimulatory, while large magnitude tension leads 
to reduced healing and even resorption [131]. Tension is a component of the common 
clinical practice of distraction osteogenesis [145]. The effects of interfragmentary shear 
and bending are less well understood. Bending incorporates elements of both compression 
and tension, and in one study of bending, the fracture callus mineralized and bridged only 
on the compressive side and not on the tensile side of bending [146]. In a recent review 
article, Betts and Muller highlighted eight studies of interfragmentary shear. Of these, six 
reported negative effects of applied shear and two reported positive effects [144]. 
Difference in animal model, strain magnitude, and strain frequency along with the ability 
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to isolate shear from any other mode of loading may explain the contradictory results. 
Interestingly, in the pseudarthrosis study discussed in 2.6.1.1 that correlated local strain 
with tissue type, 10% strain was consistently the threshold transition point from a greater 
probability of forming bone to a greater probability of a fibrous response across 
compression, tension, and shear [142].   
 
2.6.1.3 Time: Frequency, Duration, and Initiation  
Native bone exhibits sensitivity to dynamically applied loads but not static loads 
[147], which is analogous to sensitivity to walking but not to standing. Gait frequency for 
humans is approximately 1 Hertz (Hz) [148] and up to 4 Hz for rodents, making these 
commonly studied frequencies [149]. Bone formation exhibit a dose response to load 
frequency, with bone mass increasing as frequency increased from 1-10 Hz [150]. 
Interestingly, very low magnitude strains typically below the threshold of effect can be 
potentiated by applying them at high frequencies (30 Hz), both increasing native bone mass 
[151] and accelerating fracture repair [152]. The ability of dynamic loading to increase 
bone formation is potent and can be detected after only a single loading period [153]. 
However, the mechanosensitivity of bone becomes saturated [149], and the anabolic effects 
plateau after relatively few continuous cycles [154]. Partitioning the loading into multiple, 
shorter cycles [155] or inserting rest periods as short as 14 seconds can restore 
mechanosensitivity [156]. 
Finally, the initiation time of loading has also been implicated as an important 
factor in achieving an anabolic rather than catabolic effect of mechanical stimulation. 
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Gardner et al. compared the effects of loading on the day of osteotomy vs. loading four 
days following the osteotomy surgery. Early loading led to reduced failure strength relative 
to the non-loaded control, whereas delayed loading increased failure strength relative to 
the control [157]. Subsequent work by Boerckel et al. observed a similar time-dependent 
effect in a critical size bone defect. Bone volume and mechanical strength were decreased 
due to early loading but increased by delayed loading. Additionally, this study measured 
vascular volume and found that the vascular response mirrors that of bone [136], 
suggesting that the early vascular response to the mechanical environment may drive 
subsequent bone formation.     
 
2.6.2 Effect of Mechanical Stimulation on Vasculature 1 
Vascular growth and remodeling are highly sensitive to mechanical cues; however, 
much of the existing research in this field has focused on luminal mechanics related to fluid 
flow (i.e. fluid shear and cyclic stretch) rather than abluminal stimulation of the entire 
vessel network [158, 159]. Additionally, much of the existing literature has used two-
dimensional cell monolayers that likely do not fully recapitulate the cell-cell interaction 
effects present in vivo. 
                                                 
1 Portions of this section have been adapted from Section 2.1 of Krishnan, L., LaBelle, 
S.A., Ruehle, M.A., Hoying, J.B., Weiss, J.A., and Guldberg, R.E. Mechanical 
Regulation of Microvascular Growth and Remodeling, in Vascularization for Tissue 
Engineering and Regenerative Medicine, Holnthoner, W., Banfi, A., Kirkpatrick, J., Redl, 
H., Editors. 2019, Springer International Publishing: Cham. 2019. Reproduced with 
permission: license number 4584870078122. 
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2.6.2.1 Fluid Shear 
Initial in vitro models utilizing aortic endothelial cell monolayers exposed to 
constant laminar flow demonstrated that fluid shear leads to changes in cellular 
morphology, alignment, and migration. Under uniform laminar flow, cells transition from 
a polygonal to elliptical shape, with the primary axis aligning with the direction of flow 
[160-162].  Laminar flow also affects endothelial cell pinocytosis and fluid endocytosis, 
indicating that metabolism within and bulk transport across the vascular endothelium are 
also sensitive to shear [160].  These cellular responses all occur in a time and shear 
magnitude-dependent manner, with intracellular pinocytosis changes occurring before 
morphological or alignment changes [163].  
Biochemical changes also occur in response to laminar flow, including altered 
production of vasomediators such as prostacyclin, endothelin-1 (ET-1), and nitric oxide 
(NO).  Vasodilator (prostacyclin and NO) production levels are increased by pulsatile flow 
as compared to uniform flow, under which a steady-state is quickly achieved [164, 165].  
Vasoconstrictor (ET-1) production is decreased under shear stress conditions [164].  
Intracellular calcium ion concentrations also vary between pulsatile and uniform flow.  
Uniform flow increases Ca2+ concentration relative to static controls, and pulsatile flow 
further increases Ca2+ concentration.  Purely oscillatory flow (“on-off” rather than periodic 
magnitude changes) does not change Ca2+ concentration.  By affecting intracellular Ca2+ 
concentration, flow profiles mediate Ca2+ dependent signaling cascades to effect 
downstream cellular responses such as the vasomediator production previously discussed 
[166, 167].  These functional changes provided support for early in vivo observations 
implicating fluid flow properties in pathologies such as atherosclerosis.   
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2.6.2.2 Tensile Stretch 
Stretch elicits many of the same cellular responses as shear stress.  Cyclic 
mechanical stretch, as cells experience in vivo, also increases cellular proliferation and 
changes protein production profiles [168, 169].  Like shear stress, stretch increases 
mediators of signaling cascades, such as intracellular Ca2+ concentration and cyclic 
adenosine monophosphate (cAMP) [170, 171].  Production of vasomediators including NO 
synthase (NOS), ET-1, and prostacyclin is also increased by stretch [172-174].  The 
morphological effects of shear and mechanical stretch stimuli, such as cellular elongation 
and alignment, can be additive [161, 175].  
The cyclic loading of endothelial and perivascular cells has been approximated in 
vitro by growing cells on deformable substrates. Cyclic stretch can induce strain-dependent 
increases in secretion of proteolytic enzymes and accelerate the generation of cord-like 
networks on planar EC monolayers [176]. When ECs and SMCs were co-cultured on an 
elastomeric substrate, cyclic tensile stretch increased EC sprouting and migration and SMC 
recruitment. Stretching increased EC secretion of angiopoietin-2, which increased EC 
sprouting through autocrine signaling, and secretion of platelet derived growth factor 
(PDGF), which increased SMC recruitment through paracrine signaling [177]. These 
results suggest that mechanical cues could be driving many of the biochemical cues well-
known to influence vascularization.  
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2.6.2.3 Extracellular Matrix Deformation 
Vascular cells are also influenced by the mechanics of their ECM substrate, and 
matrix stiffness is well recognized as a critical element in vessel growth and function [178]. 
Softer substrates generally produce a more rounded morphology, elicit greater migration, 
and allow higher levels of protrusion and retraction activities [179, 180]. In contrast, higher 
moduli substrates are deformed less by ECs, which also proliferate more on stiffer 
substrates, show more prominent stress fiber formation, and upregulate RhoA activation 
[181, 182].  Cells have been shown to preferentially migrate towards stiffer substrates as 
well as change direction of migration in response to mechanical stimuli, termed durotaxis 
[183]. Bovine aortic endothelial cells cultured on substrates with different stiffness showed 
organization into cord like structures on more compliant substrates, but not stiffer 
substrates, when substrates were coated with the same amount of collagen [184].  ECs 
cultured on fibronectin coated surfaces form multicellular cord like structures at an optimal 
fibronectin surface coating density but not on highly adhesive (high fibronectin density) 
surfaces. Further, culturing endothelial cells within a three-dimensional gel of ECM 
components greatly facilitates angiogenesis, promoting tube formation within days rather 
than the weeks required on protein-coated rigid dishes [185]. These observations suggest 
that both ECM stiffness and cell binding motif density are important factors in capillary 
network or sprout formation. 
MVF cultured in three-dimensional collagen matrices also exhibit sensitivity to 
extracellular matrix stiffness and density. As collagen density increases, vascular network 
length, branching, and interconnectivity all decrease. Computational simulations suggest 
that the rate of growth and branching is slowed by increased matrix density [113]. Matrix 
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density cannot be completely decoupled from matrix stiffness and availability of adhesive 
ligands, both of which may independently or cooperatively influence the morphological 
effects. Additionally, MVF themselves also affect ECM stiffness. Through protease 
activity, MVF remodel collagen matrices, decreasing stiffness as sprouting initiates. 
Following the primary invasion of the matrix, however, MVF then increase the matrix 
stiffness above initial levels through ECM deposition and contraction of the collagen 
substrate [112]. Interactions between vasculature and ECM are bidirectional, and this 
interplay supports the study of angiogenesis in three-dimensional culture systems rather 
than in monolayer alone.  
Abluminal forces that deform the extracellular matrix surrounding a vascular 
network are particularly relevant to load-bearing tissues such as bone. In vitro studies have 
shown that tensile forces affect the alignment and sprouting of microvascular networks, 
with MVF aligning parallel to the direction of applied tension [111, 112]. Neither static nor 
dynamic active stretching produced more alignment of vessels than the passive stretch 
created by holding the gel within the loading fixture. All three conditions (static 6% stretch, 
dynamic 6% stretch, and passive boundary condition stretch) produced a higher number of 
vessels than unconstrained controls, and static stretch produced the greatest degree of 
branching [111, 112]. Although early studies with EC monolayers cultured on deformable 
substrates induced cell orientation perpendicular to the direction of stretch [186], 
orientation of vessels parallel to the direction of applied tension has been replicated in other 
three-dimensional culture systems. In a 3D co-culture of ECs and fibroblasts, vessel 
alignment was mediated by actin stress fibers and associated with differential protein 
secretion [187].  
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While bone tissue does experience some tensile forces, compressive forces 
dominate, and there is little existing literature on the effect of abluminal compressive forces 
on vascular network growth or remodeling. Previous in vivo research has demonstrated 
that functional loading has a potent time-dependent influence on vascular growth during 
segmental bone defect healing. Loading of the bone defect through ambulatory activity was 
allowed either early, immediately following the defect creation surgery, or delayed four 
weeks post-surgery. Early loading impaired vessel growth, whereas delayed loading 
enhanced vascular growth. Furthermore, ultimate differences in bone healing followed the 
earlier changes in vascular networks; bone healing was impaired due to early loading and 
enhanced due to delayed loading [136]. These promising results may have implications for 
both vascularization strategies for tissue engineering and physical rehabilitation following 
bone injury; however, the in vivo environment is inherently complex, and well-controlled 
in vitro studies are needed to better understand the mechanical cues associated with 
vascular growth and inhibition.  
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CHAPTER 3. CHARACTERIZATION OF VASCULAR CELL-
LADEN COLLAGEN SPONGES AS BONE TISSUE 
ENGINEERING CONSTRUCTS  
3.1 Introduction 
Bone tissue has an innate capacity for repair, and the majority of fractures heal with 
only immobilization as the primary treatment. However, approximately 5-10% of fractures 
do not heal with standard treatment and are termed non-unions [8]. Non-unions represent 
a clinical challenge for orthopaedic surgeons, as these injuries by definition require 
multiple different interventions to be implemented in an attempt to achieve bone union. 
Non-union increases the overall healing time, increasing the duration of time a patient may 
be disabled, and each procedure involves risks and pain for the patient [188]. The current 
clinical standard of care for long bone defects is autografting; however, tissue availability 
and donor site morbidity are serious disadvantages of the autograft procedure [48]. One 
clinically available alternative to autografting is the use of bone morphogenetic protein-2 
(BMP-2) delivered on collagen sponge. Originally approved for use in spinal fusion [69], 
BMP-2 on collagen sponge has now been used in tibial fractures for over 15 years [70]. 
BMP-2 is a growth factor capable of inducing bone formation, while collagen sponge 
provides a matrix both to retain BMP-2 and to support progenitor cell ingrowth [71].  
A functional vascular network is required to support the survival of cells that 
migrate into the bone defect space and is a key, enabling step of the wound healing cascade 
[10, 11, 88]. Angiogenesis and osteogenesis are known to be intimately linked [11, 17, 20, 
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189], and when vascularization is impaired, bone healing is also substantially impaired 
[16]. The importance of vascularization is also appreciated clinically; vascular damage is 
a key indicator of open fracture severity [38]. As such, bone tissue engineering strategies 
that aim to enhance vascularization, such as co-delivery of BMP-2 and vascular endothelial 
growth factor (VEGF), have been previously implemented; however, these approaches 
have achieved variable results [92, 94, 95]. While some growth factor co-delivery strategies 
report an improvement in healing [91-93], others report no lasting effect [94-96, 99]. Cell-
based approaches to vascularization have been shown to improve bone healing. However, 
these studies have tended to focus on the delivery of a single vascular cell type (e.g. 
endothelial progenitor cells) rather than all those of mature vasculature [101, 104], which 
often produces a leaky, immature vascular phenotype [105]. 
Microvascular fragments (MVF) are multicellular segments of intact vasculature 
that can sprout and form in vitro vascular networks [107, 113]. They are isolated from 
mature vasculature and are composed of a variety of cell populations including endothelial 
cells, smooth muscle cells, and pericytes [107]. MVF have been implanted in vivo, where 
they have been shown to inosculate with the host vasculature [114, 115] and increase 
vascularity of tissue defects [116]. MVF are most commonly obtained from adipose tissue 
[109], which holds potential for autologous transplantation.  
Stromal vascular fraction (SVF) is a single cell level digestion consisting of a 
heterogeneous mixture of endothelial, mesenchymal, smooth muscle, and hematopoietic 
cells and is also most commonly obtained from adipose tissue [120]. SVF forms 
interconnected networks in vitro, but because they must first assemble into tubular 
structures, the timescale is longer for SVF than for MVF. SVF has been isolated clinically 
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from liposuction aspirates and used as a therapeutic [123], representing a significant 
translational advantage over MVF.  
We aimed to develop a clinically translatable tissue engineering construct to deliver 
vascular progenitors, either multicellular microvascular fragments (MVF) or component 
single cells (SVF), along with BMP-2 on collagen sponge. We first characterized the 
constructs in vitro and observed differential in vitro BMP-2 recovery from constructs 
containing MVF vs. SVF. We subsequently hypothesized that MVF may have increased 
BMP-2 recovery from constructs due to production of BMP-2 or due to increased protease 
activity.  Finally, we implanted these constructs into a rat composite bone-muscle defect 
model that exhibits both attenuated bone healing [42] and decreased vascularity [43, 44]. 
We hypothesized that 1) a vascular cell-laden construct would improve bone healing 
relative to an acellular BMP-2 construct and 2) MVF would further improve bone healing 
relative to SVF due to their preformed tubular structure.  
 
3.2 Methods 
3.2.1 MVF and SVF Isolation  
MVF were isolated as previously described [107]. Briefly, epididymal fat pads were 
harvested from Lewis rats, minced, and digested with a collagenase solution for 7-8 
minutes at 37 °C while manually shaking. Fragments were obtained through selective 
filtration, excluding tissue larger 500 µm and single cells smaller than 50 µm. SVF was 
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obtained through a similar process; digestion time was increased to 30 minutes on an orbital 
shaker at 225 rpm and 37 °C, and only single cells smaller than 50 µm were retained.  
 
3.2.2 Cellular Characterization 
Selected cellular subpopulations of MVF vs. SVF were quantified using flow 
cytometry. Freshly isolated MVF were subsequently further digested to single-cell level 
with 30 minutes of collagenase solution digestion on an orbital shaker at 225 rpm and 37 
°C. MVF and SVF were fixed in 1% paraformaldehyde (PFA) for 10 minutes at 4 °C. Cells 
were permeabilized with 0.5% Tween-20 in PBS for 20 minutes. Cells were then stained 
for mesenchymal stem cell (MSC) surface markers CD29 (BioLegend, San Diego, CA, 
102222), CD90 (BioLegend, 202506), and CD 45 (BioLegend, 202207) [190], and mature 
endothelial cell (EC) surface marker CD 31 (Bio-Rad, Hercules, CA, MCA1334A647) 
[121], and for intracellular alpha smooth muscle actin (ΑSMA; Abcam, Cambridge, MA, 
ab8211) [120].  Cells double positive for CD31 and ΑSMA were defined as pericytes [191]. 
Stained cells were refixed as before and analyzed using a BD FacsAria Fusion.  
Flow analysis was performed using FlowJo 10 (Becton, Dickinson and Company; 
Franklin Lakes, NJ). Compensation was applied using single stained controls. Gating was 
determined using fluorescence minus one (FMO) controls. FMO controls are stained with 
all fluorophores minus one, and gating was determined such that only contained 1% of 
FMO cells were positive for the missing fluorophore [192].  
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3.2.3 Construct Loading & Viability  
MVF and SVF were suspended in αMEM (ThermoFisher Scientific; Waltham, 
MA) and loaded into collagen sponges (5 mm diameter, 1 cm height; Kensey Nash/DSM; 
Exton, PA) by pipetting 130 µL dropwise. MVF were seeded at a density of 40,000 
MVF/mL, and SVF were seeded at a density of 4 x 106 cells/mL. Following a 20 minute 
cell attachment period, 250 µL of media (αMEM supplemented with 10% fetal bovine 
serum (FBS; Atlanta Biologicals; Atlanta, GA) and 1% penicillin-streptomycin-L-
glutamine (ThermoFisher)) was added to each construct [112]. Constructs were cultured 
for 14 days to assess cell viability, which was determined with live/dead stains 
(ThermoFisher) performed at time points up to 14 days (n=3/group/time point). 
 
3.2.4 BMP-2 Release Kinetics 
To evaluate release kinetics, 500 ng BMP-2 (R&D Systems, Minneapolis, MN) was 
added to αMEM (acellular), αMEM containing MVF, or αMEM containing SVF and 
pipetted dropwise onto collagen sponges (n=3/group). BMP-2 recovery from collagen 
sponges seeded with αMEM containing MVF without exogenous BMP-2 (n=3). Following 
a 20 minute binding period, 250 µL of media was added to each construct; media was 
collected and replaced at time points up to 21 days. BMP release was also measured from 
3% type I collagen gels. 250 µL gels were formed in 48-well plates and were either 
acellular or contained 20,000 MVF/mL. Media was collected and replaced up to 14 days. 




3.2.5 Gene Expression 
To assess gene expression in the collagen sponge, MVF and SVF were seeded with 
or without 500 ng BMP-2 (n=5/group). RNA was isolated from constructs using Qiagen 
MinElute kits at hours 0, 3, 6, and 24 of culture. cDNA was created using Qiagen RT2 First 
Strand kits. Expression of BMP-2 (ThermoFisher, Rn00567818_m1), cathepsin K (CtsK; 
Rn00580723_m1), and matrix metalloproteinase 14 (MMP14; Rn00579172_m1) was 
measured and expressed at each time point relative to hour 0 and to housekeeping genes ß-
actin (Rn00667869_m1) and GAPDH (Rn01775763_g1) using the ∆∆Ct method. 
 
3.2.6 BMP-2-Primed 2D Culture 
MVF were plated directly onto tissue culture polystyrene (TCPS) at a density of 
4500 fragments/cm2 to promote their dissociation to single cells. SVF was also plated 
directly onto TCPS at a density of 4.5 x 105 cells/cm2. MVF and SVF were cultured in 
media with or without 500 ng BMP-2 for 24 hours (n=3/group). After 24 hours, all media 
was removed, cells were washed three times with fresh media, and culture was continued 
in fresh media that did not contain exogenous BMP-2. At hours 24 and 96 following the 
BMP-2 priming period, media was removed for ELISA (R&D Systems) and replaced with 
fresh, non-BMP-2-containing media. Cells were harvested at the same time points, and 
BMP-2 gene expression was assessed as in 3.2.5.  
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3.2.7 Pilot in vivo Study  
Composite bone-muscle defects were created in 13-week-old female Lewis rats by 
creating an internally stabilized 8 mm femoral defect with an overlaying 8 mm diameter 
full-thickness quadriceps defect, as described in [42]. Bone defects received a cylindrical 
collagen sponge (5 mm diameter by 10 mm height) containing BMP-2 with MVF (80,000 
fragments/mL; n=3) or SVF (4 x 106 cells/mL; n=3). Collagen sponges without BMP-2 
were used as a negative control (n=3), and acellular sponges containing 2.5 µg BMP-2 
were used as a positive control (n=3). Constructs were loaded by pipetting 130 µL dropwise 
as in in vitro studies. All muscle defects were left untreated.  
Longitudinal bone volume was assessed using micro computed tomography (μCT) 
at 4, 8, and 12 weeks post-surgery. The defect region was scanned with a voxel size of 38.9 
µm, and bone volume was quantified by Scanco software using a threshold corresponding 
to 50% of intact cortical bone [42, 193]. Terminal mechanical testing was also performed 
at the 12 week end point. Femur ends were potted in Wood’s metal and tested in torsion at 
a rate of 3°/s to failure (ELF 3200, TA ElectroForce) [61]. Failure strength was calculated 
as the maximum torque at failure, and torsional stiffness was calculated as the linear region 
of torque vs. rotation. All animal experiments were performed in accordance with the 





3.2.8 Statistical Analysis 
Data was analyzed using GraphPad Prism 5 with α=0.05. BMP-2 release data from 
collagen sponge and collagen gel were analyzed using a repeated measures ANOVA (RM 
ANOVA). Gene expression data from collagen sponge and 2D TCPS were analyzed with 
a two-way ANOVA. In vivo bone volume, failure strength, and stiffness were analyzed 
with a one-way ANOVA. ANOVAs were followed with a Bonferroni post hoc test. BMP-
2 recovery from MVF+BMP vs. SVF+BMP in the 2D TCPS environment and flow 
cytometry data were analyzed with a Student’s t-test.  
 
3.3 Results 
3.3.1 Cellular Characterization 
MVF contain more endothelial cells (EC; CD31+αSMA-; p=0.019) than SVF, 
while SVF contain more stromal cell types: smooth muscle cells (SMC; CD31-αSMA +; 
p=0.0054), pericytes (CD31+αSMA+; p=0.0012), and mesenchymal stem cells (MSC; 
CD29+CD90+CD45-; p=0.0007) (Figure 3.1).  
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Figure 3.1. Flow cytometry characterization of MVF and SVF cellular 
subpopulations. MVF have a higher proportion of endothelial cells, while SVF have a 
higher proportion of stromal cells such as MSC, SMC, and pericytes. Student’s t-test, * 
p<0.05. 
 
3.3.2 Construct Viability 
Both MVF and SVF remained viable in the collagen sponge constructs co-loaded 
with BMP-2 for at least 14 days. However, in contrast with the typical sprouting 
angiogenesis observed when MVF are cultured in collagen gels, MVF appeared to 
dissociate to a single cell level by day 5 before reforming tubular structures around day 9. 
Single cell SVF formed tubular structures by day 9 (Figure 3.2).  
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Figure 3.2. Viability of MVF and SVF over time in culture within collagen sponge. 
Collagen sponge constructs supported viability of MVF and SVF to at least day 14 of 
culture (live – green; dead – red). However, MVF dissociated from multicellular structures 
to single cells by day 3.  
 
3.3.3 BMP-2 Release Kinetics 
Acellular, SVF-containing, and MVF-containing collagen sponges were loaded 
with 500 ng BMP-2 and cultured for 21 days. Media was collected at various time points, 
and the amount of BMP-2 in the media was quantified.  By day 21, 25-30% of loaded 
BMP-2 was recovered from acellular and SVF loaded collagen sponges, which is consistent 
with previously reported in vitro BMP-2 release from collagen sponge [194]. However, 
over 75% of loaded BMP-2 was recovered MVF-containing collagen sponges by day 21. 
Significantly more BMP-2 was recovered from MVF- containing than SVF- containing or 
acellular sponges from hour 6 through 21 days (n=3; Figure 3.3 A). This result was 
confirmed in three independent experiments. No detectable BMP-2 was recovered from 
MVF-containing collagen sponges without exogenous BMP-2, which was significantly 
different than all other groups at all time points beyond hour 0 (p<0.001).  
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Approximately 40% of loaded BMP-2 was recovered from both MVF-loaded and 
acellular collagen gels; significant differences did not exist between the two groups at any 
time point (n=3; Figure 3.3 B). 
Figure 3.3. In vitro BMP-2 recovery from collagen constructs. Cumulative BMP-2 
recovery from A) collagen sponge and B) collagen gel constructs. RM-ANOVA, 
n=3/group. * indicates MVF-loaded constructs are significantly different than SVF-loaded 
and acellular constructs from hour 6 through day 21, p<0.05. # indicates MVF-loaded 
constructs without exogenous BMP-2 are significantly different from all other groups at all 
time points beyond hour 0, p<0.001. 
 
3.3.4 Gene Expression 
We hypothesized that the increased BMP-2 recovery from MVF-containing 
sponges could be due to cellular production of BMP-2 or increased protease activity in 
MVF compared to SVF. Thus, expression of BMP-2, neovessel-specific MMP14 [195], 
and cathepsin K (CtsK) were measured for MVF cultured with BMP-2 (MVF+BMP), for 
MVF cultured without BMP-2 (MVF-BMP), for SVF cultured with BMP-2 (SVF+BMP), 
and for SVF cultured without BMP-2 (SVF-BMP).  
BMP-2 expression was significantly higher in MVF than SVF both with (Figure 
3.4; p<0.01) and without BMP-2 (p<0.05) at hour 3. At hour 3, MVF expression of BMP-
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2 was approximately 4.5-fold higher than its BMP-2 expression at hour 0 (i.e. immediately 
following harvest), while hour 3 SVF expression of BMP-2 was only approximately 1.5-
fold greater than that at hour 0. At hour 6, BMP-2 expression was significantly higher in 
MVF-BMP than in SVF-BMP (p<0.01). Hour 6 MVF expression of BMP-2 was 
approximately 1.5-fold higher than at hour 0, while SVF expression of BMP-2 was 
approximately equivalent to that at hour 0. By hour 24, there were no significant 
differences in BMP-2 expression between MVF and SVF. There was no significant effect 
of exogenous BMP-2 on BMP-2 gene expression at any time point, and there were no 
significant interaction effects. 
MVF+BMP expression of MMP14 was significantly higher than SVF+BMP 
expression at hour 24 (p<0.05). CtsK expression was significantly higher in MVF than 
SVF both with (p<0.01) and without BMP-2 (p<0.05) at hour 3, and CtsK expression was 
significantly higher in MVF+BMP than in SVF+BMP (p<0.05) at hour 6. MVF expression 
of MMP14 at hour 24 is the only time point at which expression of either protease by either 
MVF or SVF was elevated above that at hour 0. There was no significant effect of 
exogenous BMP-2 in the collagen sponge culture constructs on gene expression of either 




Figure 3.4. Gene expression of MVF and SVF in collagen sponge. MVF expression of 
BMP-2 and CtsK were significantly greater than that of SVF at hours 3 and 6. MVF 
expression of MMP14 was significantly greater than that of SVF at hour 24. 2-way 
ANOVA within time point; n=5/group/time point. * indicate post-hoc differences with 
p<0.05, ** p<0.01.   
 
3.3.5 BMP-2-Primed 2D Culture 
In a culture setup designed to mimic the MVF dissociation observed in collagen 
sponges, MVF were plated directly onto TCPS and allowed to dissociate to single cells 
(Figure 3.5 A). Dissociated MVF that were first primed with BMP-2 for 24 hours then 
released approximately 25 ng of BMP-2 into fresh culture media (e.g. no additional 
exogenous BMP-2 added) within the first 24 hours of culture and approximately 6 ng 
between hours 24 and hour 96 of culture (n=3; Figure 3.5 B). This was significantly more 
BMP-2 than was recovered from BMP-2 primed SVF plated on TCPS (p<0.001), which 
released approximately 2.5 ng BMP-2 within the first 24 hours and approximately 0.8 ng 
between hours 24 and 96. Non-primed cells, MVF and SVF, did not release any detectable 
BMP-2 into fresh media over the culture period.  
BMP-2 gene expression was also measured following exogenous BMP-2 priming. 
At 24 hours following the BMP-2 priming, MVF expression of BMP-2 was significantly 
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greater than that of SVF (overall effect, p<0.05; Figure 3.5 C). However, there was no 
difference in gene expression due to BMP-2 priming. There were no significant differences 
in BMP-2 gene expression at hour 96 following the BMP-2 priming period.  
 
 
Figure 3.5. BMP-2 recovery and gene expression from 2D TCPS culture system. A) 
MVF were cultured on TCPS to allow dissociation to single cells. B) Dissociated MVF 
primed with BMP-2 released significantly more BMP-2 into fresh media than BMP-2-
primed SVF (*** post hoc, p<0.001), while non-primed cells of either type did not release 
any detectable BMP-2. C) At 24 hours post BMP-2 priming, MVF had significantly greater 
BMP-2 expression than SVF (* overall effect, p<0.05), but there was no effect of BMP-2 
priming on BMP-2 expression of MVF or SVF.  
 
3.3.6 Pilot in vivo Study 
At the 12 week end point, bone volume was significantly higher in the BMP-2 and 
BMP-2+MVF groups than in the sponge only negative control (p<0.05; Figure 3.6 A). 
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BMP-2+SVF was not significantly different than the negative control. There were no 
statistically significant differences in failure strength or stiffness among treatment groups. 
However, the average of the BMP-2+MVF group approached those of historical bone-only 
injuries treated with BMP-2 [42], shown by the dashed blue line in Figure 3.6 B-C, whereas 
the BMP-2+SVF group more closely matched historical values for composite injuries 
treated with BMP-2 [42], shown by the dashed green line.  
 
Figure 3.6. Pilot bone regeneration in composite defects treated with collagen sponge. 
A) Bone Volume (1-way ANOVA, * indicates p<0.05), B) Failure strength defined as 
maximum torque at failure, C) Regenerate bone stiffness defined as the slope of the linear 




In this chapter, we aimed to develop a clinically translatable tissue engineering 
construct to deliver multicellular MVF or single cell SVF along with BMP-2 on collagen 
sponge. We found that MVF and SVF, while obtained from the same tissue source, are 
composed of different proportions of cellular subpopulations. Both MVF and SVF 
remained viable within the collagen sponge, but multicellular MVF dissociated to single 
cells within collagen sponge rather than the sprouting angiogenesis they exhibit in collagen 
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hydrogels. We observed that significantly more BMP-2 was recovered from constructs 
containing MVF than those containing SVF and subsequently hypothesized that MVF may 
have increased BMP-2 recovery from constructs due to production of BMP-2 or due to 
increased protease activity. In a pilot in vivo experiment, BMP-2+MVF treatment 
produced significantly greater bone volume than the collagen sponge only negative control, 
whereas there was no difference between the BMP-2+SVF treatment and the negative 
control.  
Although MVF and SVF were isolated from the same adipose tissue source, the 
different digestion times, 7 minutes for MVF and 30 minutes for SVF, and filtration sizes, 
multicellular MVF are between 50-500 µm while SVF are single cells smaller than 50 µm, 
result in different cellular subpopulations. MVF were composed of a higher proportion of 
endothelial cells, while more stromal cells such as MSC, SMC, and pericytes comprised 
SVF. During the digestion process, some perivascular cells may have been detached from 
their vascular structures. These cells would then have been filtered out of MVF but remain 
within SVF, increasing their relative abundance in SVF vs. MVF. Additionally, adipose 
tissue is a widely recognized source of MSCs [67, 196-198], and adipose-derived MSCs 
have been shown to occupy a perivascular niche [199]. Thus, they too may become 
detached from their vascular structures and removed during the digestion and filtration 
process to obtain MVF.  
When cultured within collagen sponge, both MVF and SVF remained viable for at 
least 14 days. However, MVF dissociated into single cells around day 3 of culture prior to 
reforming tubular networks by day 9-14. This is in contrast with the sprouting angiogenesis 
of MVF typically observed in collagen gels [107, 113]. The macroporous structure of 
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collagen sponge may have created asymmetric cell-matrix contacts (e.g. only one side of a 
vessel fragment may have been in contact with the matrix, while the opposite side was in 
direct contact with media) that destabilized the tubular structure of MVF. Since the cells 
that primarily comprise MVF are contact-dependent, cells may have dissociated from the 
vascular structure, migrated to bind extracellular matrix, and thus maintained viability.  
Approximately 25-30% of the loaded BMP-2 was recovered from acellular and SVF-
containing collagen sponges, which is consistent with previous results from acellular 
collagen sponge [194] and from other materials such as alginate hydrogels [200, 201]. In 
contrast, nearly 75% of the loaded quantity of BMP-2 was recovered from MVF-containing 
collagen sponges, suggesting that MVF uniquely modulate BMP-2 recovery. However, 
MVF-containing collagen gels did not show increased BMP-2 recovery compared to 
acellular collagen gels. MVF dissociated within collagen sponge but retained their tubular 
structure within collagen gel, suggesting that dissociation is a likely stimulus for the 
increased BMP-2 recovery phenomenon observed in collagen sponge. We hypothesized 
that dissociating MVF may exhibit elevated protease activity that frees BMP-2 bound to 
the collagen sponge and/or directly produce BMP-2. Interestingly, previous work has 
shown that vascular cells [202] such as endothelial cells, the primary cellular component 
of MVF, can produce BMP-2 in response to exogenous BMP-2 [98].  
Gene expression of MVF and SVF cultured in collagen sponges with or without 
BMP-2 showed that MVF expressed significantly higher levels of BMP-2 than SVF at 
hours 3-6. However, there were no differences in BMP-2 expression in MVF cultured with 
vs. without exogenous BMP-2. Since increased BMP-2 recovery was only observed in 
collagen sponges containing exogenous BMP-2, the gene expression data suggest that 
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cellular production of BMP-2 was not likely responsible for the increased BMP-2 recovery. 
Although there is post-transcriptional modification of BMP-2 [203], the magnitude of 
difference between gene expression levels and protein levels was much higher than would 
typically be attributed to post-transcriptional mechanisms. MVF also expressed 
significantly greater levels of proteases than SVF. MVF expressed higher levels of CtsK, 
the most prevalent mammalian collagenase [204], at hours 3 and 6, and higher levels of 
neovessel-specific MMP14 [195] at hour 24. However, again there were no differences due 
to presence of BMP-2. This combined with the fact that the fold changes in gene expression 
were all well below common thresholds (e.g. 2-fold) of biological significance suggest that 
these proteases were also not responsible for the increased BMP-2 recovery. 
To replicate the MVF dissociation observed in collagen sponges, we cultured MVF 
on TCPS, which forced their dissociation into single cells. Both MVF and SVF were 
cultured on TCPS with or without 500 ng BMP-2 for a 24 hour priming period. Following 
priming and three washes, significantly more BMP-2 was recovered from media from 
BMP-2-primed MVF than BMP-2-primed SVF. The approximately 1-2 ng of BMP-2 
recovered from BMP-2-primed SVF media may be residual BMP-2 bound to cells or the 
well plate and not removed by washes. However, an order of magnitude more BMP-2 was 
recovered from BMP-2-primed MVF. This provides additional support for the observation 
that dissociation of MVF is a key element of their augmented BMP-2 recovery. As in the 
collagen sponge, MVF had a higher overall expression of BMP-2 than SVF 24 hours after 
the BMP-2 priming period, but there was no effect of BMP-2 priming on BMP-2 gene 
expression. This further supports that MVF are not increasing BMP-2 recovery due to 
BMP-2 production. The recovery of significantly more BMP-2 from MVF in a 2D culture 
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setup without a large amount of extracellular matrix like the collagen sponge suggests that 
increased activity of proteases, even those not included in the gene expression analysis, 
was not responsible for the increased BMP-2 recovery.  
Overall, the dissociation of multicellular MVF in the presence of exogenous BMP-2 
led to increased recovery of BMP-2 in the surrounding media, both when cultured within 
collagen sponge and on TCPS. When exogenous BMP-2 was not present, dissociating 
MVF did not release any detectable BMP-2 into their media. While early gene expression 
of BMP-2 was elevated in MVF relative to SVF, there was no difference in BMP-2 gene 
expression in MVF cultured with vs. without BMP-2, suggesting that MVF dissociating in 
the presence of BMP-2 do not produce additional BMP-2. While there were statistically 
significant differences in MVF vs. SVF protease gene expression, there were again no 
differences due to the presence of BMP-2. This combined with replication of the 
augmented BMP-2 recovery on TCPS that lacks substantial extracellular matrix material 
to be degraded suggests that increased protease activity was not responsible for the 
increased BMP-2 recovery. Despite not elucidating the mechanism for augmented BMP-2 
recovery from MVF, the replication of this phenomenon in independent experiments and 
in different culture environments increases confidence that it is a consistent phenomenon.  
Multicellular MVF, which have more extensive native extracellular matrix, may bind 
exogenous BMP-2 and release it upon dissociation. This hypothesis could be tested in 
future work by using fluorophore-labeled BMP-2 and imaging to determine whether BMP-
2 colocalizes with labeled MVF.  
Finally, we implanted collagen sponges containing BMP-2 and MVF or SVF to a 
model of composite bone-muscle injury that exhibits attenuated bone healing [42] and 
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decreased revascularization following injury [43, 44]. Even in a pilot sized experiment, 
constructs containing BMP-2 only and BMP-2+MVF achieved significantly higher bone 
volume than the collagen sponge only negative control; the BMP-2+SVF group was not 
statistically different than the negative control. Although there were no statistically 
significant differences in mechanical properties among any treatment groups, the average 
torque to failure and stiffness were greatest in the BMP-2+MVF group. Additionally, the 
mechanical properties of the BMP-2+MVF group approached those of historical values for 
bone-only injuries [42]. This promising result suggests that co-delivery of MVF and BMP-
2 may be able to overcome the bone healing deficit observed in composite bone-muscle 
injuries, perhaps through a combination of increasing vascularization and by increasing the 
availability of BMP-2. 
 
3.5 Conclusions 
Dissociation of multicellular MVF in the presence of exogenous BMP-2 consistently 
led to increased recovery of BMP-2 in the surrounding media. Although our hypotheses 
that this could be due to MVF production of BMP-2 or increased protease activity in MVF 
were not supported, increased recovery of BMP-2 was consistently observed across 
different culture environments. MVF may bind exogenous BMP-2 and release it upon 
dissociation. In a pilot sized in vivo experiment, BMP-2 and BMP-2+MVF produced 
significantly greater bone volume than the collagen sponge only negative control, while 
BMP-2+SVF was not statistically different than the negative control. Although not 
statistically significant, the mechanical properties of the BMP-2+MVF approached 
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historical data for those of bone-only injuries. Thus, the co-delivery of BMP-2 and MVF 
on collagen sponge in vivo is a promising approach that may improve bone healing, 
possibly overcoming the attenuation in bone healing observed in composite defects, by 





CHAPTER 4. EFFECTS OF BMP-2 DOSE AND DELIVERY OF 
MICROVASCULAR FRAGMENTS ON HEALING OF BONE 
DEFECTS WITH CONCOMITANT VOLUMETRIC MUSCLE 
LOSS 2 
4.1 Introduction 
Composite tissue injuries present a compelling clinical challenge to both military and 
civilian trauma populations. Of the six million fractures that occur in the U. S. each year, 
approximately 10% are open fractures, which are characterized by concomitant soft tissue 
damage. These injuries experience a complication rate about twice that of closed fractures, 
with complications including infection, malunion, and non-union [35]. As a result, open 
fractures are often subject to multiple treatment strategies, repeated surgeries, and high 
direct and indirect costs [188]. Despite these multiple interventions, nearly two-thirds of 
patients remain significantly disabled long term (at seven years post-injury, and likely 
beyond) [51].  
One treatment strategy often employed in challenging bone healing scenarios is the 
delivery of bone morphogenetic protein-2 (BMP-2) on a collagen sponge.  While most 
commonly used in cases of spinal fusion [69], BMP-2 has demonstrated clinical success in 
long bone fracture cases for over 15 years [70]. However, BMP-2 has also been linked to 
                                                 
2 Adapted from M.A. Ruehle, et al. Effects of BMP-2 dose and delivery of microvascular 
fragments on healing of bone defects with concomitant volumetric muscle loss, Journal of 
orthopaedic research, 2019. 37(3): p. 553-561. Reproduced with permission: license 
number 4541971103840.  
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side effects such heterotopic bone formation and inflammation [73], both of which can be 
exacerbated by orthopaedic trauma [205]. Segmental bone defect healing is known to 
exhibit a dose response to BMP-2 [193]; however, a minimally bridging dose for a 
segmental bone defect was unable to consistently bridge same-sized bone defects in a 
composite bone and muscle defect model [42]. Thus, the effect of BMP-2 dose is of 
particular interest in traumatic composite defects.  
The Gustilo classification system scores open fractures from class I-IIIC in terms of 
increasing severity. Assignment to broad classes I-III is determined by increasing size of 
soft tissue loss, but the hallmark of the most severe category IIIC is vascular damage – 
regardless of the degree of soft tissue damage [38]. The revascularization process is a rate-
limiting step of the wound healing [10] and plays a crucial role in the clinical success of 
treatments for open fractures. Further, it is well established that angiogenesis and 
osteogenesis are linked [16] and that impaired revascularization impairs fracture healing in 
pre-clinical animal models [15]. Numerous therapeutic strategies targeting 
revascularization of bone have been employed, largely pre-clinically, including growth 
factor and cell delivery [92, 100, 103]. 
One promising approach is the use of microvascular fragments (MVF), multicellular 
segments of mature vasculature that form angiogenic networks in vitro [107]. Due to their 
pre-patterned tubular structure and retention of vascular support cells, MVF are attractive 
candidates for tissue engineering applications [206]. MVF have been shown to inosculate 
with host vasculature [195, 207], increase tissue vascular volume [116, 195] and improve 
tissue grafting in pre-clinical models [118, 119]. MVF are most commonly obtained from 
adipose tissue and therefore have potential clinical utility in an autologous application.   
 53 
We have previously developed a pre-clinical small animal model of composite bone-
muscle injury consisting of a critical size femoral defect with an overlying volumetric 
muscle loss [42]. Our model recapitulates the clinical observation of impaired bone healing 
when concomitant soft tissue injury is present, and this has also been seen in similar pre-
clinical models of composite tissue injury [40-42, 208]. In this study, we tested the 
hypotheses that BMP-2-mediated functional regeneration of composite extremity injuries 
is dose dependent and can be further enhanced via co-delivery of adipose-derived 
microvascular fragments (MVF), which have been previously shown to increase tissue 
vascular volume.   
 
4.2 Methods 
4.2.1 MVF Isolation and Construct Preparation 
MVF were isolated as previously described [107]. Briefly, epididymal fat pads were 
harvested from two retired breeder Lewis rats to yield approximately 10-12 mL fat tissue. 
Fat was minced, and digested with a collagenase solution for 7 minutes at 37 °C. MVF 
were obtained through selective filtration to retain tissue between 50-500 µm. To prepare 
surgical constructs, MVF were suspended at a density of 80,000 MVF/mL in αMEM 
(ThermoFisher Scientific; Waltham, MA) along with BMP-2 (Pfizer, Inc.; New York, NY) 
and pipetted dropwise onto collagen sponges (5 mm diameter, 1 cm height; Kensey 
Nash/DSM; Exton, PA).  
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Viability of constructs cultured in αMEM with 10% fetal bovine serum (FBS; 
Atlanta Biologics; Atlanta, GA) and 1% penicillin-streptomycin-L-glutamine 
(ThermoFisher) was evaluated using a live/dead assay kit according to manufacturer’s 
instructions (ThermoFisher). Cylindrical constructs were cut in half lengthwise to expose 
the center of the sponge immediately prior to imaging. Three constructs were imaged per 
time point at days 1, 3, 7, 9, and 14 of culture. Viability was quantified using the ImageJ 
3D objects counter to compare the number of objects in the red channel of the image vs. 
the green channel.  
 
4.2.2 Surgical Procedure 
Unilateral composite defects were made in 13-week-old female Lewis rats (Charles 
River Laboratories; Wilmington, MA) by creating an internally stabilized 8 mm defect in 
the mid-diaphysis of the femur with an overlying 8 mm diameter full-thickness quadriceps 
defect as previously described [42]. Collagen sponges (5 mm diameter, 1 cm height) loaded 
with BMP-2 ± MVF were press fit into the defect. Sponges contained 2.5 µg BMP-2 
without MVF (n=8 animals), 2.5 µg BMP-2 with MVF (n=8), 10 µg BMP-2 without MVF 
(n=9), or 10 µg BMP-2 with MVF (n=10). Animal number was determined from previous 
studies of segmental bone defect healing, and animals were randomly assigned to treatment 
groups. Animals were double-housed, maintained on a 12-hour light/dark cycle, and 
allowed ad libitum access to food and water. At 12 weeks post-surgery, animals were 
euthanized by CO2 inhalation. All animal experiments were performed in accordance with 
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the Georgia Institute of Technology Institutional Animal Care and Use Committee 
(IACUC).  
 
4.2.3 Bone Regeneration Analyses 
Bone healing was qualitatively assessed by radiography at 2, 4, 8, and 12 weeks 
post-surgery and quantitatively assessed by micro-computed tomography (µCT) at 4, 8, 
and 12 weeks post-surgery. The defect region was scanned with a voxel size of 38.9 µm. 
The middle 6.5 mm of the defect was analyzed, and bone volume was quantified by Scanco 
software using a threshold corresponding to 50% of intact cortical bone [42, 193]. Polar 
moment of inertia was calculated for each µCT slice as a measure of the distribution of 
bone relative to the central axis using a Scanco evaluation script [209]. An average of all 
slices’ polar moment of inertia was calculated to determine a global value for each sample 
[194].  
Mechanical testing and histology were performed at the 12 week endpoint after 
euthanasia. Thighs were harvested, soft tissue was cleared, and fixation plates were 
removed. Femur ends were potted in Wood’s metal (Alfa Aesar) and tested in torsion at a 
rate of 3°/s to failure (ELF 3200, TA ElectroForce) [61]. Maximum torque (torque at 
failure) and torsional stiffness (linear region of torque vs. rotation) were calculated for all 
samples.  
Following mechanical testing, one sample from each group was fixed in 10% 
neutral buffered formalin (NBF) for 24 hours and decalcified in a formic citrate solution 
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(Newcomer Supply, Inc; Middleton, WI). Bone and muscle tissues were embedded in 
paraffin and sectioned at a thickness of 5 µm.  Bone tissue was stained with hematoxylin 
and eosin (H&E); muscle tissue was stained with H&E and with Masson’s Trichrome to 
observe fibrosis (Histotox Labs; Boulder, CO). Bone sections were also stained with 
rhodamine-labeled Griffonia simplicifolia lectin I (GS-1 lectin; Vector Laboratories; 
Burlingame, CA) at a concentration of 10 µg/mL and counterstained with DAPI 
(ThermoFisher) diluted 1:1000 in phosphate buffered saline to identify blood vessels. 
 
4.2.4 Serum Cytokine Quantification 
At the week 12 endpoint, blood was collected via the rat tail vein from a subset of 
animals from each treatment group (n=5/group). Serum was collected from whole blood 
for multiplexed analyte analysis for 27 inflammatory cytokines and chemokines. Samples 
were prepared using a multiplexed rat cytokine/chemokine magnetic bead panel 
(MILLIPLEX RECYTMAG-65K), according to manufacturer’s instructions. Data was 
collected using a MAGPIX multiplexing system (Luminex Corporation; Austin, TX).  
 
4.2.5 Statistical Analysis  
Data were analyzed using GraphPad Prism 7 and are represented as mean ± standard 
error of the mean (SEM). Bone volume, maximum torque, torsional stiffness, and cytokine 
levels were analyzed by two-way analysis of variance (ANOVA) and Bonferroni post-hoc 




4.3.1 Construct Viability 
MVF cultured in BMP-2 loaded collagen sponges maintained viability in vitro 
throughout the three-dimensional construct (Figure 4.1). However, multicellular MVF 
appeared to dissociate to single cells by day 3 of culture and reform networks by day 9-14. 
Approximately 65% of the cells were viable at day 3; over 90% of cells were viable at days 
7-14.  
 
Figure 4.1. MVF Viability in Collagen Sponge. Representative images of MVF cultured 
in collagen sponge with BMP-2 at days 1, 3, 7, 9, 14. Images were acquired from the center 
(longitudinal cross section) of the 5 mm diameter sponge. Green, calcein – live, red, 
ethidium homodimer – dead. MVF dissociated to single cells by day 3 and reformed 
networks around day 9-14. 
 
4.3.2 Bone Regeneration 
4.3.2.1 Radiography and µCT 
Radiographs demonstrated that a majority of defects bridged in all four treatment 
groups (Figure 4.2). By 12 weeks, all defects treated with 10 µg BMP-2, with and without 
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MVF, had bridged (nine of nine and ten of ten, respectively). Seven of eight defects treated 
with 2.5 µg BMP-2 without MVF bridged, and five of eight defects treated with 2.5 µg 
BMP-2 with MVF bridged. Bone volume in the defect region was measured by µCT and 
was significantly higher in the 10 µg dose groups than in the 2.5 µg dose groups (Figure 
4.3 A; overall effect, p=0.0312). There was no effect of the MVF treatment on bone volume 
and no significant interaction. The polar moment of inertia was also calculated as a measure 
of the distribution of bone relative to the central axis. pMOI was significantly lower in the 
2.5 µg dose groups (Figure 3B; overall effect, p=0.0047). This corresponds to the more 
compact morphology observed in the radiographs (Figure 4.2) and µCT reconstructions of 
the 2.5 µg dose groups (Figure 4.3 C). Bone density was approximately 870 mm 
hydroxyapatite/cm3 for all four groups.  
Figure 4.2. Representative relatively well healed and poorly healed 12-week 
radiographs of defects treated with BMP ± MVF in collagen sponge. Well healing 
samples are shown on top, and poorly healed samples are shown on bottom. Bridging rate 




Figure 4.3. 12-week bone volume data for defects treated with BMP ± MVF in 
collagen sponge. A) Bone volume and B) polar moment of inertia of defects as measured 
by µCT. C) Representative µCT reconstructions of defects from each treatment group that 
exhibited similar bone volume (~35-40 mm3) but different morphologies. * overall effect 
of BMP dose, p<0.05; # post-hoc p<0.03; 2-way ANOVA; n=8-10/group.  
 
 
4.3.2.2  Mechanics 
The torque to failure was significantly higher for the 10 µg dose BMP-2 groups 
than the 2.5 µg dose groups (Figure 4.4; post hoc, p<0.001). There was no effect of MVF 
and no significant interaction. Despite the increased strength of the 10 µg BMP-2 
treatment, the 10 µg dose without MVF group still only achieved 60.5% of intact strength.  
Stiffness was also significantly higher in the 10 µg dose groups than in the 2.5 µg dose 
groups (overall effect, p=0.0005), and stiffness was significantly decreased in groups with 
MVF compared to without MVF (overall effect, p=0.0098).  
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Figure 4.4. Mechanical properties of defects treated with BMP ± MVF in collagen 
sponge. Failure strength and B) stiffness of bone regenerated at 12 weeks. Dashed red line 
indicates failure strength of intact contralateral femur. # post-hoc differences due to BMP 




Qualitative histological assessment of bone defects supported the quantitative µCT 
data. The 10 µg dose without MVF group showed the greatest amount of bone organized 
in apparent lamellae, and both groups that received MVF showed larger areas of non-
mineralized, marrow-like tissue (Figure 4.5). There were no qualitative differences in 
relative number of lectin-stained blood vessel structures among treatment groups at the 12 
week time point (Figure 4.6). As expected, the untreated muscle defects did not heal over 
the course of this study. At the 12 week end point, muscle exhibited a large degree of 
fibrosis and fatty infiltration (Figure 4.7). No qualitative differences in muscle healing were 
apparent between the well healing 10 µg BMP-2 without MVF and poorly healing 2.5 µg 
BMP-2 with MVF groups.  
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Figure 4.5. Hematoxylin and eosin staining of bone tissue regenerated by 12 weeks in 
defects treated with BMP ± MVF in collagen sponge. The 10 µg without MVF group 
appears the most organized into apparent lamellae, while the other groups are less 
organized and contain larger areas of non-mineralized, marrow-like tissue (Ma) within the 
mineralized bone (B). 
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Figure 4.6. GS-1 lectin staining for blood vessels within regenerate bone at 12 weeks 
from defects treated with BMP ± MVF in collagen sponge. Dashed line demarcates 
mineralized bone (B) vs. marrow-like tissue (Ma). White arrows indicate blood vessels 
within mineralized tissue. Red, GS-1 lectin – vessel glycocalyx; blue, DAPI – nuclei. 
 
Figure 4.7. H&E and Masson’s trichrome staining of muscle tissue from treatment 
groups with well healed bone and poorly healed bone alongside uninjured 
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contralateral muscle tissue. Well healed samples are from the 10 μg - MVF group, and 
poorly healed samples are from the 2.5 μg + MVF group. Masson’s: red – muscle fibers, 
blue – fibrotic tissue. Muscle fibers (Mu), fibrotic tissue (F), and adipose infiltration (A) 
are denoted.  
 
4.3.3 Serum Cytokine Quantification  
Blood was collected at the 12 week end point to quantify systemic levels of 
circulating inflammatory cytokines (n=5/group). Levels of multiple interleukins (IL) were 
significantly decreased in blood samples taken from animals treated with the increased 10 
µg BMP-2 dose groups, both with and without MVF (Figure 4.8). Both pro-inflammatory 
interleukins, such as IL-1a and IL-1b, and anti-inflammatory interleukins, such as IL-5, IL-
10, and IL-13, [210] were decreased in the 10 µg BMP-2 dose groups. Pro-inflammatory 
eotaxin was also lower (p=0.0507) in the 10 µg BMP dose groups. 
 
Figure 4.8. Relative serum levels of pro- and anti-inflammatory cytokines by 
treatment group as measured by multiplexed analyte analysis. Pro-inflammatory 
cytokines on top and anti-inflammatory cytokines on bottom. * post-hoc differences due to 




Composite tissue extremity injuries represent a significant challenge to orthopaedic 
surgeons and a momentous hardship for patients. Vascularization is an enabling step of 
wound healing, and we hypothesized that BMP-2-mediated functional regeneration of 
composite extremity injuries would be dose dependent and could be further enhanced via 
co-delivery of adipose-derived microvascular fragments (MVF), which have been 
previously shown to increase tissue vascular volume.   
BMP-2 is clinically approved for a number of bone healing indications and has 
shown success in treating long bone fractures and non-unions [70, 211]. There is a BMP-2 
dose response in humans and in pre-clinical animal models, but precise dosing required for 
specific human applications is not well defined [193, 211]. High BMP-2 dosage has been 
linked a number of side effects including heterotopic ossification (HO) and increased 
inflammation [73], and HO is also often increased in cases of trauma [212-214]. While a 
2.5 µg dose of BMP-2 is a bridging dose in a segmental defect model [193], it produces 
inconsistent bridging in this challenging composite defect model [42]. In this segmental 
defect model, HO has been observed at 30 µg doses of BMP-2 [194, 200]. We showed in 
the present study that a 10 µg dose is sufficient to improve composite defect healing relative 
to the 2.5 µg dose and does not lead to mineralization outside the collagen sponge delivery 
vehicle. A moderately increased dose (e.g. 10 µg relative to 2.5 µg or 30 µg) may be 
required in composite injuries to compensate for the loss of endogenous stem and 
progenitor cells and growth factor availability as a result of the concomitant muscle loss. 
When scaled by body surface area (assuming a 60 kg human relative to a 0.25 kg rat), a 2.5 
µg rat dose would be equivalent to 0.114 mg in humans, and a 10 µg dose would be 
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equivalent to 0.454 mg [215]. This is lower than the current FDA approved dose of BMP-
2 for tibial fractures of 12 mg [70]. However, there is known species variation for BMP-2 
dose specifically, with sheep requiring higher doses than rodents and non-human primates 
requiring higher doses still [216]. Together, these studies demonstrate the need for precise 
identification of the appropriate clinical dosing window of BMP-2. While muscle loss 
constitutes an increased level of trauma, this model does not incorporate head trauma or 
muscle crush, which are known contributors to human post traumatic HO [213, 214]. 
Traumatically injured muscle can give rise to osteogenic progenitor cells [214], but it is 
unknown whether a similar effect would be present in this model which cleanly removes a 
volumetric section of muscle with a biopsy punch. While large volume muscle loss has 
been shown to have a more profound impact on bone healing than muscle crush injuries 
[217], the VML model utilized here may not fully recapitulate the HO risk associated with 
trauma of clinical open fractures that often also have significant muscle damage. Future 
work may be warranted to investigate more aggressive debridement of damaged muscle 
adjacent to bone injuries as prophylaxis for HO, though this could potentially lead to 
reduced functional outcomes.  
Local healing at the site of a regenerative intervention, as well as HO, are both 
thought to be influenced by the systemic immune response. Interestingly, the 10 µg BMP 
dose resulted in lower levels of both pro- and anti-inflammatory systemic cytokines relative 
to the 2.5 µg dose at the 12-week time point. The 2.5 µg dose group’s failure to completely 
heal may have prolonged the inflammatory stage of the wound healing process, which 
previous studies have shown to be increased in composite tissue injuries [40]. That 
persistent local inflammation may then have resulted in altered systemic immune cytokine 
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profiles. Rather than a high BMP dose inducing inflammation, the successful bridging and 
restoration of function may have resolved the local inflammation and led to lower cytokine 
levels by the 12 week time point.  Future studies investigating inflammatory profiles at 
earlier time points would be required to more definitively address the composite injury’s 
inflammatory response to various BMP doses.  
MVF were used as a proposed therapeutic approach to enhance revascularization and 
subsequently bone regeneration; however, the MVF treatment did not improve bone 
volume or failure strength and in fact decreased the stiffness of the regenerated bone. 
Although MVF treatment had no significant effect on bone volume, the mineralization 
pattern of the regenerated bone appeared more fragmented in MVF-treated defects as 
observed with µCT. The fragmented mineralization of MVF-treated groups may have 
contributed to the differences in mechanical properties. MVF have been shown to improve 
tissue vascularization and integration; however, this has been primarily demonstrated in 
subcutaneous implantation [195], skin flaps [218], and dermal substitutes [118, 119], all of 
which are considerably thinner and thus closer to native vascular sources than the critical 
size bone defect used here. MVF have also been shown to increase tissue perfusion in VML 
models when delivered in collagen gel [116, 117], which allows for sprouting angiogenesis 
[107, 110, 116, 219]. In this study, while in vitro viability of MVF was maintained in 
collagen sponge, the multicellular MVF first dissociated to single cells and then reformed 
networks. This is not consistent with the sprouting angiogenesis typically observed within 
a collagen gel and may have contributed to the lack of effect of MVF on bone healing. 
While collagen sponge is a clinically available BMP-2 delivery vehicle, it may not be an 
optimal delivery vehicle for MVF, which are exquisitely sensitive to extracellular matrix 
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properties [110, 112]. Further, MVF exert traction forces on their matrices and can contract 
collagen hydrogels [107, 113, 219]; cell-mediated contraction of collagen sponge may have 
contributed to the more fragmented mineralization observed in the MVF-treated defects 
(Fig 3C). 
Beyond the vascular components of adipose-derived MVF, these structures also 
contain mesenchymal stem cells (MSCs) [119, 220]. Exogenously delivered adipose-
derived MSCs have previously been shown to negatively affect mineralization when co-
delivered with BMP-2 [67]. While BMP-2 upregulates osteogenic signaling of bone 
marrow-derived MSCs, adipose-derived MSCs may differentially interact with BMP-2 to 
dampen or alter its signaling to endogenous host cells. However, adipose-derived MVF 
contain only about 2%-7% MSCs [108, 119], so their relative contribution may be 
proportionally small. Retention of other adipose-derived cells may have contributed to the 
larger marrow spaces histologically observed in MVF-treated defects (Figure 4.5), and 
adipose-derived MVF may not be suitable for bone defect applications.  
Delivery of MVF also did not result in qualitative differences in lectin-stained blood 
vessel structures at 12 weeks. Cell implantation strategies broadly are challenged by issues 
of viability and retention [68, 106, 221]. Although vascularization is hypothesized to 
improve viability by enabling nutrient and oxygen transport, the implanted MVF may have 
failed to survive long enough to inosculate with the host vasculature – particularly due to 
their dissociation within the collagen sponge. Future studies to assess MVF retention, 





This is the first investigation of BMP-2 dose in a composite defect model. While the 
delivery of MVF did not improve bone healing in the composite defect model, an increased 
dose of 10 µg BMP-2 significantly improved bone healing and regenerate bone mechanics 
relative to a 2.5 µg dose. While 2.5 µg BMP-2 restored bone failure strength to only 20% 
of intact strength, a 10 µg BMP dose restored failure strength to 60% of intact. This 
improvement may represent significant functional improvements but also underscores the 
challenging nature of healing composite tissue injuries. Collagen sponge is a clinically 
approved, and therefore translationally relevant, BMP-2 delivery vehicle but may not be 
an appropriate MVF delivery vehicle. A modest increase in BMP-2 dosage may be a 
clinically relevant treatment strategy for critical size bone defects with concomitant muscle 
damage while a biomaterial delivery system for co-delivery of MVF is developed. 
Approaches that enhance early vascularization may be required to restore regenerated bone 
to greater than 60% of intact strength in cases of composite bone and muscle traumatic 
injury, and development of a more suitable biomaterial delivery vehicle may enable 




CHAPTER 5.  DEVELOPMENT OF DECORIN-
SUPPLEMENTED COLLAGEN HYDROGELS AS 
DIMENSIONALLY STABLE SCAFFOLDS 3 
5.1 Introduction  
  Vascular growth and remodeling are processes that are highly sensitive to 
mechanical cues; however, much of the existing research in this field has focused on 
luminal mechanics related to fluid flow (i.e. fluid shear and cyclic stretch) rather than 
abluminal stimulation of the vessel network itself [222]. Abluminal forces are particularly 
relevant to load-bearing tissues such as bone, and it is well established that angiogenesis 
and osteogenesis are intimately linked in both development and healing [11, 88]. 
Additionally, previous work in vivo showed that functional loading has a potent time-
dependent influence on vascular growth during segmental bone defect healing; early 
loading impaired vessel growth, whereas delayed loading enhanced vascular growth [136]. 
Well-controlled in vitro studies are needed to better understand the mechanical cues 
associated with vascular growth and inhibition. 
 Microvascular fragments (MVF) are multicellular segments of vasculature that can 
sprout and form networks in vitro [107]. In combination with an appropriate 3D substrate, 
MVFs allow for interactions between multiple cell types and between cells and their 
                                                 
3 Adapted from Ruehle, M.A., et al., Decorin-containing collagen hydrogels as 
dimensionally stable scaffolds to study the effects of compressive mechanical loading on 
angiogenesis. MRS Communications, 2017. 7(3): p. 466-471. Reproduced with 
permission: license number 4510920697725. 
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matrix, thereby better representing the complex in vivo processes of angiogenesis than 
models utilizing single cells or 2D substrates. Previous work utilizing MVF constructs has 
shown that they are sensitive to chemical cues, extracellular matrix (ECM) mechanical 
properties, and tensile forces [111-113]; however, they have yet to be studied under 
compressive forces. MVF are typically cultured in three dimensions within type I collagen 
gels, which contract significantly over time in culture [107, 113]. Gel contraction prevents 
longitudinal analysis of cultures, which is a serious limitation for studies aiming to 
investigate time-dependent effects. Thus, to study the role of a compressive mechanical 
environment on MVF growth over time in vitro, there is a need for a material substrate that 
both supports MVF growth and has greater dimensional stability than a low percentage 
collagen gel.  
Although increasing the percentage of collagen within the gel increases structural 
stability, MVF growth is hindered at high collagen densities [113]. Crosslinking methods 
exist to chemically link the collagen fibrils rather than relying on physical interactions; 
however, unreacted crosslinking reagents can be cytotoxic and are therefore not amenable 
to cell encapsulation prior to crosslinking [223]. While synthetic materials offer advantages 
of tunability and batch-to-batch consistency, both scaffold development and MVF culture 
would require optimization, whereas MVF growth in collagen is quite well characterized. 
Thus, this research focused on techniques to modify the mechanical properties of collagen 
hydrogel constructs. 
Decorin (DCN) is a small leucine-rich proteoglycan (SLRP) expressed in 
connective tissue that modulates collagen fibrillogenesis and alters the mechanical 
properties of collagen hydrogels [224-228]. A previous in vitro study demonstrated that 
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addition of DCN during collagen fibrillogenesis led to a denser fibril network with a higher 
tensile modulus [228]. Our objective here was to investigate the ability of DCN-
supplemented collagen hydrogels to 1) support microvascular growth, 2) maintain 
dimensional stability throughout at least 14 days in culture, and 3) withstand physiologic 
compressive loads.  
 
5.2 Materials and Methods 
5.2.1 Decorin Purification 
Methods for decorin purification were based on published protocols [228, 229].  
Bovine knee ligament samples were frozen in liquid nitrogen and pulverized. The powder 
was suspended in an extraction solution [229] at 4 °C overnight before centrifugation at 
20,000 g for 2 hours. The resulting supernatant was then sequentially filtered through a 1.1 
μm glass fiber filter and a 0.45 μm regenerated cellulose filter. The filtrate was subjected 
to anion exchange chromatography over a POROS PI column at 4 °C. GAG-containing 
fractions were identified by dimethylmethylene blue (DMB) assay, pooled, concentrated 
via ultrafiltration, and purified by gel chromatography with a sepharose CL-4B column. 
GAG-containing fractions were pooled as above, and DCN-containing fractions were 
identified by SDS-PAGE [225] before ultrafiltration and buffer exchange. Hydrophobic 
chromatography was performed on the DCN fractions using an octyl-sepharose column at 
25 °C. DCN-containing fractions were monitored and concentrated as above before buffer 
exchange into phosphate buffered saline (PBS) using PD-10 desalting columns. The 
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solution was sterilized by filtration. DCN purity was confirmed with SDS-Page [225], and 
concentration was determined by DMB assay.  
 
5.2.2 Gel Formation and Characterization 
 Collagen gels were created from rat-tail type I collagen (Corning Life Sciences, 
Corning, NY). Collagen solutions, 3 mg/mL or 6 mg/mL with or without 50 µg/mL DCN, 
were buffered with 1X Dulbecco’s modified eagle medium (DMEM) and mixed on ice. 
Gels were formed at 37 °C unless otherwise stated.  
For turbidity measurements, which assess collagen fibrillogenesis kinetics, 100 µL 
of ice cold collagen solution was pipetted into a 96-well plate (n=5-6/group). Absorbance 
readings at 405 nm were made every minute for 60 minutes at room temperature [228]. 
Acellular gels were imaged using second harmonic generation (SHG) for qualitative 
comparison of collagen fibrils using a Zeiss LSM 710 confocal microscope (800 nm 
excitation).  
To evaluate gel mechanical properties, acellular gels were tested in unconfined 
compression using a Bose ELF 3100 system with a 25 g load cell (Bose, Framingham, MA; 
Transducer Techniques, Temecula, CA). Gels were formed in a custom mold (8 mm 
diameter x 5.7 mm height) and incubated in PBS at 37 °C overnight prior to testing; gels 
were submerged in PBS in an acrylic chamber during testing at room temperature. Gels 
were preconditioned with 10 cycles of a triangle waveform varying from 0 to 10% strain 
at 0.05 Hz; testing was then performed using a monotonic ramp to 30% strain at 0.02 mm/s. 
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Gels were held at 30% strain for 150 s to allow stress relaxation. Peak stress was 
determined by averaging the stress during the last one second of the strain ramp. The 
equilibrium modulus was calculated after stress relaxation by averaging the last ten seconds 
of the 150 s hold time at 30% strain. The linear modulus was defined as the slope of a linear 
regression fit to the linear region (10%-30%) of the applied strain ramp; all linear fits had 
a correlation coefficient ≥ 0.9.  
 
5.2.3 Microvascular Fragment Culture and Analysis 
 MVF were isolated as previously described [110]. Briefly, adipose tissue was 
harvested from epididymal fat pads of Lewis rats, minced, and partially digested with a 
collagenase solution. Selective filtration was then used to remove tissue larger than 500 
µm and single cells smaller than 20 µm. MVF were suspended at 20,000 fragments/mL of 
gel and cultured in rhVEGF-supplemented serum-free media [112].  
 Quantification of vessel growth was done on day 9 of culture. MVF-containing gels 
were fixed with 4% paraformaldehyde, and rhodamine labeled Griffonia simplicifolia (GS-
1) lectin (Vector Laboratories, Burlingame, CA) was used to stain vessel structures for 
quantification. GS1-lectin-stained MVF networks were imaged using a Zeiss LSM 700 
confocal microscope. Five randomly selected fields were imaged at 10x to a depth of 402 
µm for each gel, and 7-8 gels were imaged per group. Maximum intensity z-projections 
were created for each stack, thresholded, and skeletonized in ImageJ to determine branch 
number and total length. Gel contraction was determined by quantification of gel area 
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(ImageJ) from photographs (Gel Doc XR, Bio-Rad, Hercules, CA) of well plates over time 
in culture.  
 
5.2.4 Statistics   
 All experiments were performed with n≥5, and results are presented as mean ± 
SEM. All analyses were performed as a two-way ANOVA with α level of 0.05 and 
Bonferonni post hoc tests. GraphPad Prism 5 was used for all statistical analyses. 
 
5.3 Results 
5.3.1 Collagen Fibillogenesis 
The addition of DCN to both 3% and 6% collagen solutions led to a lower ultimate 
turbidity (p<0.001 for 3%, p<0.01 for 6%). DCN did not affect the lag time, the initial 
phase of fibrillogenesis during which nucleation sites form and turbidity is low, in 3% 
collagen. However, in 6% collagen, DCN shortened the lag time (p<0.05), allowing for an 
earlier onset of fibrillogenesis. The rate of fibrillogenesis as evidenced by the slope of the 
turbidity curve growth phase was not significantly affected by DCN in either group (Figure 
5.1). There were overall effects of collagen percentage on both ultimate turbidity 
(p<0.0001) and rate of fibrillogenesis (p<0.0001), with higher collagen density increasing 




Figure 5.1. Collagen Density and DCN affect Collagen Fibrillogenesis. Turbidity 
curves for 3% and 6% collagen ± 50 μg/mL DCN (n = 5–6/group). 
 
 
Qualitatively, in both 3% and 6% gels, the addition of DCN during polymerization 
of the collagen gels appeared to cause a more spatially uniform but diffuse organization of 
collagen fibrils with fewer short, wide bundles. Both 6% gels appeared denser than either 
3% gel (Figure 5.2). 
 
 
Figure 5.2. Collagen Fibril Structure ± DCN. Representative single-plane 60× SHG 
images of (a) 3% collagen without DCN, (b) 3% + DCN, (c) 6% − DCN, and (d) 6% + 





5.3.2 Compressive Properties of Collagen Hydrogels  
 Both collagen density (p<0.0001) and DCN (p<0.0001) increased the peak stress 
experienced at 30% strain. There was also a significant, ordinal interaction effect 
(p=0.0004); the effect of DCN was greater in 6% than in 3% collagen (Fig. 3A). The 
equilibrium modulus was significantly higher in 6% vs. 3% collagen (p<0.001) but was not 
affected by DCN (p=0.125) (Fig. 3B). The linear modulus was also increased by increasing 
collagen density (p<0.0001), and DCN increased the linear modulus of 6% gels (p<0.01). 
The linear modulus of 3% gels was not affected by DCN, and there was no significant 
interaction (Figure 5.3).  
Figure 5.3. Compressive Properties of Collagen Gels ± DCN. Gel compression testing 
results showing (a) peak stress experienced at 30% load, (b) equilibrium stress level under 
maintained 30% strain, and (c) linear modulus (n = 5/group). *Indicates significant 
differences between 3% and 6% gels (2-way ANOVA, P < 0.0001). # Indicates significant 
differences between ±DCN (P < 0.01 for 6%; P < 0.05 for 3%). 
 
 
5.3.3 Microvascular Growth  
 MVF cultured in 3% collagen gel resulted in significantly greater total network 
length (p<0.0001) and number of branches (p<0.0001) than those cultured in 6% gel. There 
was no significant effect of DCN on MVF growth, and there was no significant interaction. 
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Qualitative observations of the cultures showed that the 3% gels had more multidirectional 
branch-points (arrows, Figure 5.4 A-D) while 6% gels promoted bidirectional growth from 
the two fragment ends. 
 
5.3.4 Gel Contraction  
 At day 16 of MVF culture, 3% collagen gels with no decorin had contracted to an 
average of 48% of their original (day 1) area, while 3% collagen gels with decorin and both 
6% gels retained about 95% of their initial area. Both increased collagen density 
(p<0.0001) and DCN (p<0.0001) significantly attenuated gel contraction. A significant 
interaction effect was also revealed (p<0.0001), and post hoc tests showed that contraction 
of only 3% collagen gel was significantly reduced by the presence of DCN (p<0.001; 
Figure 5.5).  
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Figure 5.4. MVF Growth ± DCN. Representative 10x maximum intensity z-projections 
of MVF growth at day 9 in (a) 3% collagen without DCN, (b) 3% + DCN, (c) 6% − DCN, 
and (d) 6% + DCN and quantification (n = 5 frames/7–8 gels/group) of (e) total network 
length number of branch-points. * Indicates significant differences between 3% and 6% 






Figure 5.5. Gel Contraction ± DCN. Red outlines show border of gels within 48-well 
plate. B) Average fractional area retained by MVF-seeded gels over 16 days in culture (n 





5.4 Discussion  
The vasculature is an integral component of musculoskeletal regeneration, both 
providing nutrient transport and participating in VEGF-BMP-2 signaling interplay [97, 98]. 
Changes in the mechanical environment of bone injury repair tissue have been associated 
with vascular changes in vivo [136]. However, it has been challenging to directly examine 
the relationship between the compressive loads of a large bone defect and vascular 
regulation. Accordingly, the goal of this work was to investigate the ability of DCN-
supplemented collagen scaffold to maintain dimensional stability while supporting 
microvascular growth in vitro. The addition of DCN markedly increased the stability of 
3% collagen gel through day 16 in culture. Further, although DCN increased the 
compressive properties of both 3% and 6% collagen gels, DCN-supplemented constructs 
supported robust MVF growth.   
The addition of DCN significantly reduced contraction of 3% collagen. Although 
6% collagen was not impacted by the addition of DCN, the 6% gels do not undergo 
appreciable contraction during culture, and thus it is logical that their mechanical properties 
were less affected by DCN. The reduction in contraction of the 3% gel by DCN was 
dramatic despite a relatively modest increase in compressive properties, potentially 
suggesting a biological effect of DCN rather than a purely mechanical phenomenon. 
Endothelial cells cultured on a DCN substrate have shown reduced focal adhesion 
formation [230], and DCN has shown reduced collagen contraction by fibroblasts through 
transforming growth factor ß (TGF-ß) inhibition [231, 232]. In contrast, DCN has also been 
shown to increase cell-mediated collagen contraction [233]; however, that study utilized 
highly contractile smooth muscle cells, and they may respond differently to DCN than 
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other vascular cell populations. Despite potential biological effects of DCN, MVF growth 
was not significantly different as a result of DCN supplementation.  
Collagen is known to have a higher tensile than compressive modulus [227, 234]. 
Since DCN affects collagen properties via affecting fibrillogenesis, the tensile properties 
of resultant fibers may better show the effect of DCN. Thus, while a primary objective of 
this work was to establish whether collagen with DCN could withstand compression, the 
tensile properties of the gels may have been affected to a greater degree than the 
compressive properties. Additionally, forces exerted by cells during sprouting 
angiogenesis that ultimately cause the gels to contract are primarily tensile rather than 
compressive, perhaps suggesting that gel contraction was mitigated by an increased tensile 
modulus [185].  
While increased substrate stiffness tends to decrease microvascular growth [113], 
using DCN to increase the modulus of the vascularized collagen gels did not have this 
effect. DCN is known to play a complex role in angiogenesis, with studies suggesting both 
pro- and anti-angiogenic effects depending on the context [230, 235-237]. Many of these 
studies focus on the expression of DCN by endothelial cells rather than on its function as 
an ECM component [237]; however, when endothelial cells were cultured on a two-
dimensional DCN substrate, tube-like structure formation was inhibited, suggesting an 
anti-angiogenic role [230]. While tube-like structure formation is a critical step in de novo 
angiogenesis, DCN may not affect the subsequent steps such as sprouting and elongation 
that are more relevant to the microvascular fragment model presented in this study. Also, 
the use of pure DCN in isolation from other ECM moieties may have magnified effects of 
DCN. DCN is also known to interact with growth factors such as TGF-ß and has been 
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shown to upregulate vascular endothelial growth factor (VEGF) [238, 239]. In the system 
presented here, DCN may bind, sequester, and better present growth factors [240], thereby 
potentially promoting angiogenesis and effectively balancing the inhibitory effect of 
increased substrate stiffness. 
 Finally, the 50 µg/mL DCN dose used in this study was chosen based on previous 
research utilizing DCN in 2% collagen; while higher concentrations of DCN further 
affected fibrillogenesis, the tensile modulus plateaued at 50 µg/mL [228]. In this study, we 
used 3% collagen to compare microvascular growth to results from previous studies using 
this in vitro model for angiogenesis [107, 110-112], and it is possible that a higher dose of 
DCN would produce a greater effect in higher percentage collagen. As the concentration 
of collagen monomer is increased, collagen-collagen interactions may dominate over any 
effects between collagen and DCN and effectively dampen the response to DCN. Both 3% 
and 6% collagen showed a reduction of final turbidity in the presence of DCN, consistent 
with previous results in 2% collagen. However, the rate of fibrillogenesis, evidenced by 
the slope of the growth phase, was not affected by DCN in either 3% of 6% collagen, and 
the lag time was not affected in 3% collagen and was in fact reduced in 6% collagen (Fig. 
1), contrasting previous results [228]. Taken together, these data suggest that the 50 µg/mL 
dose of DCN does have differing effects on different densities of collagen. Despite the 
variances in turbidity curves, SHG images of the gels qualitatively showed collagen 
organization differences, which were also noted in 2% collagen [228], and the compressive 
modulus was increased for both densities.  
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5.5 Conclusions  
By quantifying collagen hydrogel construct mechanical properties and vascular 
growth as a function of collagen density and presence of DCN, this study has demonstrated 
a method to improve dimensional stability of collagen gels without compromising vascular 
growth. While it is unclear whether the reduction of gel contraction is primarily due to 
biological or mechanical effects of DCN, both compressive modulus and fibril structures 
were altered. Taken together, these data suggest that decorin-supplemented collagen 
constructs are an attractive candidate for in vitro model studies on the effects of 
compressive mechanical loading on three-dimensional microvascular growth.  
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CHAPTER 6. DECORIN-SUPPLEMENTED COLLAGEN 
HYDROGELS FOR THE CO-DELIVERY OF BONE 
MORPHOGENETIC PROTEIN-2 AND MICROVASCULAR 




Traumatic musculoskeletal injuries resulting in open fractures, which are 
characterized by concomitant soft tissue injury, represent a major clinical challenge. Cases 
of open fracture have a two-fold increased rate of complications including infection, 
delayed union, malunion, and non-union compared to closed fractures [35]. These 
complications often lead to repeated surgical interventions that are still not able to avert 
long-term disability 7 years following injury [51]. One of the key clinical indicators of 
composite injury severity is vascular integrity; composite injuries that include vascular 
damage are considered the most severe [38]. We have previously established a pre-clinical 
rat model of composite bone-muscle extremity injury that recapitulates the attenuation of 
bone healing seen clinically [42], and similar pre-clinical models have also observed 
                                                 
4 Adapted from Ruehle, M.A., et al., Decorin-Supplemented Collagen Hydrogels for the 
Co-Delivery of Bone Morphogenetic Protein-2 and Microvascular Fragments to a 
Composite Bone-Muscle Injury Model with Impaired Vascularization. Acta Biomaterialia, 
2019. Doi: 10.1016/j.actbio.2019.01.045.  
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impaired bone healing with concomitant muscle injury [40, 41]. Previous studies in our 
composity injury model also demonstrated a dysregulated vascularization response 
following injury [43]. 
Early revascularization is a critical step of the wound healing cascade, providing a 
transport mechanism for oxygen, pro-regenerative growth factors, and stem and progenitor 
cells [10]. When vascularization is impaired in fracture models, bone healing is also 
severely impaired [15, 16]. Osteoprogenitor cells migrate into the bone defect region along 
with nascent vasculature, and osteoprogenitor cells and endothelial cells participate in 
bidirectional chemical signaling to stimulate growth [17]. As such, vascularization has 
been a promising target in bone regeneration, and many previous strategies have been 
employed including the co-delivery of osteogenic and angiogenic growth factors (e.g. bone 
morphogenetic protein-2 (BMP-2) vascular endothelial growth factor (VEGF)) as well as 
mesenchymal stem cell (MSC) and endothelial cell delivery [241]. However, while some 
growth factor co-delivery strategies report an improvement in healing [91-93], others 
report only a temporary transient effect or no effect at all [94-96, 99]. Although endothelial 
cell-based strategies have been shown to increase bone regeneration [101, 104], the 
resultant vasculature is often immature and leaky [105]. Another promising option is the 
use of microvascular fragments (MVF), which are multicellular segments of mature 
vasculature [107]. MVF are able to serve as a template for vascular growth and thus 
accelerate the establishment of vascular networks. Additionally, MVF retain vascular 
support cells and may therefore accelerate vessel maturation and patency. MVF form 
networks in vitro and have been previously shown to anastomose with host vasculature 
[195, 207] and increase tissue vascular volume [116] following implantation. Previous 
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vascularization therapies without an osteoinductive factor have not improved bone healing 
[96, 100]. Therefore, we investigated the co-delivery of MVF with BMP-2, a potent 
osteoinductive growth factor.  
Design criteria for a co-delivery biomaterial are the support of MVF growth and 
sustained BMP-2 release. MVF have typically been cultured in type I collagen gels, which 
support in vitro sprouting and network formation [107, 116]. However, collagen-based 
materials tend to have a burst release of BMP-2 [242], which necessitates 
supraphysiological dosing and can cause exuberant bone formation outside the defect site 
[194].  Biomaterials with a more sustained BMP-2 release profile, such as alginate, have 
shown improved healing compared to collagen sponge [74]. MVF are sensitive to their 
extracellular matrix [110, 112], and we have previously developed a decorin-supplemented 
collagen culture substrate that supports robust angiogenesis of MVF [219]. Decorin (DCN) 
is a small leucine-rich proteoglycan naturally found in connective tissue [243]. DCN alters 
collagen fibrillogenesis, which in turn affects the mechanical properties of collagen 
hydrogels [219, 228] and limits the cell-mediated contraction of collagen [219].This 
increased dimensional stability allows vessel networks to grow and exert traction forces 
without collapsing the collagen matrix. DCN has also been shown to sequester 
transforming growth factor ß (TGF-ß) family growth factors [239, 240], such as BMP-2, 
which may allow for a more sustained release as compared to collagen alone. 
Here, we evaluated decorin-supplemented collagen hydrogels (collagen+DCN) as a 
biomaterial vehicle for the co-delivery of BMP-2 and MVF. We hypothesized that 
collagen+DCN would increase BMP-2 retention over collagen alone due to DCN’s ability 
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to sequester TGF-ß growth factors. We further hypothesized that MVF would increase both 
early vascularization and subsequent BMP-2-mediated bone regeneration.  
6.2 Methods 
All animal experiments were performed in accordance with protocols approved by 
the Georgia Institute of Technology Institutional Animal Care and Use Committee 
(IACUC).  
 
6.2.1 In vitro Construct Preparation & Characterization 
MVF growth and the acellular BMP-2 release kinetics of collagen+DCN hydrogels 
were assessed and compared to collagen alone and to alginate. Collagen gels were made at 
3% w/v and buffered with Dulbecco’s modified eagle medium (DMEM; ThermoFisher 
Scientific; Waltham, MA). Collagen+DCN gels consisted of 3% collagen supplemented 
with 50 µg/mL DCN as previously described [219]. To prepare alginate hydrogels, RGD-
functionalized alginate (FMC BioPolymer; Ewing, NJ) dissolved in αMEM was 
crosslinked with calcium sulfate for a final concentration of 2% [75].  
MVF were isolated as previously described [107]. Briefly, epididymal fat pads were 
harvested from Lewis rats, minced, and digested with a collagenase solution for 7 minutes 
at 37 °C. MVF were obtained through selective filtration to retain tissue between 20-200 
µm. Tissue was first passed through a 200 µm filter to remove partially undigested adipose 
tissue; the flow-through was then passed through a 20 µm filter to remove single cells. 
MVF were suspended at a density of 80,000 fragments/mL in solution prior to gelation.  
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To assess BMP-2 release kinetics, acellular gels were loaded with 500 ng BMP-2 
(n=4/group) by incorporation within solution prior to gelation. Gels were incubated at 37 
°C in αMEM (ThermoFisher) supplemented with 10% fetal bovine serum (Atlanta 
Biologics; Atlanta, GA). Media was collected and replaced at time points up to day 20. 
BMP-2 present in the collected media was quantified by ELISA according to 
manufacturer’s instructions (R&D Systems, Minneapolis, MN). BMP-2 release was then 
compared for acellular vs. MVF-containing collagen+DCN hydrogels as above up to day 
7 (n=5/group).  
MVF growth in collagen+DCN gels ± BMP-2 was assessed at day 7 (n=5/group). 
MVF-containing constructs were cultured in αMEM (ThermoFisher) supplemented with 
10% fetal bovine serum (Atlanta Biologics) and 1% penicillin-streptomycin-glutamine 
(ThermoFisher). In the BMP-2 containing group, 500 ng BMP-2 was incorporated into the 
collagen+DCN solution prior to gelation. Gels were fixed with 4% paraformaldehyde and 
stained with rhodamine-labeled Griffonia simplicifolia (GS-1) lectin (Vector Laboratories, 
Burlingame, CA). Five randomly selected fields were imaged per gel to a depth of 402 μm 
using a Zeiss LSM 700 confocal microscope. Maximum intensity z-projections were 
created for each stack, thresholded, and skeletonized using the AngioAnalyzer ImageJ 
plugin to determine branch number and total length [116, 219]. 
 
6.2.2 Surgical Procedures 
Composite defects were made in 13-week-old female Lewis rats for syngeneic 
implantation of MVF harvested from Lewis rats. Lewis rats that ubiquitously express GFP 
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(LEW-Tf(CAG-EGFP)YsRrrc) were obtained from the Rat Resource and Research Center 
(RRRC, Columbia, MO) to enable the detection of implanted MVF. Bone defects received 
either collagen+DCN loaded with 2.5 µg BMP-2 and MVF (BMP-2+MVF), 
collagen+DCN loaded with BMP-2 (BMP-2), or an empty collagen+DCN gel (gel only). 
Gels were formed in custom polycarbonate molds to achieve a diameter of 5 mm and a 
length of 1 cm and placed inside perforated PCL mesh tubes for implantation. 36 animals 
were used to evaluate the effect of MVF on BMP-2-mediated revascularization and 
subsequent bone healing. A subset of animals (n=6/BMP-containing group) were 
euthanized at 7 days post-surgery to assess vascularization using µCT angiography. The 
remaining animals (n=9/BMP-containing group, n=6/gel only group) were euthanized at 
12 weeks post-surgery to assess bone regeneration.  
 
6.2.3 µCT Angiography 
Animals were sequentially perfused with 0.9% saline to clear blood vessels, 0.4% 
papaverine hydrochloride to dilate vessels, 10% neutral buffered formalin to fix, saline to 
rinse, and a lead chromate radiopaque contrast agent (Microfil MV-22 diluted 2:1; Flow 
Tech, Inc., Carver, MA). Samples were stored overnight at 4 °C to allow complete 
polymerization of the contrast agent prior to dissection and µCT analysis. Hind limbs from 
the hip to the knee were excised. No bone had yet formed in the defect area by day 7, so 
limbs were analyzed immediately.  
Two volumes of interest (VOIs) were used to analyze either the bone defect region 
only or the entire thigh, including both the bone defect and surrounding muscle. All scans 
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were performed at a 21 μm voxel size. The thigh VOI encompassed the entire diameter of 
the thigh for the length of the defect, and the bone defect VOI consisted of a cylindrical 
volume 6 mm in diameter to encompass the outer diameter of the treatment-containing 
PCL mesh tube. A global threshold was applied for segmentation of vasculature, and a 
Gaussian low-pass filter was used to suppress noise (σ = 0.8, support = 1). Total vascular 
volume and voxel diameter histograms were computed using native Scanco software. The 
number of voxel counts per diameter bin was used as a measure of vessel number [116]. 
 
6.2.4 Bone Regeneration Analysis 
Bone tissue regeneration was assessed by radiography at 2, 4, 8, and 12 weeks post-
surgery and by µCT at 4, 8, and 12 weeks post-surgery. For quantitative µCT analysis, the 
defect region was scanned with a voxel size of 38 µm. The middle 6.5 mm of the defect 
was analyzed, and bone volume was quantified by Scanco software using a threshold 
corresponding to 50% of intact cortical bone [193]. Functional regeneration was assessed 
by mechanical testing at 12 weeks endpoint. Thighs were harvested, soft tissue was cleared, 
and fixation plates were removed. Femur ends were potted in Wood’s metal (Alfa Aesar) 
and tested in torsion at a rate of 3°/s to failure or to 30° of rotation (ELF 3200, TA 
ElectroForce) [61]. The failure strength (torque at failure) and stiffness (linear region of 
torque vs. rotation plot) were calculated for all samples.  
 
6.2.5 Histology and Immunohistochemistry 
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Bone tissue was decalcified, sectioned at a 5 µm thickness, and stained with 
hematoxylin and eosin (H&E; Histotox Labs; Boulder, CO). Immunohistochemistry was 
also performed on bone tissue sections to evaluate the presence of implanted GFP-
expressing MVF. Deparaffinized sections were blocked, incubated with anti-GFP antibody 
(ab290, Abcam; Cambridge, UK) at a dilution of 1:100, washed, incubated with secondary 
antibody (A-11036, ThermoFisher) at a dilution of 1:50, washed, and counterstained with 
DAPI (ThermoFisher) at a dilution of 1:1000. 
 
6.2.6 Statistical Analysis  
Data were analyzed using GraphPad Prism 5, and all statistical tests were conducted 
with α=0.05. BMP-2 release data were analyzed with a repeated measures one-way 
ANOVA with Bonferroni’s multiple comparisons test. MVF network length and branching 
with and without BMP-2 were compared with a Student’s t-test with Welch’s correction 
for unequal variances. Total vascular volume data were analyzed with a one-way ANOVA 
(thigh) with Bonferroni’s multiple comparisons test or with a Student’s t-test (bone defect 
area). Vessel thickness histograms were compared using a two-way ANOVA [116] with 
Bonferroni’s multiple comparisons test. Longitudinal bone healing and mechanical testing 
had significantly different variances among treatment groups (Bartlett’s test, p<0.05) and 
were therefore analyzed with Kruskal-Wallis tests and Dunn’s multiple comparisons test. 
Data are plotted as mean with standard error of the mean (SEM) or as a box plot with 




6.3.1 In vitro Biomaterial Characterization  
Acellular hydrogels were then tested for BMP-2 release. Collagen+DCN released 
significantly less BMP-2 over days 1-5 than either collagen alone or alginate. By day 10, 
collagen+DCN released less BMP-2 than collagen alone but was not statistically different 
than alginate. At days 15-20, the quantity of BMP-2 released by all three materials was 
significantly different (Figure 6.1 A; RM-ANOVA, p<0.05). At day 20, collagen had 
released about 35% of the loaded BMP-2, collagen+DCN had released about 28%, and 
alginate had released about 25%. 
Release of BMP-2 from acellular vs. MVF-containing collagen+DCN gels was 
compared up to day 7. Beginning at day 3, the MVF-containing gels released significantly 
more BMP-2 than acellular gels (Figure 6.1 B; RM-ANOVA, p<0.05). This difference 
persisted through day 7 (p<0.01). At day 7, MVF-containing gels had released 12.9% of 
the loaded BMP-2, and acellular gels had released 11.6%. BMP-2 significantly increased 
total MVF network length and branching (Figure 6.1 C) and qualitatively appeared to 
accelerate MVF network formation (Figure 6.1 D-E). 
 
6.3.2 Effect of MVF on Early Revascularization Following Composite Injury 
Composite defects were treated with either collagen+DCN gels loaded with BMP-
2 and MVF, collagen+DCN gels loaded with BMP-2 alone, or empty collagen+DCN gels 
only. Based on the reduced number of small diameter vessels within both the thigh and 
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bone defect region at day 7 of the early revascularization study, 6 animals per BMP-
containing treatment group were euthanized 7 days post-surgery for µCT angiography. 
Both treatment groups had significantly greater thigh vascular volume than the 
contralateral leg (Figure 6.2 A-B; p<0.0001).  However, the total vascular volume was not 
significantly different between BMP and BMP+MVF in the thigh region or the bone defect 
region. Analysis of vessel size distributions revealed that compared to BMP alone, 
BMP+MVF treated defects had significantly fewer vessels in the bone defect regions 
(Figure 6.2 C; 2-way ANOVA, overall effect p<0.01, n.s. interaction effect). The thigh 
region possessed fewer small diameter vessels, ranging 0-200 µm and 600-1000 µm in the 
BMP+MVF animals compared to the BMP animals (overall effect p<0.0001, interaction 
effect p<0.01). 
 
Figure 6.1. In vitro characterization of BMP-2 release and effect on MVF growth. A) 
Cumulative in vitro BMP-2 released by acellular gels into surrounding media. RM-
ANOVA, * p<0.05 between all three materials, # p<0.05 between collagen and 
collagen+DCN and collagen and alginate; n=4/group. B) Cumulative in vitro BMP-2 
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released by acellular vs. MVF-containing collagen+DCN gels into surrounding media. 
RM-ANOVA, * p<0.05, ** p<0.01; n=5/group. C) Quantification of total MVF network 
length and branching without BMP-2 (D) and with 500 ng BMP-2 incorporated into the 




Figure 6.2 Effect of MVF delivered in collagen+DCN on early revascularization 
following composite injury.  Quantitative µCT angiography results for total volume of A) 
the thigh region and B) the bone defect region. 2-way ANOVA, * p<0.0001 between BMP 
groups and contralateral control; n=6/group. Vascular thickness distributions for C) the 
thigh region and D) the bone defect region. Insets show E) small 0-200 µm diameter and 
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F) intermediate 600-1000 µm diameter voxel within the thigh. Voxel counts indicate the 
number of voxels with a given diameter and are utilized as a measure of vessel number.2-
way ANOVA, ** p<0.01 between BMP+MVF and BMP (overall effect), *** p<0.001.   
 
6.3.3 Effect of MVF on Bone Regeneration in Composite Injury 
At 12 weeks, radiography demonstrated inconsistent bridging in both BMP-
containing groups (with and without MVF; Figure 6.3). Semi-quantitative bridging scores 
0-4 were assigned to each animal: 0, no mineralization; 1, sparse, isolated areas of mineral; 
2, substantial but discontinuous mineralization; 3, near but incomplete bridging; 4, 
complete bridging [244]. Both BMP-containing groups had approximately one third of 
defects completely bridge (score 4), one third produce substantial mineralization without 
bridging (score 2-3), and one third with little to no mineral (score 0-1). The gel only control 
group did not induce substantial bone formation in any animal (all scored 0-1).  
Bone volume as measured by µCT was significantly higher in both BMP-
containing groups than the gel only control at 12 weeks (Kruskal-Wallis test, p=0.011; 
Figure 6.4 A); there was no effect of MVF on bone volume. There was no difference among 
treatment groups in failure strength or stiffness, and all groups were significantly below 
that of the intact contralateral control (Kruskal-Wallis test, p<0.001; Figure 6.4 B-C).  
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Figure 6.3 Representative radiographs of bone defects treated using collagen+DCN 
delivery vehicle. Representative 12 week radiographs of non-mineralized (top; bridging 
score 0-1), mineralized but not bridged (middle; bridging score 2-3), and completely 
bridged (bottom; bridging score 4) samples from each treatment group. The Gel Only 
group produced only non-mineralized samples. Inset chart shows the semi-quantitative 
bridging score distribution and mean for each group.  
 
 
Figure 6.4. Properties of bone regenerated using collagen+DCN delivery vehicle. A) 
Longitudinal bone volume as measured with µCT. Kruskal-Wallis test, * p=0.011 between 
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both BMP groups and the Gel Only material control group. B) Failure strength and C) 
Stiffness of regenerated bone tissue at the 12 week endpoint. Kruskal-Wallis test, * 
p<0.001 between all treatment groups and the contralateral control.  
 
6.3.4 Histology and Immunohistochemistry 
H&E staining demonstrated that even in samples with moderate bone volume, the 
defect area often failed to bridge with one or both intact bone ends (Figure 6.5 A); this is 
in agreement with the radiography shown in Figure 6.3. Due to the high variability of bone 
volume, H&E was performed on three samples representing low, moderate, and high bone 
volume for each treatment group (the collagen+DCN gel only group only produced low 
bone volume, so only one sample was stained; Figure 6.5 B). The low bone volume samples 
displayed primarily fibrous tissue. The low bone volume samples from the BMP-
containing groups appeared more loosely structured than the gel only group, which was 
very densely cellular. The moderate bone volume samples appeared to have islands of 
mineralized tissue within larger areas of marrow-like tissue. The high bone volume samples 
had fewer and smaller areas of marrow-like tissue. Although there were larger areas of 
mineralized tissue, they appear more disorganized than intact mature bone tissue.  
Immunohistochemistry was performed to determine whether the implanted GFP-
expressing MVF remained within the defect at either 1 week or 12 weeks post-surgery. At 
1 week, GFP+ cells were identifiable in the defect region (Figure 6.6); however, rather than 
being evenly distributed throughout the defect, these GFP+ cells appeared to be clustered 
together. Additionally, they appeared as distinct, single cells rather than multicellular 
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vessel structures and are not associated with vascular structures. At week 12, no cells 
stained positive for GFP.  
 
Figure 6.5. Hematoxylin & Eosin staining of bone regenerated using collagen+DCN 
delivery vehicle. A) Representative H&E mosaic images of samples from the BMP-2 (top) 
and BMP-2+MVF (bottom) treatment groups. The PCL nanofiber mesh denotes the 
boundaries of the defect area, and the proximal intact bone end is marked with dotted line. 
Scale bar = 1000 µm. B) Representative low (top), moderate (middle), and high (bottom) 
bone volume samples from each treatment group at the 12 week endpoint. The Gel Only 
group produced only low bone volume samples. Location of moderate bone volume 
samples within mosaics are outlined in blue and green for the BMP-2 and BMP-2 + MVF 
groups, respectively. Scale bar = 200 µm. 
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Figure 6.6. Immunohistochemistry to determine presence of implanted GFP+ MVF. 
Anti-GFP immunohistochemistry (top) to determine retention of implanted GFP+ MVF at 
1 week and 12 weeks post-surgery. Red – anti-GFP antibody, blue – DAPI. Serial sections 
stained with H&E (bottom). Scale bar = 50 µm. 
 
6.4 Discussion 
A key indicator of traumatic composite injury severity is vascular integrity [38]. 
Clinically, bone injuries with concomitant muscle damage are more prone to complications 
and long-term disability, and those with vascular damage are the most susceptible [35, 51]. 
We have previously developed a rat model of composite injury that recapitulates the bone 
healing deficit seen clinically [42] and a vascular deficit [43].  
In an effort to rescue this vascular deficit, collagen+DCN hydrogels were developed 
as a biomaterial delivery vehicle for both BMP-2 and MVF. This material has previous 
been shown to support vascular growth in vitro with minimal cell-mediated contraction of 
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the gel [219]. Similar vascularized constructs have been implanted and progressed to 
connect with the host vasculature [195], increase tissue vascular volume [116], and respond 
to local microenvironmental characteristics [207]. However, in this application, MVF were 
not able to overcome the vascular deficit and in fact were associated with decreased number 
of vessels relative to BMP alone at day 7. The timing of VEGF expression has been 
implicated as an important regulator of bone healing [94, 99], and delivering MVF 
immediately following injury may have disrupted the endogenous timeline of wound 
healing angiogenesis. Endogenous VEGF expression typically peaks around day 5-10 post-
injury [99], while delivering MVF immediately following defect creation may have 
introduced larger amounts of VEGF much earlier. Early presence of VEGF may have then 
disrupted growth factor gradients and prevented the full endogenous angiogenic response. 
However, a majority of BMP-2 and VEGF co-delivery studies that ultimately did not show 
improved bone healing did observe increased vascularity [94-96, 99, 100]. A previous 
study examining the effect of hindlimb ischemia on segmental defect healing observed a 
beneficial effect of transient ischemia on revascularization and subsequent bone healing 
[245]; the complexity of the relationship between vascularization and bone regeneration is 
not yet fully understood. Although GFP+ cells were observed within the defect area at day 
7, they appeared as single cells rather than the GFP+ multicellular vessel fragments that 
were implanted. While some loss of support cells is a normal element of sprouting 
angiogenesis, the GFP+ cells do not appear to be associated with vessel-like structures, 
suggesting instead that a majority of the cells comprising the MVF dissociated to a single 
cell level. As the implanted vessel fragments dissociated, vessel destabilization cues may 
possibly have been transmitted to the surrounding tissue, resulting in a decreased number 
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of vessels within the thigh compared to BMP alone. Previous studies delivering MVF that 
showed increased tissue vascular volume had pre-cultured the MVF in vitro prior to 
implantation, which allowed for provisional network formation [116]. While the freshly 
isolated MVF tested in this study potentially have greater translational applicability, the 
pre-culture of constructs accelerates inosculation [115] and may be critical to functional 
revascularization by implanted cells.  
MVF also did not have a statistically significant effect on bone volume or mechanical 
properties. However, the mean and median bone volume, failure strength, and torsional 
stiffness were all lower in the BMP-2 + MVF group than in the BMP-2 alone group. This 
may primarily be due to their negative effect on the already dampened revascularization 
response in the composite defect model. GFP+ MVF-derived cells were not observed in 
the defect tissue at the 12 week end point, indicating that they did not integrate into the 
regenerated tissue. Cell-based therapies broadly are challenged by issues of retention and 
survival [106, 246]; although the implanted cells in this study were able to persist to day 7, 
without inosculating with the host vasculature, they may have failed to survive within the 
harsh, hypoxic injury environment. Additionally, exogenous cells may metabolize or 
degrade BMP-2, thereby reducing its effective dose and availability to osteoprogenitors 
[68]. However, the in vitro BMP-2 release experiment showed that MVF-containing 
collagen+DCN gels released modestly but significantly more detectable BMP-2 than 
acellular gels. This may be due to proteolytic activity of MVF as they sprout and invade 
the matrix. BMP-2 also significantly increased MVF network length and branching at day 
7, which is in agreement with previous reports of BMP-2 increasing angiogenesis [247, 
248].  Previous literature showed decreased mineralization when adipose-derived MSCs 
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were co-delivered with BMP-2, whereas bone marrow-derived MSCs increased BMP-2-
mediated mineralization [67]. While adipose-derived MVF do contain MSCs, they 
represent only about 5% of the cellular constituents [119, 220]. Cell source more broadly 
may be an important consideration when using MVF therapeutically. Further, even in 
samples with moderate bone volume, the defect area often failed to bridge with one or both 
intact bone ends across both BMP-containing treatment groups. While we have established 
an association between altered revascularization and impaired bone healing, other factors 
may also contribute to reduced healing. There is evidence for crosstalk between growth 
factors secreted by muscle tissue and the periosteum [42], perhaps contributing for the 
relatively low bridging rates observed in this study.  The loss of adjacent muscle tissue 
sustains the pro-inflammatory stage of wound healing [40], and immunomodulatory agents 
have been shown to improve bone healing in traumatic injuries with volumetric muscle 
loss [208]. Composite tissue injuries are complex and may require adjunct therapies to 
address multiple facets of the healing process.   
The collagen+DCN delivery vehicle met the in vitro design criteria as a matrix 
supporting both MVF growth and sustained BMP-2 delivery. MVF grow robustly in 
collagen+DCN [219], and DCN increased the retention of BMP-2 in vitro compared to 
collagen alone. At an intermediate timepoint (day 10 of 20), the BMP-2 release of 
collagen+DCN was not statistically different than alginate. DCN preferentially binds TGF-
ß family growth factors such as BMP-2 [239]. As such, DCN may have transiently bound 
BMP-2, increasing retention, and released it, allowing BMP-2-induced mineralization 
[240]. Interestingly, DCN has been shown to play a role in angiogenesis, with studies 
showing both positive and negative effects [230, 236, 237, 249, 250]. DCN deficient mice 
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exhibit deficiencies in angiogenesis [235], and sprouting endothelial cells express DCN 
[251]. As an extracellular matrix component, DCN has been shown to inhibit endothelial 
cell tube formation [230]. However, collagen+DCN is an effective in vitro culture substrate 
for MVF and facilitates network branching and extension [219]. Collagen+DCN supports 
angiogenesis in vivo as well. Vessels were able to migrate into the bone defect area, and 
the 7 day perfusion results appeared qualitatively similar to those observed at day 7 in the 
alginate system.  
As a delivery vehicle for BMP-2, collagen+DCN gels are capable of bridging the 
challenging composite defect model, albeit inconsistently; mineralization occurred in 
approximately two-thirds of BMP-treated defects. A previous study of bone healing in the 
composite defect model observed very comparable bone volume and mechanical properties 
in composite defects using a well-established alginate delivery vehicle for a functionally 
equivalent dose of BMP-2 (2 vs. 2.5 µg) [42]. In the present study, the average 12 week 
bone volume of the BMP only group was 33.38 mm3, and the average failure strength was 
0.0779 Nm; Willett et al. observed a 12 week bone volume of 28.99 mm3 and a failure 
strength of 0.0558 Nm in composite defects treated with BMP-2 delivered in alginate. 
Thus, the inconsistent bone healing observed here may speak more to the extraordinarily 
challenging nature of composite tissue injuries rather than the efficacy of collagen+DCN 
as a BMP-2 delivery vehicle. Although not able to promote consistent bridging in 
challenging composite tissue injuries, collagen+DCN performed as well as RGD-alginate 




Composite injuries to bone and adjacent soft tissue are more prone to clinical 
complications and poor healing outcomes.  Previous studies in an established rat bone-
muscle injury model demonstrated a modest but significant impairment in early 
revascularization, which may contribute to impaired bone healing. In an attempt to 
overcome this vascular deficit, we developed and characterized collagen+DCN hydrogels 
as a co-delivery vehicle for a vascular therapeutic, MVF, and the osteoinductive growth 
factor, BMP-2. However, despite in vitro data suggesting synergistic effects between BMP-
2 and MVF, we unexpectedly found that MVF did not increase vascular volume and in fact 
decreased the number of vessels both within the bone defect area and the surrounding 
tissues of the thigh. GFP+ cells from the implanted GFP+ MVF were present within the 
bone defect at 1 week post-surgery but appeared as single cells rather than as vessel 
structures, and no GFP+ cells were observed at 12 weeks post-surgery. Although MVF did 
not improve bone healing, the collagen+DCN biomaterial delivery of BMP-2 was able to 
achieve bridging in the challenging composite defect model, reaching endpoint bone 
volume and mechanical properties comparable to a well-established RGD-alginate delivery 
system. Decorin-supplemented collagen hydrogel is therefore a promising biomaterial 
delivery vehicle for treating composite extremity injuries, and future studies will explore 
pre-culturing MVF in vitro to allow stable network formation prior to implantation.   
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CHAPTER 7. MECHANICAL LOADING TEMPORALLY 
REGULATES MICROVASCULAR ANGIOGENESIS 
7.1 Introduction 
Vasculature is an abundant and vital component of nearly all tissues, and 
revascularization is a critical step of the wound healing cascade [10]. Angiogenesis, the 
primary mode of new vessel formation in wound healing, begins as new vessels sprout 
from adjacent intact blood vessels. New vessels invade the wounded area and begin to form 
microvascular networks within just a few days. Concurrent with the early steps of 
angiogenesis, a collagenous provisional matrix is formed, which appears characteristically 
granular due to its high density of newly formed capillaries. Granulation tissue is then 
remodeled into mature tissue through a complex series of chemical and physical cues [252] 
such as the coordinated expression of growth factors and cytokines [253] and dynamically 
changing ECM properties [130]. During this healing process, granulation tissue also 
experiences tissue-specific applied forces that are known to influence healing. For 
example, bone experiences functional compressive loading [209], ligaments and tendons 
undergo tension [254], venous ulcers are often treated with compression bandages [255], 
and even cutaneous wound experience tension during closure [256]. While the vasculature 
has long been recognized as mechanosensitive [222], remarkably little is known about the 
effects of abluminal forces experienced by healing tissues on angiogenesis.  
Previous in vivo work from our lab has shown that abluminal forces, such as bulk 
compression of the extracellular matrix, can have potent effects on vascular growth – both 
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inhibitory and stimulatory. When functional loading was applied immediately following 
injury, angiogenesis and subsequent tissue healing were inhibited. However, when loading 
was delayed until initial matrix deposition had already occurred, blood vessel growth and 
subsequent tissue healing were enhanced [136], implicating abluminal loading in 
differential temporal regulation of angiogenesis.  
 Sprouting angiogenesis is a dynamic process involving multiple phases of 
concerted cellular activities. For organized, directed sprouting to occur rather than 
indiscriminate growth, a subset of endothelial cells within the vessel are selected as sprout 
tip cells, while adjacent endothelial cells are maintained as stalk cells through lateral 
inhibition. Tip cells extend filopodia into the surrounding matrix and lead the matrix 
invasion and migration of the nascent sprout [30]. Stalk cells follow the migrational pattern 
established by tip cells [257] and proliferate to drive the sustained elongation of nascent 
vessels [30]. Many of the processes involved in angiogenesis are responsive to mechanical 
stimuli. Tip cell selection depends on the balances of Notch1 and its ligands Jag1 and Dll4 
[30], which have recently been identified as mechanosensitive [258, 259]. Invasion of the 
ECM by tip cells involves a balance of proteolysis and matrix deposition [30, 32, 33]; 
expression and secretion of proteases that are involved in angiogenesis such as Mmp2, 
Mmp9, and Mmp14 are also mechanosensitive [260, 261]. Collective cell migration of both 
leading tip cells and following stalk cells requires the binding and release of ECM by 
adhesion molecules such as integrins [31], which are important mediators of 
mechanotransduction between the ECM and cells [262]. Intracellular 
mechanotransduction, often activated by integrins, is required to elicit a cellular response. 
Recently, yes-associated protein (YAP) and its paralog transcriptional coactivator with 
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PDZ-binding motif (TAZ) have been identified in flow-mediated vascular 
mechanotransduction [263]. YAP and TAZ are also regulate a number of processes crucial 
to angiogenesis, including VEGF signaling [264], cell migration [265], proliferation, and 
cell-cell junction formation [266]. While many stages of angiogenesis have exhibited 
mechanosensitivity in isolation, little is known about how functional mechanical loading 
regulates the concerted processes of angiogenesis.  
 The bone environment is one of the few in which the effects of abluminal forces on 
vascularization have been investigated [136, 267]. Early functional loading disrupted 
vascularization, whereas delayed loading enhanced vascular networks [136]; however, the 
specific parameters of loading involved in regulating angiogenesis are poorly defined. 
Functional loading typically occurs with a frequency around 1 Hz [148], and strain 
magnitude is an important regulator of bone formation. Peak bone formation occurs at low 
strains, whereas a fibrous response occurs at high strains; 10% strain is thought to be a 
transition point between an anabolic and catabolic response [142]. Furthermore, functional 
loading includes modes of loading other than pure compression. For example, large bone 
defects include a shear interface between intact cortical bone and the soft defect space or 
implanted graft material [268], and shear has been shown to reduce revascularization of 
bone [267].  
The in vivo injury environment is highly complex, which hinders mechanistic 
understanding of the role played by each loading parameter. To exert more precise control 
and begin to better understand these effects, we employed an in vitro model system of 
angiogenesis. Microvascular fragments (MVF) are segments of mature vasculature and 
thus composed of multiple cell types, including endothelial cells, smooth muscle cells, 
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mesenchymal stem cells, and fibroblasts [108, 269]. MVF are typically cultured in 
collagen-based hydrogels [107],  which has similarities to the collagenous granulation 
tissue characteristic of early stage wound healing. MVF represent a 3D culture system that 
recapitulates the major stages of in vivo angiogenesis including sprout tip cell selection, 
matrix invasion, neovessel elongation, and branching. These processes require complex 
cell-cell and cell-matrix interactions, which are vastly simplified in traditional 2D 
monolayer cultures. Additionally, MVF are known to respond to mechanical cues. 
Increased collagen matrix density decreased the rate of MVF growth and branching [113], 
and one of the relatively few studies examining the effect of abluminal forces observed 
MVF alignment parallel to the direction of applied tension [111]. 
 In this chapter, we studied the effects of three strain magnitudes, 5%, 10%, and 
30%, and two modes of loading, compression and compression with a shear interface zone, 
on MVF network growth when applied early and when delayed. Based on existing bone 
literature, we hypothesized that vascularization would be enhanced by delayed, moderate 
compression and inhibited by early, high magnitude compression and in regions of shear 
stress. We subsequently investigated the changes in viability, proliferation, perivascular 
coverage, and gene expression profiles associated with early vs. delayed loading. Based on 
our previous in vivo results, we hypothesized that early loading would decrease cell 
viability, pericyte-vessel attachment, and expression of genes associated with early stage 
angiogenesis, such as sprout tip cell selection, thereby leading to impaired vascular 
networks. Conversely, we hypothesized that delayed loading would increase cellular 
proliferation and increase expression of genes associated with later stages of angiogenesis, 
such as matrix invasion, collective cell migration, and cell recruitment, thereby leading to 
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more extensive and mature vascular networks. Finally, we investigated the role of YAP 
mechanotransduction in the differential angiogenic responses to early and delayed loading.  
 
7.2 Methods 
7.2.1 MVF Isolation and Culture 
MVF were isolated as previously described [107]. Briefly, epididymal fat pads of 
retired breeder Lewis rats were harvested, minced, and digested in a collagenase solution. 
MVF were obtained through selective filtration to retain multicellular structures between 
20-200 µm. MVF were suspended at a density of 20,000 fragments/mL in 3% collagen gels 
supplemented with 50 µg/mL decorin (DCN) to improve construct dimensional stability 
[219]. Gels were formed by 15-20 minutes of incubation at 37 °C in custom polycarbonate 
molds to create gels with a diameter of 5 mm and a height 4 mm. MVF-containing gels 
were cultured in serum-free media supplemented with 10 ng/mL recombinant human 
vascular endothelial growth factor (rhVEGF; R&D Systems, Minneapolis, MN) [112]. 
Media was changed on days 3, 5, and 7 of culture, and gels were fixed with 4% 
paraformaldehyde on day 10.  
 
7.2.2 Dynamic Loading 
 MVF-containing gels were loaded using an Electroforce 5500 with a multi-
specimen compression chamber containing a 24-well plate loading assembly (TA 
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Instruments; New Castle, DE). Loading was applied in a triangle wave with amplitudes 
corresponding to 5%, 10%, or 30% strain (0.2 mm, 0.4 mm, and 1.2 mm, respectively) at 
a frequency of 1 Hz. Gels were loaded in compression using polyetheretherketone (PEEK) 
platens with a diameter greater than that of the gel (1 cm) or in compression with a shear 
interface zone (compression+shear) using PEEK platens with a 3 mm gel-contacting 
diameter. Loading was applied continuously, breaking only for media changes, for either 
the first five days of culture, early loading, or the final five days of culture, delayed loading. 
To ensure gels remained centered within the well, gels sat within the inner diameter of 1 
mm thick 3D printed poly(lactic-co-glycolic acid) rings during loading.  
 To study the effects of loading type and time of initiation, dynamic loading at 5%, 
10%, and 30% strain experiments included the following groups (n=6/group): early 
compression, early compression+shear, delayed compression, delayed compression+shear, 
and a non-loaded control.  
 
7.2.3 Staining, Imaging, and Image-Based Analyses 
 To assess network morphology at day 10, fixed gels were stained with rhodamine-
labeled Griffonia simplicifolia (GS-1) lectin (Vector Labs, Burlingame, CA) at a 
concentration of 5 µg/mL in phosphate buffered saline (PBS) overnight at 4 °C 
(n=6/group). Gels were imaged using a Zeiss 700 confocal microscope with a 5X objective. 
The entire diameter of each gel was imaged to a depth of 200 µm. Confocal z-stacks were 
median filtered, deconvolved, and thresholded using Amira for Life Sciences 
(ThermoFisher Scientific, Waltham, MA). Islands smaller than 30 voxels (e.g. single cells, 
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debris, or noise) were also removed using Amira. Thresholded images were exported for 
skeletonization and quantification of length and branching using the 4-D open snake 
method [270] of the Farsight Toolkit [271, 272].   
 Viability and proliferation of non-loaded vs. loaded MVF were measured at day 3 
for early loading and at day 7 for delayed loading. Viability was determined using a 
live/dead assay kit performed according to manufacturer’s instructions (ThermoFisher). 
Gels were imaged at 10X, and three randomly selected fields were imaged per gel to a 
depth of 25 µm. Maximum intensity z-projections were created to quantify viability using 
Fiji’s Analyze Particles feature. Percent viability was calculated as the pixel area of live 
cells (green channel) over the pixel area of all cells (green+red channels). Proliferation was 
assessed using a Click-iT EdU Alexa Fluor 594 Imaging Kit (ThermoFisher; 
n=3/group/time point). EdU was added to media at a concentration of 10 µM at days 2 and 
6 of culture and incubated for 24 hours before gels were fixed at days 3 and 7. Gels were 
imaged at 10X to a depth of 25 µm, and four images were taken to capture the diameter of 
each gel. Proliferation was quantified as the number of EdU+ nuclei over the total number 
of nuclei.   
To assess the degree of perivascular coverage of endothelial cells by smooth muscle 
cells over time, non-loaded gels were fixed at days 0, 3, 5, 7, and 10 (n=3/time point), early 
loaded samples were analyzed at days 3, 5, and 10 (n=3/time point), and delayed loaded 
samples were analyzed at days 7 and 10 (n=3/time point). Following fixation, gels were 
stained with Alexa Fluor 488-conjugated anti-alpha smooth muscle actin (αSMA) antibody 
(ab184675, Abcam, Cambridge, UK) at a 1:100 dilution, DyLight 649-conjugated GS-1 
isolectin B4 (DL-1208, Vector Labs) at 5 µg/mL, and DAPI (ThermoFisher) at a 1:1000 
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dilution. Gels were imaged at 40X to a depth of 25 µm, which is the approximate depth of 
a single vessel. A region of interest (ROI) was drawn around vascular structures, and signal 
overlap between αSMA and isolectin B4 were quantified for the ROI using Manders 
coefficients as determined by the Fiji plugin coloc2 [273].  
 
7.2.4 Gene Expression Analyses  
 To assess gene expression changes due loading, RNA was harvested from non-
loaded and loaded constructs 24 hours after load initiation (i.e. after 24 hours of culture 
total for early loaded samples and their non-loaded controls and after 6 days of culture total 
for delayed loaded samples and their non-loaded controls). RNA was collected from non-
loaded and loaded gels at both early and delayed time points (n=5-6/group/time point). 
RNA was extracted using Qiagen MinElute kits, and cDNA was made using Qiagen RT2 
First Strand kits (Qiagen, Hilden, Germany). RNA concentration as determined by 
NanoDrop spectrophotometer (ThermoFisher) was used to ensure cDNA concentrations 
were equivalent. Taqman probes were used to assess gene expression of 43 genes known 
to be involved in various stages of angiogenesis (see Table 1) and five housekeeping genes. 
Gene expression was quantified using a Biomark real-time PCR integrated fluidic circuit 
array (Fluidigm, South San Francisco, CA). Rat universal cDNA (Gene Scientific, 
Rockville, MD) and ultrapure water (ThermoFisher) were used as positive and negative 
controls, respectively. Data were normalized on a per sample basis to the mean of three 
housekeeping genes that did not have significantly different levels of expression across 
groups (Gapdh, Ubc, Hrpt1) using the ∆Ct method.  
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Table 1. List of Genes Measured with Taqman Probes Using Fluidigm System.  
Stage of 
Angiogenesis 
Gene Protein Encoded Taqman 
Reference 
Number 
Sprout Tip Cell 
Selection 
Notch1 Notch 1 Rn01758633_m1 
Sprout Tip Cell 
Selection 
Jag1 Jagged 1 Rn00569647_m1 
Sprout Tip Cell 
Selection 
Dll4 Delta-like ligand 4 Rn01512886_m1 
Sprout Tip Cell 
Selection 
Tie1 Tie 1 Rn01417182_m1 




Tie 2 Rn01433346_m1 
Sprout Tip Cell 
Selection 
Cxcr4 C-X-C Motif Chemokine 
Receptor 4 
Rn01483207_m1 
Vessel Growth and 
Maturation 
Vegfa Vascular endothelial growth 
factor a 
Rn01511602_m1 
Vessel Growth and 
Maturation 
Vegfc Vascular endothelial growth 
factor c 
Rn01488076_m1 




Vascular endothelial growth 
factor receptor 1 
Rn01409533_m1 




Vascular endothelial growth 
factor receptor 2 
Rn00564986_m1 
Vessel Growth and 
Maturation 
Angpt1 Angiopoietin 1 Rn01504818_m1 
Vessel Growth and 
Maturation 
Angpt2 Angiopoietin 2 Rn01756774_m1 
Vessel Growth and 
Maturation 
Pdgfb Platelet derived growth factor 
subunit b 
Rn01502596_m1 
Matrix Invasion and 
Deposition 
Mmp2 Matrix metalloproteinase 2 Rn01538170_m1 
Matrix Invasion and 
Deposition 
Mmp9 Matrix metalloproteinase 9 Rn00579162_m1 
Matrix Invasion and 
Deposition 
Mmp14 Matrix metalloproteinase 14 Rn00579172_m1 
Matrix Invasion and 
Deposition 
Timp2 Tissue inhibitor of 
metalloproteinase 2 
Rn00573232_m1 
Matrix Invasion and 
Deposition 
Timp3 Tissue inhibitor of 
metalloproteinase 3 
Rn00441826_m1 
Matrix Invasion and 
Deposition 
CtsK Cathepsin K Rn00580723_m1 
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Table 1 continued 
Cell Adhesion and 
Migration 
Cdh5 Vascular endothelial cadherin Rn01536708_m1 
Cell Adhesion and 
Migration 
Cdh2 Neural cadherin Rn00580099_m1 
Cell Recruitment Bmp2 Bone morphogenetic protein 2 Rn00567818_m1 
Cell Recruitment Cxcl12 
(Sdf1a) 
Stromal derived factor 1 alpha Rn00573260_m1 
Cell Recruitment Fgf Fibroblast growth factor Rn00570809_m1 
Cell Recruitment S1pr1 Sphingosine 1-phosphate 
receptor 1 
Rn02758712_s1 
Cell Recruitment Tgfb1 Transforming growth factor b Rn00572010_m1 
Cell Adhesion and 
Migration 
Pecam1 Platelet endothelial cell 
adhesion molecule 1 
Rn01467262_m1 
Cell Adhesion and 
Migration 
Itga5 Integrin alpha 5 Rn01761831_m1 
Cell Adhesion and 
Migration 
Itgb1 Integrin beta 1 Rn00566727_m1 
Cell Adhesion and 
Migration 
Itgav Integrin alpha v Rn01485633_m1 
Cell Adhesion and 
Migration 
Itgb3 Integrin beta 3 Rn00596601_m1 
Cell Adhesion and 
Migration 
Itga2 Integrin alpha 2 Rn01489315_m1 
Inflammation and 
Apoptosis 
Il12 * Interleukin 12 Rn00584538_m1 
Inflammation and 
Apoptosis 
Il10 * Interleukin 10 Rn01483988_g1 
Inflammation and 
Apoptosis 
Tnfa Tumor necrosis factor alpha Rn01525859_g1 
Matrix Invasion and 
Deposition 
Fn Fibronectin Rn00569575_m1 
Matrix Invasion and 
Deposition 
Coll1a1 Collagen type 1 alpha 1 Rn01463848_m1 
Mechanotransduction Amotl2 Angiomotin-like 2 Rn01446301_m1 
Mechanotransduction Ankrd1 
* 
Ankyrin repeat domain 1 Rn00566329_m1 
Mechanotransduction Ctgf Connective tissue growth 
factor 
Rn01537279_g1 
Mechanotransduction Cyr61 Cyr61 Rn00580055_m1 
Inflammation and 
Apoptosis 
Bax Bcl-2-associated X protein Rn01480161_g1 
 114 
Table 1 continued 
Inflammation and 
Apoptosis 
Bcl2 B-cell lymphoma 2 Rn99999125_m1 
Housekeeping Gapdh Glyceraldehyde 3-phosphate 
dehydrogenase 
Rn01775763_g1 
Housekeeping Bactin Beta-actin Rn00667869_m1 
Housekeeping Hprt1 Hypoxanthine-guanine 
phosphoribosyltransferase 
Rn01527840_m1 
Housekeeping Ubc Poly-ubiquitin C Rn01499642_m1 
Housekeeping Ppia Peptidylprolyl isomerase A Rn00690933_m1 
* Indicates gene expression was below the limit of detection and thus excluded from 
analyses. 
 
7.2.5 Multivariate Analysis of Gene Expression Data 
 Partial least squares discriminant analysis (PLSDA) was performed in MATLAB 
(Mathworks, Natick, MA) using Cleiton Nunes’s partial least squares algorithm, which is 
available on the MathWorks File Exchange. To avoid biasing results with the absolute 
magnitude of different genes’ expression levels, data were z-scored prior to being analyzed 
with PLSDA. Orthogonal rotations were applied to the z-scores to maximally separate 
groups (non-loaded, compressive loading, and compression+shear loading) based on latent 
variables 1 and 2 (LV1 and LV2) created by the PLS algorithm. LV loading plots show the 
mean and standard deviation of each gene’s relative contribution to the latent variable; 
mean and standard deviation were calculated using Monte Carlo sub-sampling that 
iteratively excluded and replaced samples 1000 times [274].  
 
7.2.6 YAP Inhibition  
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The YAP inhibitor verteporfin (VP; MilliporeSigma, Burlington, MA) was 
dissolved in DMSO and added to serum-free MVF media at a concentration 5 µM. Non-
VP controls received an equal volume of DMSO. VP and DMSO were added to MVF-
containing gels 30 minutes prior to initiation of loading to allow diffusion throughout the 
gel. After 24 hours of loading, RNA was collected from early and delayed samples as 
above. The groups for the YAP inhibition study were compression+shear + VP, 
compression+shear + DMSO carrier only, non-loaded + VP, and non-loaded + DMSO at 
both early and delayed time points (n=5-6/group). All culture of samples containing light-
sensitive VP [275] was conducted in the dark.  
 
7.2.7 Statistical Analysis  
 For day 10 MVF network morphology data, a two-way ANOVA was used to 
compare early vs. delayed loading and compression vs. compression+shear loading. A one-
way ANOVA was used to compare early loading to the non-loaded control and delayed 
loading to the non-loaded control. To directly compare the effects of different load 
magnitudes, loaded groups were normalized to their respective non-loaded controls and 
analyzed within time point and loading type (e.g. early compression+shear compared at 
5%, 10%, and 30% strain) using a one-way ANOVA. Viability, proliferation, and 
perivascular coverage data were analyzed by two-way ANOVA. Gene array data were 
studied in aggregate using PLSDA as detailed above, and the expression levels of 
individual genes were compared within time point using a one-way ANOVA. The effect 
of verteporfin on gene expression of non-loaded vs. loaded constructs was analyzed with a 
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two-way ANOVA. Bonferroni’s post hoc test followed all ANOVAs. All statistical 
analyses were performed in GraphPad Prism 5 with α=0.05. Data are presented as mean ± 
standard error of the mean.  
 
7.3 Results 
7.3.1  Non-Loaded MVF Progress Through Distinct Stages of Angiogenesis in vitro  
Under static, non-loaded culture conditions, MVF form in vitro networks in a 
predictable time course. At day 0 (e.g. day of harvest), the freshly isolated fragments have 
characteristically rounded ends, denoted by white arrows in  Figure 7.1. By day 3 in culture, 
the fragment ends adopt a pointed appearance, indicative of early sprouting and invasion 
of the extracellular matrix. By day 5, the initial sprouts extend and begin to branch. Existing 
sprouts continue to elongate between days 5-7, and some secondary branching appears 
between days 7-10. Because sprout and branch initiation processes occur within the first 
five days of culture, while days 5-10 consist primarily of elongation, we selected days 0-5 
as “early loading” and days 5-10 as “delayed loading” (Figure 7.2 A). 
 
Figure 7.1. Representative images of in vitro MVF network formation over time. 
White arrows denote ends of freshly isolated fragments (d0) and resulting sprouts (d3, d5, 
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d7, d10). Maximum intensity z-projections (200 um depth) of samples stained with GS-1 
lectin. 
 
7.3.2 MVF Exhibit Sensitivity to Magnitude and Mode of Dynamic Loading 
 At 5% strain, delayed loading led to significantly greater total network length (two-
way ANOVA, Bonferroni post hoc p<0.05) and number of branches (post hoc p<0.05) than 
early loading (Figure 7.2 B-C). There was no effect of loading type at 5% strain (e.g. 
compression vs. compression+shear) and no significant interaction effect. Delayed 5% 
loading, both compression and compression+shear, increased length (one-way ANOVA, 
Bonferroni post hoc p<0.01 and p<0.001, respectively) and branching (post hoc p<0.05 
and p<0.01, respectively) relative to the non-loaded control. Early 5% loading was no 
different than the non-loaded control.  
 At 10% strain, delayed loading again significantly increased total network length 
(two-way ANOVA, overall effect p<0.05) and number of branches (overall effect p<0.05) 
relative to early loading (Figure 7.2 D-E). At 10% strain, compression+shear loading also 
increased length (overall effect p<0.05) and branching (overall effect p<0.05) relative to 
compression only. There was no significant interaction effect. Delayed compression+shear 
loading increased total length (one-way ANOVA, Bonferroni post hoc p<0.01) and number 
of branches (post hoc p<0.01) compared to the non-loaded control. Early 10% loading was 
no different than the non-loaded control.  
 At 30% strain, delayed compression+shear loading significantly increased total 
network length (two-way ANOVA, Bonferroni post hoc p<0.001) and number of branches 
(post hoc p<0.001) compared to early compression+shear (Figure 7.2 F-G). Delayed 
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compression+shear also increased length (post hoc p<0.01) and branching (post hoc 
p<0.01) relative to delayed compression alone. There was no significant interaction effect. 
Further, delayed compression+shear significantly increased length (one-way ANOVA, 
Bonferroni post hoc p<0.01) and branching (post hoc p<0.01) over the non-loaded control. 
At 30% strain, early loading, both compression and compression+shear, decreased the total 
network length relative to the non-loaded control (one-way ANOVA, Bonferroni post hoc 
p<0.01 and p<0.05, respectively). Early compression only also decreased branching as 
compared to the non-loaded control (post hoc p<0.05). Qualitatively, the early loaded 
constructs at day 10 appear to have only early stage sprouts (Figure 7.3) more comparable 
to the non-loaded sprouting observed at day 3 (Figure 7.1).  
When all loaded groups’ length and branching were normalized to that of their 
respective non-loaded experimental controls, early loading exhibited significant strain 
magnitude-dependence (Figure 7.4). 30% compression decreased network length and 
branching relative to both 5% (one-way ANOVA, Bonferroni post hoc p<0.01) and 10% 
compression (post hoc p<0.05). 30% compression+shear decreased network length and 
branching relative to 10% compression+shear (post hoc p<0.05). There were no 





Figure 7.2. Quantification of MVF growth under strain. Experimental design (A) and 
quantification of MVF network length and branching at 5% (B-C), 10% (D-E), and 30% 
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(F-G) strain. Quantification based on 3D confocal z-stacks of 200 um depth. * significant 
difference from NL; 1-way ANOVA, * p<0.05, ** p<0.01, *** p<0.001. # 2-way ANOVA 
with Bonferroni post hoc test; @ overall effect of loading type; ^ overall effect of time; 




Figure 7.3. Representative images of MVF networks formed under 30% strain.Early 
compression and early compression+shear groups exhibit only very early stage sprouts, 
white arrows. Delayed compression+shear appears qualitatively more densely vascularized 
than the non-loaded or delayed compression groups. Maximum intensity z-projections (200 




Figure 7.4. Length and branching under 5%, 10%, and 30% strain normalized to 
non-loaded group. 1-way ANOVA, * p<0.05, ** p<0.01. n=6/group.  
  
7.3.3 Dynamic Loading Differentially Affects MVF Proliferation but not Viability or 
Pericyte-Vessel Attachment 
 Based on our results comparing strain magnitude and type of loading, we selected 
early and delayed 30% compression+shear loading, the loading parameters that led to the 
greatest network morphology differences, for subsequent cellular analyses.  
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 To assess the effects of dynamic loading on MVF viability, non-loaded and loaded 
samples were live/dead stained on days 3 (early loading) and 7 (delayed loading) of culture 
(Figure 7.5). There was no effect of loading on viability, and viability was greater at day 7 
of culture than at day 3 for both non-loaded (two-way ANOVA, Bonferroni post hoc 
p<0.01) and loaded samples (post hoc p<0.01). Viability was approximately 75% at day 3 
and 90% at day 7.  
 
Figure 7.5. MVF viability under early and delayed 30% compression+shear loading. 
A) Representative maximum intensity z-projections (25 um depth) of calcein (green; live) 
and ethidium homodimer (red; dead) stained MVF at days 3 (early) and 7 (delayed). B) 
Image-based quantification of live/dead stain. 2-way ANOVA, ** Bonferroni post hoc 
p<0.01. No effect of loading. No interaction effect. n=3 random images/gel, n=3 
gels/group/time point. 
 
Proliferation was measured by EdU incorporation also at days 3 and day 7. There 
was no effect of early loading on proliferation, and approximately 5-10% of cells were 
proliferative at day 3 (Figure 7.6). Proliferation was greater at day 7 (two-way ANOVA, 
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overall effect p<0.001), and delayed loading led to increased proliferation, approximately 
25%, compared to non-loaded controls, approximately 15% (two-way ANOVA, 
Bonferroni post hoc p<0.05). There was a significant disordinal interaction effect (p<0.05), 
indicating that early loading and delayed loading have opposite effects on cellular 
proliferation.    
 
Figure 7.6. MVF proliferation under early and delayed 30% compression+shear 
loading. A) Representative maximum intensity z-projections (25 um depth) of DAPI (blue; 
all cells) and EdU (red; proliferating cells) stained MVF at days 3 (early) and 7 (delayed). 
B) Image-based quantification of proliferation. 2-way ANOVA, ^^^ overall effect of time, 
p<0.001, post hoc effect of loading ** p<0.01. Significant interaction effect, p<0.05. n=3 
gels/group/time point. 
 
The interaction between αSMA+ pericytes and endothelial cells of vessels was 
assessed at various time points. There were no significant differences in perivascular 
coverage of endothelial cells due to either early or delayed loading at any time point (Figure 
7.7). Perivascular coverage was approximately 75-80% at day 0 through day 10. 
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Qualitatively, there tended to be relatively less pericyte coverage at the ends of nascent 
sprouts.  
 
Figure 7.7. Perivascular coverage of MVF under early and delayed 30% 
compression+shear loading. A) Representative maximum intensity z-projections (25 um 
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depth) of DAPI (blue; nuclei), αSMA (green; perivascular SMCs), and isolectin B4 (red; 
ECs) stained MVF at days 3 (early) and 7 (delayed). B) Image-based quantification of 
perivascular coverage. 2-way ANOVA, no significant differences due to loading or time. 
n=3 gels/group/time point. 
 
7.3.4 Dynamic Loading Differentially Regulates MVF Gene Expression 
  Partial least squares discriminant analysis (PLSDA) was performed on gene 
expression data to create profiles of the RNA-level changes that were associated with the 
differential effects of early and delayed 30% strain loading (compression and 
compression+shear). For both the early and delayed time points, PLSDA created a latent 
variable (LV2) that separated non-loaded from loaded samples (Figure 7.8 A, C). LV2 is 
composed of a weighted average of genes, and each individual gene’s relative contribution 
can be visualized with a latent variable loading plot.  In general, gene expression was 
downregulated by early loading (negative values in Figure 7.8 B) and instead upregulated 
by delayed loading (positive values in Figure 7.8 D).  
When considered in aggregate, genes known to be involved in sprout tip cell 
selection (5 of 6) and protease homeostasis (6 of 6) tended to be downregulated by early 
loading. In contrast, genes known to be mechanosensitive (2 of 3) and involved in matrix 
deposition (2 of 2) tended to be upregulated by early loading. When considered at the 
individual gene level, Tie1, Mmp14, Timp3, Cxcr4, Cxcl12, Mmp9, and Itgav were all 
significantly downregulated by early loading. Cyr61, Ctgf, Vegfa, and Fgf2 were all 
significantly upregulated by early loading (Figure 7.9). These genes are some of the 
strongest contributors to the early loading LV2, as they have the largest absolute values in 
Figure 7.8 B.   
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Figure 7.8. PLSDA of MVF gene expression under 30% compression and 
compression+shear loading. PLSDA plots of latent variable 2 vs. latent variable 1 reveals 
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separation of loaded and non-loaded samples along LV2 for both early loading conditions 
(A) and delayed loading conditions (B). Loading plots of early LV2 (C) and delayed LV2 
(D) demonstrate the relative contribution of each gene to the separating LV2. Genes are 
color coded by angiogenesis functions they are known to be involved in. E) When 
interleaved, the loading plots of early vs. delayed loading reveal differential regulation of 
a number of genes. n=6 gels/group. Error bars created by 1000 iterations of Monte Carlo 
sub-sampling.  
Figure 7.9. Individual genes significantly affected by early loading. 1-way ANOVA, 
Bonferroni post hoc *p<0.05, **p<0.01. n=6/group. 
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When considered in aggregate, genes known to be involved in sprout tip cell 
selection (5 of 6), adhesion and migration (8 of 8), and mechanosensation (2 of 3) tended 
to be upregulated by delayed loading. Genes known to be involved in inflammation and 
apoptosis (3 of 3) tended to be downregulated due to delayed loading. At the individual 
gene level, the strongest contributors to the delayed loading LV2 are Flt1, Ctgf, Itgb1, 
Cxcr4, Timp3, and Tgfb1, which are all significantly upregulated by delayed loading, and 
Cxcl12, which is significantly downregulated by delayed loading (Figure 7.10).  
Figure 7.10. Individual genes significantly affected by delayed loading. 1-way 
ANOVA, Bonferroni post hoc *p<0.05, **p<0.01, ***p<0.001. n=6/group. 
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A number of these genes are differentially regulated by early vs. delayed loading 
(Figure 7.8 E). The strongest downregulated contributors to early loading LV2 tend to 
instead be upregulated by delayed loading, and the strongest upregulated contributors to 
delayed loading LV2 tend to instead be downregulated by early loading (e.g. Tie1, Mmp14, 
Timp3; Flt1 or Vegfr1, Itgb1, Cxcr4). There are two strongly upregulated contributors to 
both early LV2 and delayed LV2: Ctgf and Cyr61, which are canonical targets of the YAP 
mechanotranduction signaling pathway [276].  
Interestingly, of the 43 genes tested, there was only one gene with statistically 
significant differences in expression by delayed compression vs. compression+shear 
samples, despite the large morphological differences observed at day 10. Itga2 showed a 
significant difference between compression and compression+shear samples (Figure 7.10). 
Itga2 expression was upregulated in compression+shear samples relative to compression 
only (one-way ANOVA, Bonferroni post hoc p<0.05) and to the non-loaded control (post 
hoc p<0.01).  There were no genes with expression differences between compression and 
compression+shear loading at the early time point.  
 
7.3.5 YAP is Involved in MVF Response to Delayed Loading  
 To investigate the increased YAP target expression observed in the gene expression 
array, a pharmacological inhibitor of YAP, verteporfin (VP), was employed. Since the gene 
expression profiles of compression and compression+shear were nearly identical, only 
compression+shear loading was studied. At the early time point, loading increased 
expression of Ctgf (overall effect p<0.01; Figure 7.11), but there was no statistically 
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significant effect of VP on early gene expression of either Ctgf or Cyr61. At the delayed 
time point, delayed loading without VP increased expression of both Ctgf (two-way 
ANOVA, Bonferroni post hoc p<0.001) and Cyr61 (post hoc p<0.001) relative to the non-
loaded control. VP significantly decreased expression of Ctgf (post hoc p<0.05) and Cyr61 
(post hoc p<0.001) by loaded samples.  
 
Figure 7.11. Loading-induced expression of YAP target genes with YAP inhibitor VP. 
2-way ANOVA, overall effect of loading ## p<0.01; Bonferroni post hoc *p<0.05, 




 Mechanical cues influence tissue regeneration, and although vasculature is known 
to be mechanically sensitive, remarkably little is known about the effects of abluminal 
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mechanical stimulation of nascent vessel networks found in healing tissues. Time of 
loading has previously been shown to be a potent determinant of vascular network 
formation [136], but regulatory roles of loading parameters such as magnitude and mode 
remain poorly understood. Here, we tested the effects of dynamic load magnitude, mode, 
and time of initiation on in vitro MVF growth.  
We hypothesized that vascularization would be enhanced by delayed, moderate 
compression and inhibited by early, high magnitude compression and in regions of shear 
stress. At all tested strain magnitudes, delayed loading produced longer, more branched 
vessel networks than early loading. Consistent with our hypothesis, early, high magnitude 
loading inhibited vessel growth relative to non-loaded controls, and delayed, moderate 
magnitude loading enhanced vessel growth. However, contrary to our hypothesis, 
compression+shear loading led to longer, more branched networks than compression alone 
– particularly at higher strain magnitudes. Differential morphological effects of early vs. 
delayed 30% compression+shear loading were supported by differences in proliferation. 
Delayed 30% compression+shear loading significantly increased proliferation, and while 
early 30% compression+shear did not significantly decrease proliferation relative to its 
non-loaded control, there was an interaction effect between loading and time. Contrary to 
our hypothesis, there were no differences in viability or pericyte-vessel attachment due to 
loading. Gene expression was also differentially regulated by early vs. delayed loading. As 
hypothesized, genes known to be involved in early stage angiogenesis were downregulated 
due to early loading, along with many other genes. Genes known to be involved in later 
stages of angiogenesis, particularly matrix invasion and collective cell migration, were 
upregulated by delayed loading. Finally, pharmacological inhibition suggests that the YAP 
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mechanotransduction pathway is involved in the enhanced vascular response due to 
delayed loading.  
 Consistent with previous in vivo results [136], all strain magnitudes tested here in 
vitro showed an overall effect of time of loading, where delayed loading produced greater 
network length and number of branches. At low strains (5% and 10%), early loading did 
not affect vessel network formation; however, at a much higher (30%) strain, early loading 
significantly decreased network length and branching. Together, these data suggest that 
low magnitude strain may be permissive to early stage angiogenesis, whereas higher 
magnitude strains disrupt this process. Inhibitory effects of delayed loading were not 
observed, even at 30% strain. Once a critical stage of vascular network maturity is reached, 
even high magnitude loading may be permissive to vessel growth. Day 5 was chosen as the 
inflection point of early vs. delayed loading in the present studies to distinguish between 
sprout and branch initiation vs. elongation, suggesting that the initial formation of 
sprouts/branches may be this critical stage. Future work is required to better define a time 
point or stage of angiogenesis that becomes robust to higher magnitude loads.  
 Contrary to our hypothesis, compression+shear loading increased vessel length and 
branching overall compared to compression alone at strains above 5%. While our 
compression+shear platens were designed to introduce a shear interface zone, the interface 
of contact between the platen and gel was not visually apparent in the resulting vessel 
networks, and there was no difference in the spatial distribution of vessels. The 
compression+shear platens may create shear only at the very superficial surface of the gel 
but more profoundly change the bulk stress experienced by the gel and likely the local 
stress and strain gradients. Future computational work may more precisely define these 
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effects. Considering the platen surface area alone, our compression+shear platens have 
approximately 36% of the surface area initially in contact with the gels compared to the 
compression only platens. This difference may have placed the lowest magnitude strains 
within a similar range of stress, ultimately leading to similar results at 5% strain, but 
progressively amplified stress differences as strain increased, potentially explaining the 
morphological differences observed at 10% and 30% strain. However, of the 43 genes 
tested in our array, only one (Itga2) demonstrated differential expression between delayed 
compression and compression+shear. These similar gene expression profiles may be due 
to sampling after only 24 hours of loading; gene expression, and subsequent morphologies, 
may diverge later within loading. Alternatively, the similar gene expression profiles may 
suggest that later (after 5 days of loading rather than 24 hours) differences may be primarily 
mediated by differences in fluid flow patterns, which are difficult to decouple from in vitro 
loading systems. However, if all effects observed in these experiments were due to an 
increase in fluid flow and thus nutrient transport, early 30% loading would likely have also 
had a beneficial effect rather than the inhibitory effect we observed.  Interestingly, there 
were no significant differences between early compression and early compression+shear, 
suggesting that even if mediated primarily by stress rather than strain, stresses applied by 
both loading configurations at 30% were inhibitory to early loading.     
Looking at the effects of load magnitude in compression only loading reveals a 
beneficial effect of 5% strain, no statistically significant post-hoc difference between non-
loaded and 10% strain, and no effect at 30% strain. These data suggest that there is a “sweet 
spot” of compressive strain magnitude, even when loading is delayed. In contrast, 
compression+shear loading increased length and branching at all three magnitudes, and 
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normalization to the non-loaded control suggests there may be a dose response to 
compression+shear magnitude that these studies were simply not sufficiently powered to 
detect. If the observed morphological differences are stress-mediated, the 
compression+shear platen at 30% strain may have still been within the optimal range that 
the compression only platen surpassed at 30% strain.  
 We investigated several cell-level phenomena as possible explanations for the stark 
morphological changes induced by dynamic 30% compression+shear loading: viability, 
proliferation, and perivascular-endothelial cell interactions. We hypothesized that early 
loading may have inhibited network formation by decreasing cell viability or destabilizing 
pericyte-vessel attachment. However, there were no differences in cell viability or 
perivascular coverage by αSMA+ cells due to early or delayed loading. Overall viability 
was higher at day 7 of culture than at day 3. Some cell death may occur shortly after the 
isolation of MVF, and these dead cells likely remain entrapped within the gel as the live 
cells proliferate and increase in number. Quantification of perivascular coverage remained 
at 75-80% at all time points examined, and qualitatively, vessels maintained pericyte 
coverage along their length except for growing sprout tips. Endothelial cells appear to lead 
sprout invasion of the matrix, and pericyte proliferation and thus coverage may occur 
secondarily in response to the primary proliferation and extension of endothelial cells in 
both non-loaded and loaded constructs. We also hypothesized that cell proliferation may 
have mirrored the morphological results, with early loading decreasing proliferation but 
delayed loading increasing proliferation. Indeed, delayed loading increased proliferation. 
While there was no statistically significant post hoc difference between early loaded and 
non-loaded samples, there was a significant interaction effect of time and loading. This 
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suggests that early and delayed loading differentially affect proliferation, with delayed 
loading having a stimulatory effect and early loading having a (more modest) dampening 
effect. The proliferation results support the changes in length and branching; however, the 
underlying biological mechanisms for these changes remained unclear.  
 To broadly probe a number of processes involved in angiogenesis (e.g. sprout tip 
cell selection, matrix invasion, etc.), we utilized a high throughput gene expression array. 
Gene expression profiles of non-loaded vs. loaded MVF were parsed using PSLDA. 
Overall, more genes were downregulated by early loading, and more genes upregulated by 
delayed loading. This was true across for genes known to be involved in early stage 
angiogenesis, e.g. genes known to be involved in sprout tip cell selection, and those known 
to be involved in later stages, e.g.  matrix invasion and collective cell migration.  
The strongest contributor to the early loading gene expression was the 
downregulation of Tie1, an orphan receptor that regulates angiogenic sprouting through 
Angpt/Tie2 signaling. Tie1 is expressed by active sprout tip cells and is strongly 
downregulated in quiescent endothelial cells [34], suggesting that early loading shifts 
endothelial cells to a more quiescent state. Two other genes associated with tip cells were 
also downregulated by early loading: Cxcr4 and Mmp14. Cxcr4 is expressed by activated 
tip cells [277] and may also play a role in sprout anastomosis [30]. The ligand for Cxcr4, 
Cxcl12 or Sdf1, was also downregulated by early loading. Mmp14 is expressed by tip cells 
that lead the invasion of surrounding matrix [30, 33]. Timp3 is able to inhibit all MMPs 
[278], and the fact that it was also downregulated by early loading suggests that the 
homeostatic balance of MMP-Timp activity may be perturbed by early loading. While a 
number of proteases were downregulated by early loading, the two ECM protein genes 
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included in our array, Coll1a1 and Fn, were upregulated according to PLSDA. Rather than 
invading the surrounding gel matrix, these cells may have laid down more of their own 
matrix as a function of being less migratory. Interestingly, Vegfa was also upregulated by 
early loading. While Vegfa is a necessary component of the sprouting process, it alone is 
not sufficient to induce sprouting; the balance of other factors, especially angiopoietins 1 
and 2, is also a key determinant of whether angiogenesis will occur [279]. The increase in 
Vegfa may be a compensatory response of MVF pushed into a more quiescent state by 
early loading. Alternatively, there is evidence that endothelial cells can produce an anti-
angiogenic isoform of Vegfa [280]. The two genes most strongly upregulated in response 
to early loading are Ctgf and Cyr61, which are both canonical targets of the YAP 
mechanotransduction pathway [276].  
In response to delayed loading, the strongest contributor to the gene expression 
profile represented by PLSDA was the upregulation of Flt1 or Vegfr1. By increasing 
expression of Vegfr1, delayed loading may increase the sensitivity of MVF to pro-
angiogenic Vegf signaling. This may be in contrast with early loading, in which Vegfa 
upregulation was not accompanied by Vegfr1 or Vegfr2 upregulation. Also in contrast with 
early loading, delayed loading led to strong upregulation of both Cxcr4 and Timp3 and a 
more modest upregulation of Mmp14 in the PLSDA gene expression profile. Together, 
these divergent effects of early vs. delayed loading suggest that tip cell activation may be 
the mechanism through which loading affects neovascularization. Although Cxcr4 was 
differentially affected by early vs. delayed loading, its ligand Cxcl12 or Sdf1a was strongly 
downregulated by both loading scenarios. We initially hypothesized that genes known to 
be involved in cell recruitment such as Cxcl12 or Sdf1a would be upregulated by delayed 
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loading. The lack of bidirectional signaling between the nascent vessel and free cells, which 
are absent in this culture model, may decrease cell recruitment signaling of MVF. 
Additionally, while these genes are known to be involved in cell recruitment, they also play 
other roles that may be larger in this context. Bcl2, Bax, and Tnf were all negative 
contributors to the delayed loading LV2. However, the ratio of pro-apoptotic Bax and anti-
apoptotic Bcl2 [281] was not significantly different, which is supported by the live/dead 
stain. Tnf was also a negative contributor to the early loading LV2, suggesting it is not a 
mediator of differential mechanical effects. Mmp2 and Mmp9 were also negative 
contributors to both delayed and early loading LV2. Although they are implicated in 
angiogenesis [31, 32], neovessel-specific Mmp14 [30, 33]  may play a more critical role in 
our model of microvascular sprouting.  
Itgb1, which is an essential adhesion molecule for angiogenesis [282], was 
upregulated by delayed loading. When looking at the overall gene expression profile of 
delayed loaded MVF, all eight vascularization-associated adhesion molecules included in 
our array were upregulated. Interestingly, the one molecule that was differentially 
expressed by delayed compression vs. compression+shear samples was also an integrin, 
Itga2. The a2 and b1 integrin subunits form a complex that can bind both collagen [283] 
and decorin [284], the two components of our gel matrices. In our system, integrins a2b1 
may couple cells to the mechanically dynamic matrix and thus act as an element of the 
mechanotrasduction pathway. In delayed loaded samples as in early loaded samples, two 
of the most strongly upregulated genes were canonical YAP targets Cyr61 and Ctgf.  
To more deeply investigate the potential involvement of YAP/TAZ in the 
neovascular response to compressive loading, we employed a pharmacological YAP 
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inhibitor, verteporfin (VP). VP prevents the binding of YAP to the rest of the 
transcriptional complex, thus suppressing YAP activity [275]. Interestingly, we did not 
observe the same significant upregulation of Cyr61 and Ctgf due to early loading in the VP 
experiment as in the initial gene expression array. There was a statistically significant 
overall upregulation of Ctgf in response to early loading, suggesting YAP may also be 
involved in the early response, but there was no effect of VP on early expression of either 
Ctgf or Cyr61. These samples contained DMSO to appropriately control for the delivery 
of VP within DMSO, and DMSO may have altered the baseline response of MVF to early 
loading. However, VP abrogated the upregulation of both Cyr61 and Ctgf due to delayed 
loading, implicating YAP signaling in the stimulatory effect of delayed loading. Together, 
these results suggest that delayed loading activates YAP signaling, perhaps through 
integrins, which stimulates the upregulation of genes associated with active tip cells, 
leading to enhanced vascularization. Ctgf and Cyr61 themselves have been shown to 
increase endothelial cell proliferation, promote cell adhesion, and modulate the expression 
of MMPs and TIMPs [285]. Future work is required to more precisely investigate the 
molecular mechanisms at play and why only delayed loading potentiates a beneficial effect 
on microvascular growth in vitro.  
 
7.5 Conclusions 
Mechanics influence tissue regeneration, and although vasculature is known to be 
mechanically sensitive, this is the first known in vitro study of the effects of compressive 
loading on nascent vascular networks. We demonstrated that delayed loading increases 
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vessel network length and branching compared to early loading at all three strain 
magnitudes tested (5%, 10%, and 30%). The stimulatory effects of delayed loading were 
potentiated by loading in gels with a smaller diameter platen designed to introduce 
compression+shear, which was contrary to our hypothesis. Delayed 5%, 10%, and 30% 
compression+shear increased length and branching above that of non-loaded controls, and 
early 30% strain, both compression+shear and compression only, diminished network 
formation. The morphological differences created by early vs. delayed 30% 
compression+shear were supported by differential effects on cell proliferation. Using a 
high-throughput array, we identified gene expression profiles associated with early and 
delayed loading. Genes associated with active tip cells were downregulated by early 
loading but upregulated by delayed loading. Delayed loading also led to the upregulation 
of genes involved in cell adhesion and migration. Both early and delayed loading increased 
the expression of canonical YAP targets Cyr61 and Ctgf, and this effect was abrogated in 
delayed loading by YAP inhibitor verteporfin (VP). Overall, this work motivates future 
investigation of delayed mechanical loading as a component of tissue engineering or 
physical rehabilitation strategies to enhance revascularization following injury as a means 




CHAPTER 8. CONCLUSIONS AND FUTURE DIRECTIONS 
8.1 Overall Conclusions 
Overall, this thesis has investigated adipose-derived vascular cell sources as bone 
therapeutics, developed and characterized a novel biomaterial for in vitro and in vivo 
applications, and increased fundamental knowledge about the effects of abluminal 
compressive loading on neovascularization. These results can be leveraged to more 
effectively treat challenging bone injuries, through informing both future tissue 
engineering strategies and physical rehabilitation regimens.    
 
8.1.1 Specific Aim 1: Evaluate effect of vascular cell source co-delivered with BMP-2 to 
composite defect model 
 In Chapter 3, we characterized collagen sponge, a clinically available BMP-2 
carrier, as a co-delivery vehicle for both BMP-2 and MVF/SVF. Both MVF and SVF 
maintained viability in collagen sponge for at least 14 days; however, multicellular MVF 
first dissociated to single cells before reforming networks. This is in contrast with the 
sprouting angiogenesis MVF exhibit in collagen gel matrices. Interestingly, MVF 
dissociation in the presence of exogenous BMP-2 appeared to trigger an increased recovery 
of BMP-2, both on collagen sponge and on TCPS. The increased BMP-2 recovery was not 
due to MVF producing additional BMP-2 or increased protease activity. MVF may bind 
exogenous BMP-2 that is subsequently released upon dissociation. A pilot in vivo 
experiment was performed to evaluate the effects of MVF+BMP-2, SVF+BMP-2, and 
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BMP-2 alone delivered by collagen sponge on bone healing with concomitant muscle 
damage. This pilot study suggested that co-delivering MVF, but not SVF, may increase 
regenerate bone mechanical properties compared to BMP-2 alone.  
In Chapter 4, we conducted a fully powered in vivo study comparing the effects of 
MVF and an increased dose of BMP-2 on bone healing in a composite bone-muscle defect 
model. Consistent with our hypothesis, a modestly increased 10 µg dose of BMP-2 
improved bone healing relative to a minimally bridging 2.5 µg dose. However, contrary to 
our hypothesis, MVF did not improve healing and in fact significantly decreased regenerate 
bone stiffness. Although dissociation of MVF within collagen sponge augmented BMP-2 
recovery in vitro, we speculated that MVF dissociation in vivo did not recapitulate this 
phenomenon and instead likely led to cell death before vascular networks could reform and 
anastomose with host vasculature. This motivated the development of an alternative 
biomaterial delivery vehicle.  
 
8.1.2 Specific Aim 2: Develop a biomaterial for in vitro studies and in vivo delivery of 
microvascular fragments. 
MVF are typically cultured in low percentage collagen gels; however, these are not 
suitable for in vivo MVF delivery. Collagen gels allow robust in vitro network formation, 
but as the networks grow and exert increasing traction forces on the matrix, the collagen 
gel will eventually contract and collapse the vascular network within. Thus, dimensional 
stability was a key design criterion for both in vivo MVF delivery and extended in vitro 
culture. Additionally, collagen gels exhibit a burst BMP-2 release that is not favorable for 
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bone regeneration. In Chapter 5, we developed and characterized DCN-supplemented 
collagen hydrogels as in vitro MVF culture substrates. The addition of DCN increased gel 
compressive properties and achieved improved dimensional stability without 
compromising MVF growth. In Chapter 6, we also demonstrated that collagen+DCN gels 
exhibit a more sustained release of BMP-2 than collagen alone and evaluated 
collagen+DCN as an in vivo co-delivery vehicle for BMP-2 and MVF. Despite in vitro 
results showing synergistic effects of BMP-2 and MVF, there was no effect of MVF on 
bone healing, and MVF significantly decreased early revascularization following injury. 
Together, Chapters 4 and 6 suggest that freshly isolated, adipose-derived MVF are not 
viable segmental bone defect therapeutics. However, collagen+DCN gel is a dimensionally 
stable culture substrate for long-term MVF culture that withstands compressive loading.  
 
8.1.3 Specific Aim 3: Investigate effects of mechanical loading on microvascular growth 
and remodeling. 
In Chapter 7, we utilized MVF as an in vitro model system to study the effects of 
compressive loading on neovascularization. MVF represent a 3D culture system that allows 
for cell-cell and cell-matrix interactions, thereby better representing physiologic conditions 
than traditional 2D monolayer approaches. Although vasculature is a vital component of 
nearly all tissues and reestablishment of a functional vascular network is required for 
wound healing to proceed, remarkably little is known about the effects of abluminal forces 
on vascular growth. We used MVF as a platform to investigate the effects of dynamic 
compressive strain magnitude, mode, and time of initiation. We demonstrated that delayed 
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loading led to longer, more extensively branched microvascular networks than early 
loading at all strain magnitudes tested, and contrary to our hypothesis, the stimulatory 
effects of delayed loading were potentiated by loading in gels with a smaller diameter 
platen designed to introduce compression+shear. Early loading exhibited strain magnitude-
dependence, and 30% strain, both compression+shear and compression only, inhibited 
network formation. Gene expression analysis revealed differential mechanoregulation of 
gene expression profiles by early vs. delayed loading. Interestingly, some of the same genes 
were differentially affected by early vs. delayed loading; genes associated with active tip 
cells were downregulated by early loading but upregulated by delayed loading. Delayed 
loading also led to the upregulation of genes involved in cell adhesion and migration. Both 
early and delayed loading increased the expression of two canonical YAP targets, Cyr61 
and Ctgf, and this effect was abrogated in delayed loading by YAP inhibitor verteporfin 
(VP), demonstrating YAP’s involvement in the pro-angiogenic response to delayed 
loading.  
 
8.2 Future Directions 
8.2.1 MVF and SVF as Therapeutics for Bone 
 In Chapters 3-4, we investigated MVF and SVF as therapeutics for bone 
regeneration. Intriguing in vitro BMP-2 recovery results that demonstrated augmented 
BMP-2 recovery from MVF-containing collagen sponges and promising results of a pilot 
in vivo experiment led us to focus on MVF; however, SVF have been used clinically as not 
only a vascular cell source but also a source of osteoprogenitor cells [123]. The MVF dose 
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used in the studies presented in this thesis was determined by a pilot study, and the SVF 
dose used was chosen to deliver approximately the same number of cells as the MVF dose. 
By more rigorously studying both the dose of SVF and its osteogenic potential, SVF may 
prove to be an attractive therapeutic for segmental bone defects with concomitant muscle 
damage.  
 After completion of Chapters 3-4, we speculated that the collagen sponge delivery 
vehicle promoted MVF dissociation that prevented a beneficial healing response. MVF 
decreased regenerate bone stiffness, and, while not statistically significant, tended to 
decrease the absolute value of bone volume as well. After using a different biomaterial 
delivery system that was specifically tailored to the co-delivery of BMP-2 and MVF, we 
still observed no beneficial effect of MVF on bone healing in the composite defect model 
and observed a decrease in vascularization. Additionally, while the implanted GFP+ MVF 
were identifiable by immunohistochemistry at seven days post-surgery, they appeared as 
single cells, which we did not observe in collagen+DCN in vitro, and did not appear to be 
associated with vascular structures.  
We harvested MVF from retired breeder rats, which are by definition older. Other 
groups have reported more robust network formation with MVF from young donor rats 
[220], perhaps due to increased abundance or potency of progenitor cells, which may 
improve outcomes. Previous work in our lab that has shown an increased vascular volume 
with MVF treatment used MVF that were cultured in vitro for four days prior to 
implantation [116], allowing a provisional network to form. Pre-culturing MVF, which has 
been shown to accelerate inosculation with the host vasculature [115], may improve their 
success in large volumetric defects such as segmental bone defects. Future studies may 
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investigate the delivery of MVF pre-cultured in collagen+DCN gels. However, co-delivery 
of a consistent BMP-2 dose is a challenge in pre-cultured constructs. Development of a 
biomaterial capable of stimulus-responsive release of BMP-2 or a strategy to load BMP-2 
into existing gels could be investigated. Since we see a negative effect of MVF treatment 
rather than simply no effect at all, MVF are likely disrupting some part of the endogenous 
healing process. Adipose-derived MSCs, which MVF do contain (see Figure 3.1), have 
previously been shown to diminish BMP-2-mediated bone formation [67]. Although 
adipose-derived MVF have potential for autologous transplantation, MVF isolated from 
tissue-specific sources (e.g. bone marrow) may prove more successful in bone.  
 
8.2.2 Increased BMP-2 Dose to Treat Bone Injuries with Concomitant Muscle Damage 
 Although MVF did not improve bone healing with concomitant muscle damage, a 
modestly increased 10 µg dose of BMP-2 did improve healing compared to a minimally 
bridging 2.5 µg dose. Although extremely high BMP-2 doses have been linked to a number 
of adverse effects including heterotopic ossification and an increased inflammatory 
response [73], we did not observe any mineralization outside the defect area, and levels of 
both pro- and anti-inflammatory cytokines were lower in the higher BMP-2 dose group. A 
modestly increased BMP-2 dose may be able to overcome the attenuated bone healing 
observed with concomitant muscle damage, but future studies to precisely determine 
species-specific dosing are required.  
The mechanisms by which BMP-2 can begin to overcome the bone healing deficit 
also warrant investigation. The inflammatory stage of wound healing has been shown to 
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be prolonged in composite defects [40], and future studies investigating inflammatory 
profiles at earlier time points would be required to more definitively address the composite 
injury’s inflammatory response to various BMP doses. The composite defect model used 
here exhibits both attenuated bone healing and altered revascularization; BMP-2 can 
indirectly promote angiogenesis [286], which may be a factor. Increased dose of BMP-2 
may also simply amplify the cell recruitment and differentiation signaling it is known to 
stimulate [59]. 
 While clinically available, collagen sponge exhibits a burst release of BMP-2 [242], 
which necessitates the usage of supraphysiological doses that have led to adverse effects 
[73]. We conducted a pilot composite defect study where we delivered both 2.5 µg and 10 
µg of BMP-2 in collagen+DCN gels (Figure 8.1). Similar to the dose differences observed 
when delivered on an acellular collagen sponge, we saw an approximate two-fold increase 
in failure strength with increased dose. In contrast with the acellular collagen sponge 
delivery vehicle, we also observed a nearly 30% increase in bone volume with increased 
BMP-2 dose delivered in acellular collagen+DCN gels. Again, we did not observe 
mineralization outside the defect area. These data both provide additional support for the 
use of a moderately increased BMP-2 dose in composite injuries and demonstrate that 
collagen+DCN is a capable BMP-2 delivery vehicle, even at moderately increased doses. 
Future work may include fully powered studies using collagen+DCN gels as delivery 
vehicles for higher dose BMP-2. 
Ongoing work is also investigating the use of heparin microparticles to delivery 
higher dose BMP-2 (e.g. 30 µg) to composite defects. Heparin sequesters positively 
charged growth factors including BMP-2 and thus allows for a much more controlled, 
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sustained release of BMP-2 [287]. Defect bone volume, heterotopic bone volume, and the 
inflammatory response should all be considered in the optimization of BMP-2 dose and 
delivery vehicle.  
  
 
Figure 8.1. Pilot study deliverying 2.5 µg and 10 µg of BMP-2 to composite defect 
model in collagen+DCN gels. 12-week radiographs of A) 2.5 µg and B) 10 µg BMP-2-
treated defects. Relative to 2.5 µg BMP-2, 10 µg BMP-2 tended to increase both C) bone 
volume and D) failure strength.   
 
 
8.2.3 Mechanical Regulation of MVF Growth  
 The in vitro loading setup used in Chapter 7 presents a rich platform for future 
work, as nearly every parameter could be varied: frequency, strain magnitude, initiation 
time of loading, duration of loading, and platen design. We consistently used a 1 Hz 
frequency for all studies. In bone, high frequencies have been shown to potentiate the 
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response of smaller magnitude strains [151, 152]. Therefore, the effects of high frequency, 
low magnitude loading on microvascular growth may be of particular interest. 
Additionally, preliminary data suggests that the frequency parameter is important to the 
stimulatory effect of loading. At 30% strain, delayed static loading (e.g. frequency of 0 Hz) 
increased network length and branching relative to early loading but had no effect relative 
to the non-loaded control.  
 
 
Figure 8.2. Preliminary Static Loading Data. A) Static compression device; the larger 
diameter platen pegs (left) create unconfined compression (UC), while the smaller diameter 
pegs (right) create UC with a shear interface zone. Representative day 10 images of B) 
non-loaded, C) early UC, D) delayed UC, E) early UC+shear, and F) delayed UC+shear. 
G) Quantification of microvascular network length and branching under static unconfined 
compression, with or without a shear interface zone, vs. unloaded controls; quantification 
performed on thresholded maximum intensity z-projections using Fiji AngioAnalyzer 
plugin; two-way ANOVA, n=4/group; * indicates p<0.05, ** p<0.01. 
 
 
Looking at delayed 5%, 10%, and 30% compression only, we observed a significant 
beneficial effect of 5% strain, no significant increase but higher absolute value at 10% 
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strain, and no effect at 30% strain, suggesting there is an optimal strain for increasing 
vascular growth. By investigating additional strain magnitudes, particularly those between 
10-30%, this peak may be more precisely identified. Similarly, early loading was inhibitory 
at 30% strain but not at 5% or 10% strain; the strain threshold at which early loading 
becomes disruptive could also be more precisely identified by testing strains between 10-
30%. To more precisely define what critical step must occur or level of vascular maturity 
must be achieved for networks to be permissive to loading, loading could be initiated at 
different time points, particularly those between days 0-5. An interesting experimental 
group is early loading that is applied continuously throughout the 10 day culture. We chose 
not to include that group to keep the overall duration of loading consistent between early 
and delayed loading, but it may provide valuable insights into whether early loading 
completely impedes or simply delays angiogenesis. Another interesting variation would be 
to introduce rest periods within loading, e.g. load for 12 hours and rest for 12 hours. This 
may better mimic physiologic loading due to normal activity, and bone can be effectively 
restimulated by loading after a rest period as brief as 14 seconds [155, 156].   
 Contrary to our hypothesis, we saw that compression+shear loading led to increased 
vascular length and branching at 10% and 30% loading. While we designed the 
compression+shear platens to introduce a shear interface zone, no interface was visually 
apparent in the resulting vessel networks, and there was no difference in the spatial 
distribution of vessels. Ongoing computational work in collaboration with Jeff Weiss’s 
group at the University of Utah led by Steven LaBelle suggests that the compression+shear 
platens create shear only at the very superficial surface of the gel but do profoundly change 
the fluid flow patterns into and out of the gel (Figure 8.3). These compression+shear 
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platens also change the bulk stress experienced by the gel and the local stress and strain 
gradients, which computational modeling in the Weiss group will help to define. Different 
platen designs could be optimized with the aid of computational modeling to answer 
specific questions about the roles of shear, bulk stress vs. strain, and local stress and strain 
gradients. Computational data may also be useful in narrowing the wide parameter space 
discussed above.   
 
Figure 8.3. Preliminary computational modeling results of loading 3% collagen+DCN 
gels. A) Maximum shear stress experienced by collagen+DCN gels to 30% strain in 
compression+shear loading configuration. Fluid flux profiles due to 30% strain in B) 
compression+shear and C) compression only. (Figures provided by Steven LaBelle.) 
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 Within the parameters we did investigate, it would be interesting to assess 
expression of the same genes probed at 30% strain at 5% and 10% strain. The gene 
expression profiles leading to a beneficial effect of loading may be similar regardless of 
strain magnitude (i.e. they achieve the same net effects), or they may differ, suggesting that 
different strains modulate vascular growth through differing mechanisms. The expression 
of YAP targets upregulated by 30% strain, Cyr61 and Ctgf, would be of particular interest 
at lower strains. Early compression+shear loading was not significantly different than the 
non-loaded group, but the absolute value of length and branching were higher. Exploring 
gene expression at 10% compression+shear could elucidate whether early loading can have 
a beneficial effect at the proper parameters.  
 The involvement of YAP in the response to loading warrants further investigation. 
Although we initially saw strong upregulation of YAP targets Cyr61 and Ctgf in response 
to both early and delayed loading, we only saw their strong upregulation in response to 
delayed loading in the YAP inhibitor study. However, VP did abrogate the upregulation of 
these genes due to delayed loading, demonstrating that YAP signaling is indeed involved 
in the response of microvasculature to delayed loading. There was a statistically significant 
overall upregulation of Ctgf in response to early loading, suggesting YAP may also be 
involved in the early response, but there was no effect of VP on early expression of either 
Ctgf or Cyr61. It would be interesting to examine the expression of other genes strongly 
affected by loading when YAP signaling is inhibited. We made an effort to investigate this, 
but the inclusion of DMSO appeared to starkly alter the overall baseline gene expression 
profiles of MVF, both loaded and non-loaded. VP itself also had baseline effects on non-
loaded constructs, which is not as surprising; VP inhibits YAP binding to the TEAD 
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transcriptional complex but also has a number of other effects and is used clinically in 
combination with photostimulation to ablate endothelial cells [288]. Titrating the 
concentration of DMSO and precise dose of VP may help alleviate this technical issue, but 
these questions may have to a wait until a more specific inhibitor of YAP activity is 
developed. In the meantime, immunohistochemistry can be used to begin investigating the 
integrins such as Itgb1 that may also play a role in YAP-mediated mechanotransduction. 
Investigating cytoskeletal effects of loading may also provide insight into the 
mechanotransduction pathway at play. Ultimately, conventional pathway identification 
techniques (e.g. kinase inhibitors and western blotting to examine protein phosphorylation) 
could be used to precisely identify the signaling cascade that generates a microvascular 
response to dynamic compressive loading.  
 One advantage of using MVF as a model system is that they are composed of 
multiple cell types characteristic of mature vasculature. However, this is also a limitation 
in identifying cell type specific responses to loading. The immunohistochemistry 
performed in Chapter 7 suggests that the relative abundance of the two most prevalent cell 
types, SMCs and ECs, does not substantially change over time or in response to loading. 
However, flow cytometry would be a more precise method of assessing this, and there are 
additional cell types that could be investigated, including macrophages, which are known 
to be components of MVF (unpublished data, Jay Hoying; macrophages also comprise 
around 20% of related adipose-derived SVF [120]) and to play a role in angiogenesis [30, 
289]. To begin to understand cell type specific responses to loading, single cell RNA 
sequencing could be employed.   
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 Once the vascular cell-specific responses are characterized, utilizing a co-culture 
of MVF with osteoblasts, osteocytes, myoblasts, etc. may provide more tissue-specific 
insights into the effects of loading on microvascular growth in a more physiologically 
relevant context. The addition of soluble signals thought to be more tissue-specific (e.g. 
BMP-2) may be another way to begin to understand inter-tissue crosstalk. MVF cultured 
in collagen+DCN gels hold great potential as microphysiologic systems that could be used 
to understand the effects of mechanical cues and chemical cues and could be utilized as a 
drug screening platform, especially for drugs intended to target pathways convergent with 
mechanotransduction pathways.   
 The effects of abluminal compressive loading on neovascularization gained here 
can begin to inform clinical practice. In particular, the benefits of delayed loading here may 
inform guidance on how soon patients can and, in fact, should resume load-bearing 
activities. In combination with well-characterized fixation strategies that apply strain of a 
known, favorable magnitude, enhanced bone healing may follow enhanced angiogenesis. 
More broadly, the fundamental understanding of how abluminal compressive forces 
regulate microvascular growth is relevant to all vascularized tissues and motivates further 





APPENDIX A. PROTOCOLS 
A.1 Microvascular Fragment (MVF) Isolation 
Materials  
• HBSS + 5% FBS, need about 250ml per isolation 
• 1X PBS with Ca and Mg 
• Collagenase Type I (Worthington Biochemical) 
• DNase (Sigma 11284932001) 
• Bovine serum albumin (BSA; Sigma A3294) 
• 0.22 um sterile filters (e.g. Steriflip, Millipore SCGP00525) 
• Small (50 -125 mL) autoclavable plastic Erlenmeyer flask  
• Small Teflon stir bar 
• Large aperture steel mesh (McMaster 9322T65) 
• 20 µm nylon filter sheet (Small Parts CMN-0020-D) 
• 200-500 µm nylon filter sheet (Small Parts B0043D1TVO or CMN-0500-C) 
• 50 mL conical tube – sterile  
• 15 mL conical tubes – sterile  
• Serological pipettes (5 mL, 10 mL, 25 mL) 
• Wide bore pipette tips (e.g. Thermo 2079G and 2069G) 
• Petri dish (non-TC treated) – sterile  
• Curved hemostats (1) – sterile 
• Large scissors (2) – sterile 
• Small scissors (1) – sterile 
• Forceps (2) – sterile 
• Male rats – retired breeders as large as possible 
• Alcohol-soaked gauze 





• Collagenase Type 1 (Clostridial collagenase, Worthington Biochemicals, USA) 
o Lot tested by empirical microvascular yield and quality assessment and in 
vitro culture testing. Lots SM2P13900 and 45N16191 have worked well.  
• Total volume of digestion solution is 1.5 times the fat volume in mL PBS.   
• Add 7.5x fat volume of BSA in mg. 
• Add 3.5x fat volume of collagenase in mg  
• Add 2x fat volume of DNase in mg.  
• Mix to dissolve and sterile filter.  Prepare right before use.  Must be at room 
temperature when added to fat. 
• Example calculation: 
Have 15 mL fat. Use 22.5 mL PBS to dissolve 52.5 mg collagenase, 30 mg 
DNase, and 112.5 mg BSA. 
 
Methods 
Fat Isolation   
1. After anesthetizing the animal with isoflurane, lay the animal down in the supine 
position. Put pressure on the middle of the abdomen area with 2 fingers and wipe 
animal well with alcohol-soaked gauze – pelvic area first, then feet. 
2. Grip animal with hemostats on the skin directly at the base of the penis.  
3. Cut the skin below the hemostat with large scissors to expose the testes.  Gently 
draw out the epididymal fat and vessels using forceps and harvest the fat only 
using small scissors without cutting the large testicular vessels or the epididymal 
head/tail. 
4. Expose the animal’s thorax with large scissors and induce a hemo-pneumothorax 
to euthanize the animal. 
5. Harvest the fat and place it in a tube with a known volume of FBS-HBSS (e.g. 20 
mL) to measure the fat volume and calculate the appropriate material amounts for 
the digestion solution. 
6. Transfer fat to non-TC treated Petri dish with new, sterile forceps.  
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7. Manually mince the fat pads using new, sterile large scissors for about 7 minutes 
to get a homogenous mix that can be drawn up into a 10 mL pipette.  
8. Mix the digestion solution with the minced adipose tissue using a 10 mL 
serological pipette and transfer to small Erlenmeyer flask with a small Teflon stir 
bar and digest in a 37oC water bath with agitation (shaking water bath or manually 
shaking vigorously for 7 – 8 minutes). 
9. Stop the digestion by adding FBS-HBSS to the digestion solution (at least 1:1 
volume). 
10. Transfer the digestion solution into 50 mL conical tubes and spin in a clinical 
centrifuge at 4000 rpm for 4 minutes. 
11. Aspirate the supernatant and wash the pellet in further FBS-HBSS, breaking the 
pellet and re-suspending it in this new wash buffer.  Transfer the solution to 15 
mL tubes. 
12. Spin again at 3000rpm for 3 mins.  Repeat this wash step once more. 
13. After the above wash, re-suspend the pellet in FBS-HBSS and filter first through a 
200-500 µm nylon membrane.  Discard the membrane and retain the flowthrough. 
14. Filter the flow through a 20 µm filter, supported on a large aperture steel grid, and 
discard the flow-through. 
15. Wash the 20 µm membrane and collect the microvessel fragments retained on top 
of it.  Wash the mesh with 40 – 50 ml of BSA-PBS and collect the solution (10 
mL at a time in a petri dish).  Count a representative volume (3 drops of 20 µL 
drawn out into straight lines) from a well-mixed suspension. 
16. Pellet the microvessel fragments (3000 rpm for 3 minutes, clinical centrifuge), re-
suspend the pellet in about 50 µL of BSA-PBS using a wide-bore pipette tip. 
17. Make adequate collagen solution to suspend the fragments at 20,000 
fragments/mL of solution.  Incubate for 20 – 45 minutes to allow gelation. 
18. Cover with serum-free media (1:1 DMEM:F12 base with insulin, transferrin, 
µnutrients, and VEGF) culture in a humidified incubator at 37 °C with 5% CO2. 
19. Change media on Day 3-4 and every other day thereafter. Angiogenic sprouts 
should be visible by day 3- 4, and a network of microvessels should be visible 
within 7 -10 days. 
 157 
A.2 Collagen ± Decorin Gel Protocol 
Materials  
• Fresh 4X DMEM (Thermo Fisher 31600-026 or -034) 
o 0.37 g HEPES + 0.476 g NaHCO3 per 1 g DMEM powder into 25 mL dH2O 
o Only need to make ~0.25 g DMEM at a time 
o Use within ~2-3 weeks  
o Sterile filter for use with cells  
• Rat tail type I collagen (Corning 354249) 
• Deionized water, sterile filtered for use with cells  
• Purified decorin (DCN), if using 
• ≥1 M NaOH 
• 0.22 µm sterile filters for use with cells (e.g. Steriflip, Millipore SCGP00525) 
• 50 mL conical tubes 
• Wide bore pipette tips (e.g. Thermo 2079G) 
 
Methods 
1. Gather all solutions and keep on ice!!!! 
2. Calculate amounts needed. Final concentration is typically 3 mg/mL collagen (can 
be adjusted to achieve different gel stiffness) in 1X DMEM. Make about 0.5-1 
mL more collagen than needed due to losses in preparation. 
a. Example calculation: 
Want 1 mL collagen gel total. Need: 
(3 mg/mL)(1 mL)/(9 mg/mL stock) = 0.333 mL collagen stock @ 9 
mg/mL 
1 mL/4 = 0.25 mL 4X DMEM 
1 mL – (0.333 mL coll. + 0.25 mL DMEM) = 0.417 mL dH2O 
i. If using DCN, incorporate at 50 μg/mL. Subtract DCN volume 
from dH2O volume added.  
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3. Add 4X DMEM, collagen stock, and dH2O into a 50 mL conical, even if making a 
small volume, and swirl tube to mix. Pipette collagen stock with wide bore tip (or 
serological pipette for larger volumes).  
4. Adjust pH with NaOH as necessary. Yellow/orange is too acidic, but purple is too 
basic. Try to keep at the color of fresh 1X DMEM: bright light red with a tint of 
pink.  
5. If using decorin, add it after adjusting pH. Swirl tube to mix.  
6. Resuspend cells with collagen solution at this point if desired. Use wide bore 
pipette tip and pipette up and down then gently swirl tube to mix.  
7. Pipette into well plate, mold, etc. using wide bore pipette tips. Incubate at 37 °C 
for 20-30 minutes to allow gelation. 
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A.3 Serum-Free Media for Microvessel Fragments 
Prepare aliquots based on 50 mL media prep at a time and store at -20 °C: 
1. Transferrin (Sigma T-2252) – Aliquot 0.5 mL of 10  mg/mL in media.  
2. Insulin (Sigma I-5500) – Aliquot 0.5 mL at 1 mg/mL in media; can use small 
volume of 1 N HCl to increase solubility if necessary.  
3. Micronutrients – Aliquot 1 mL each with: 
a. 1 µM Progesterone (Sigma P7556) 
b. 5 mM Putrescine (Sigma P7505) 
c. 1.5 µM Sodium selenite (Sigma 55261) 
d. 5 mg/mL Bovine serum albumin (BSA; Sigma A3294) 
e. Resuspend components a-d at known concentration based on amount 
weighed out. Dilute in media to achieve above concentrations. Add BSA, 
which can be much more reliably weighed to a specific mass, last.  
4. rhVEGF (R&D Systems 293-VE; MVF will grow without, but this accelerates) – 
Aliquot 5 µL at 100 µg/mL. 
 
For 50 mL of media (50% DMEM + 50% F-12; VWR 10-103-CV), add 1 aliquot 
each of transferrin, insulin, micronutrients, and rhVEGF. Sterile filter.  
 
Final concentrations in 50% DMEM + 50% F-12 should be: 
Transferrin: 100 µg/ml 
Insulin: 10 µg/ml 
VEGF: 10 ng/mL 
Progesterone: 20 nM 
Putrescine: 100 µM 
Sodium Selenite: 30 nM 
BSA: 100 µg/ml  
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A.4 Rat Vascular Perfusion  
Materials: 
• 0.9% normal saline 
• 0.4% papaverine hydrochloride in 0.9% normal saline 
• 10% neutral buffered formalin  
• 1 pair small surgical scissors, 1 pair large scissors, 2 hemostats, 1 small curved pair 
of forceps, additional instruments by personal preference 
• 18 gauge 2” long catheter  
• needles 
• peristaltic pump  
• peristaltic pump tubing (Cole-Parmer Masterflex 96410-16) 
• small tubing for connecting pump tubing to catheter (Cole-Parmer 95802-02) 
• male and female luer lock connectors as needed 
• diaper pads 
• gauze and cotton swabs 
• 2-0 needle-less suture 
• Safety goggles 
• Lab coat 
• CaviWipes 
• 50 mL conicals 
• 20 mL syringes 
• Contrast agent solutions (current preferred contrast solution is Microfil MV-122 – 
www.flowtech-inc.com – yellow colored lead chromate compound) – includes 
Microfil compound, diluent, and catalyst 
 
Procedure: 
Prepare solutions I 
• 0.4% papaverine hydrochloride in 0.9% normal saline 
• 0.9% normal saline (~200 mL/rat) 
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9 g sodium chloride 
1000 mL DI water 
• 10% neutral buffered formalin (~150 mL/rat) 
 
Perfusion I – Saline (to clear blood), Papaverine (to dilate vessels), and Formalin (to 
perfusion fix vessels) 
1. Within chemical fume hood, set up the peristaltic pump, check the flow, and bleed 
all air out of the line using the saline solution. You may have to start flow by 
siphoning the saline through the tubing using a syringe. 
2. Euthanize animal or induce anesthesia at 5% isoflurane in an induction chamber. 
a. If anesthetized switch animal over to the face mask at 2% isoflurane. 
b. Check for pedal withdrawal reflex using the toe pinch.  When this reflex is 
not observed, the animal has reached a deep surgical plane and the 
procedure can begin. 
3. Using needles, pin animals hands and feet to Styrofoam.  Legs should be as straight 
as possible. 
4. Using scissors, cut transversely through the skin & muscles just below the xyphoid 
process of the rib cage to expose the diaphragm.  
5. Gently cut the diaphragm, taking care not to puncture the heart or underlying 
vessels. 
6. Cut through the rib cage to allow opening of the chest cavity.  A large hemostat can 
be used to help keep the chest cavity open by clamping to xyphoid and positioning 
the instrument as necessary. 
7. Carefully dissect the heart free of the connective tissue holding it to the rib cage. 
8. Using small blunt tip forceps, pass a piece of 2-0 suture behind the aorta.  
9. While the heart is still pumping, insert the 18g catheter into the left ventricle (apex 
of the heart).  Blood should begin to back out of the catheter.   
10. Carefully advance the soft catheter end up into the ascending aorta while backing 
the needle out.   
11. Using a single loop with the 2-0 suture, constrict the aorta around the catheter 
within its lumen to prevent back-flow later in the perfusion process.   
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12. Transfer the animal pinned to Styrofoam to a metal rack placed on top of a plastic 
collection tub within chemical fume hood. 
13. Attach the connection tubing to the catheter, making sure to minimize any air in the 
tubing. 
14. Cut the inferior vena cava and the external muscle wall to allow fluids to drain. 
15. Immediately, turn on the pump, pefusing with saline ~50 mL  
a. Perfusion volume is an estimate.  The goal is to perfuse until vessels are 
clear.  The liver should blanch quite quickly.  Kidneys can be inspected to 
evaluate perfusion also. Average rat blood volume is 25 mL.  
b. Note: stop pump when switching solutions to avoid air bubbles in the 
perfusion tubing. 
16. Perfuse with 0.4% papaverine ~50 mL to dilate vessels. 
17. Perfuse with saline ~50 mL to flush out papaverine. If papaverine and NBF come 
into contact, the papaverine will precipitate out! 
18. Perfuse with 10% NBF ~100 mL. Again, perfusion volume is an estimate.  The goal 
is to perfuse until the extremities are fully fixed.  Inflation of the lungs is an 
indicator of backflow in the system.  After ~100 ml, one may observe muscle 
twitching and/or relative inflation of the GI system, which is not abnormal.  
19. Final saline perfusion - reconnect saline to clear formalin, ~25-50 mL 
 
Prepare Solutions II 
• Contrast agent solutions (~20 mL/rat) 
Just prior to contrast agent perfusion (during final saline perfusion): 
o In a 50 mL conical, combine: 
20 mL Microfil MV-122 
10 mL diluent (dilution can be up to preference, recommended no more than 
1:1, diluent:MV) 
1 mL catalyst  
o Immediately before injection, shake well to mix. 




Perfusion II – Microfil Contrast Agent 
1. Disconnect perfusion pump tubing from catheter 
2. Connect 20 mL syringe with catalyzed Microfil solution to catheter. 
3. Carefully inject Microfil into animal, maintaining steady pressure. 
o Caution:  Pressurized Microfil may cause ruptures in fixed vessels and 
may squirt out at high pressure so be sure to perform this step in the fume 
hood while wearing safety goggles and protective clothing 
o All vessels should yellow, turning the musculature and internal organs 
including liver, kidneys, etc quite yellow as well 
4. Allow Microfil to polymerize at least 2 hrs or overnight at 4 °C before harvesting 
tissues. 
5. Clean any surface that has come in contact with lead-containing Microfil with 
CaviWipes. Dispose of all Microfil waste in biohazard bag in biohazard box 
labeled “chemotherapeutic waste”. Dispose of perfusion fluids drained from rat in 
waste bottle and label appropriately.  
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A.5 Confocal Imaging for MVF Quantification 
I. Power on the system, Zeiss 700 Confocal, and open Zen 2012. After software has 
loaded click “Start System” and wait for hardware to initialize. 
II. System Setup 
A. Click on the Acquisition Mode tab, click “Show all” 
1. Enlarge scan area to max size by pulling the corners 
2. Make sure that Direction is set to →  
B. Click the “Smart Setup” button 
1. Choose rhodamine red and the “Smartest” setup (adjust for other 
fluorophores) 
C. Set 555 nm laser to 20.0 
III. Find Sample 
A. Under Locate menu, choose correct objective lens (5x) 
B. Place circular slide and slide holder (with gel) onto stage 
C. Choose red light and the lower fluorescent lens button 
D. Use joystick and to find gel, then focus on an area 
E. Return to Acquisition Mode and increase gain to visualize sample 
IV. Z-Stack 
A. Under Acquisition Mode check the z-stack box 
B. Click “Show all” under the Z-Stack tab 
C. Set up z-stack 
1. Find the bottom of the sample and click “Set First”  
2. Scroll up until the Range reads 200 um by clicking “Set Last” 
3. Set interval to 5 um (within Nyquist sampling range, and creates 
isotropic voxel size; adjust for different objectives) 
D. Set up Correction 
1. Check the “Use Correction” box 
2. Click the circle with an F in it (the first slice, previously set) 
3. Adjust gain to clear any noise 
4. Click the “Add” button  
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5. Repeat for the top layer 
6. Select “save …” and save the correction file  
V. Tile Scan 
A. Under Acquisition Mode check the Tile Scan box 
B. Click “Show all” under the Tile Scan tab 
C. Go to the Convex hull tab 
1. Use the joystick to find an edge of the gel (top, bottom, left, or 
right) 
2. Click the “Add” button 
3. Find the other three points and add them 
4. Find the center by guess and check 
5. Once the five points are added, find the midpoint between the 
center and right side of gel and add it 
D. Go to Centered grid tab 
1. Exit Live imaging 
2. Select 2 horizontal and 1 vertical 
3. Uncheck z-stack and click “Run Experiment” to see if the edge is 
visible in the scan 
4. Click “Scan Overview Image” at the bottom of the tab and collect 
3 horizontal and one vertical snap. Save.  
5. Re-check z-stack and run experiment 
VI. Save file in Data drive with appropriate name 
VII. Shut Down 
A. Close software 
B. Remove sample  
C. Log off computer 




A.6 Quantification of MVF Confocal Image Stacks of MVF  
I. FEI Amira for Cell Biology: 
1. Import stitched .tif stack into Amira and set voxel size to 5 x 5 x 5 um (5X). 
2. Image Pre-processing 
a. 3D median filter 
i. Under project view, right click the > on the .tif box and type “median 
filter” in the search bar 
ii. Under “interpretation”Æ 3D (not XY planes) 
iii. Project View sidebar should look like this: 
  
iv. Click “Apply” 
 
b. Blind 3D Deconvolution  
i. Click the > of the .filtered box and search for “Deconvolution” (Image 
processingÆ Frequency DomainÆ Deconvolution) 
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ii. Under parameters, set border width to 0,0,0; iterations to 15; initial 
estimate to input data; overrelaxation to fixed; regularization to none; 
and method to blind. 
iii. Under microscope, set PSF to no source, numerical aperture (NA) = 
0.16, wavelength = 0.520 um, refractive index of collagen = 1.35, and 
mode to confocal. 
iv.  
v. Click “Apply” 
 
3. Threshold deconvolved image. Interactive thresholding – change lower bound of 
Intensity Range to conservatively apply threshold to remove noise while preserving 
segment connectivity. Verify threshold by visually comparing with raw image; pay 




4. Remove Islands 
a. Select > of .thresholded and go to Segmentation tab  
b. Ensure Exterior is assigned to gel and Interior (or Material1) is assigned to the 
vessels 
c. Change the color of Exterior to black by clicking on color square to left of 
Exterior text, and change the color of Interior to white 
d. Select Interior by clicking “select” to its right 
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e.  
f. Click on Segmentation menu (top bar of dropdowns, right of File Edit etc.) 
and select Remove Islands… 
g. Consider as islands all connected regions smaller than 30 voxels and select 
Apply to: All slices 
h.   
 





II. FARSIGHT Toolkit 
1. Load Amira preprocessed Image into Farsight Tracing System 0.4.4 (“Load 
Image”, middle RH panel). Different views available above image itself. Click 
Next (bottom R). 
 
 
2. Default settings ok (threshold = 1 used here since image was thresholded in 
Amira). Click Preprocessing. This finds the seeds from which to create snakes and 





3. Select “4-D Open Snake (Elliptic)” from the top drop down and “Vessel Tube 
Coding” from the second drop down. Set min length to 30. Other default settings 
are fine. Click Tracing. On Tracing view, you can watch the snakes trace in real 






4. Output .swc file by clicking Output Raw SWC. Can also tick boxes below image 
to show radius circles, radius spheres, etc. and export these images from the 





5. Open TraceEdit 0.4.5. Load .swc (yellow) and image files (red) and click Start. 
 
6. Visually confirm agreement between image file and .swc tracing. Note: can delete 
snakes due to artifact (e.g. bubble on surface of gel) by right clicking and pressing 
delete in upper left. 
 
7. Analysis -> Cell Analysis outputs (x,y,z) coordinates, segment length, branch 
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